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AIM OF THESIS 
 
To date, monotherapy with VX-809 (Lumacaftor) or VX-770 (Ivacaftor) has not resulted in obvious 
clinical benefits for CF patients, while their combination regimen has provided positive results, 
stabilizing disease progress. Consequently, therapy combined with dual modulators or triple 
combination represents today the most promising prospect for developing new therapies. In this 
context, the research group in which I have been carrying out this thesis has dealt with rational 
design and computational studies of CFTR modulators during the past few years. The information 
obtained from our previous studies allowed us to proceed with the rational design and to predict 
the possible corrective activity of a new series of compounds with an aminoarylthiazole structure 
(AAT)1.,165. The previously proposed studies' reliability was supported by biological studies carried 
out on the newly synthesized molecules in collaboration with the research group led by Dr. 
Nicoletta Pedemonte (Istituto Giannina Gaslini, Genoa) verifying the corrective activity for 
F508del-CFTR of the newly designed derivatives. About the computational approaches so far 
applied, a QSAR model has been developed on the correctors available in literature guiding the 
following design and synthesis of hybrids compounds. This ligand-based method was used to 
overcome the paucity of information regarding a single and specific mechanism of action 
responsible for the corrective activity of VX-809. Indeed, as described in the literature, several 
hypotheses suggest multiple sites on the CFTR protein to which VX-809 could bind, first of all, the 
NBD1 domain. This thesis deepened the structure-based approach concerning various correctors 
described in the literature, including the hybrids developed by the present research group. In this 
context, experimental but partial data of the NBD1 domain of F508del-CFTR (PDB code: 4WZ6) 
were considered to perform molecular docking simulations of the compounds mentioned above. 
This research has been completed by molecular docking calculations performed on a whole model 
of the F508del-CFTR protein, which has been built in silico by our research group. Unlike what 
occurs for CFTR correctors, applying structure-based methods in the rational design of 
potentiators appears to be a more straightforward strategy since the experimental data concerning 
the binding mode of the VX-770 potentiator has recently become available (PDB code = 6O2P) and 
GLP1837 (PDB code = 6O1V). Starting from these assumptions, in this thesis, several libraries of 
compounds, described in the literature as CFTR potentiators, such as indoles, pyrazolquinolines, 
thienopyranes, cyanoquinolines, and AAT, have been studied to perform molecular docking 
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studies and QSAR analysis activities. These approaches allowed us to obtain information to guide 
the rational design and future synthesis of new CFTR modulators. 
The research activity's further goal was to apply - in parallel to the studies just mentioned - ligand-
based drug design analysis, using classical QSAR type analysis. This approach made it possible to 
overcome any limitation related to uniquely examining a single possible target for CFTR 


















Cystic fibrosis (CF) is an autosomal recessive disorder caused by mutations in the gene that 
encodes the cystic fibrosis transmembrane conductance regulator protein (CFTR)2. Around 2500 
mutations were discovered that could cause the disease, but the most common is the F508 
deletion. This mutation leads to the instability of the protein that is being formed and its structural 
modification. Furthermore, F508del-CFTR is unstable on the cell surface by losing its anion 
channel function, so that it is rapidly degraded by lysosomes 3. The primary cause of death is 
respiratory problems caused by the lack of functional CFTR in membrane4, which determines a 
reduction of anionic permeability in the respiratory tract cells and leads to a succession of related 
problems. In particular, dehydration of the pulmonary epithelium increases mucus, making it 
difficult to eliminate through ciliary movement. Therefore, this results in airway obstructions and 
inflammation, favoring colonization of the airways by pathogens, such as Pseudomonas Aeruginosa5.  
Another problem that affects people with cystic fibrosis is salt loss syndrome. It consists of 
compromised reabsorption of chloride ions and other small ions in the sweat glands, and 
consequently, their elimination. For this reason, the iontophoretic sweat test is one of the most 
important diagnostic tools for the diagnosis of CF, along with the genetic test. 6  
Cystic fibrosis occurs with the respiratory system's symptoms and at the level of other tissues, 
being a multiorgan disease. Among the organs affected is the digestive one, with clinical 
manifestations expressed above all with pancreatic insufficiency. Other symptoms include 
cirrhosis, diabetes, bone disease, and infertility; the latter mainly affects male patients 7. 
The first treatments for cystic fibrosis approved in the 1960s to the present day are based on a 
holistic approach 8. Scientific advances of the past few years have enabled us to expand the 
knowledge about the disease; this was the main reason for the increased CF patients' life 
expectancy that has changed and improved over the years. CF was initially considered a fatal 
disease in the first years of life. Today statistics suggest a life expectancy of around 40 years, while 





1.1 Cystic Fibrosis: A brief history   
Cystic fibrosis (CF) is an autosomal recessive disease that occurs mainly in childhood. The first 
description of CF was found in a medieval text dating back to 1595, which described a correlation 
between infant death and pancreatic damage and salty skin. Furthermore, there was a saying in 
this text which states: "Woe to that child which when kissed on the forehead tastes salty. He is bewitched 
and soon must die'9. The first documented cases of CF date back to the 1930s. In 1936, Dr. Guido 
Fanconi, a pediatrician at the University of Zurich, published the disease's first description. 
During an autopsy, he noticed on two children the presence of pancreatic fibrosis and 
bronchiectasis, typical of the disease. 
Nevertheless, on that occasion, he was unable to recognize the genetic basis of the disease. For a 
more detailed description of this pathology, it is necessary to wait two years when Dr. Dorothy 
published her data collected. Up to that period, the diagnosis was performed only on autopsy 
subjects; the American pathologist was able to study many cases of children who died 
prematurely and went to highlight in all these subjects severe alterations of the pancreas, finding 
the formation of abnormal cysts. These were due to the dilation of the secretory ducts drenched in 
fibrous tissue, justifying the pathology as "cystic fibrosis of the pancreas." She was also the first to 
theorize that a lack of vitamin A could cause C.F 10. . Starting from this hypothesis, in vivo tests were 
performed through the duodenal incubation tried to demonstrate the abnormal digestion of 
vitamin A which was then found in the blood. 
In 1949, CF was described by Dr. Sidney Farber as a multiorgan disorder with an excess of mucus, 
leading to a secondary staphylococcal infection 11. Since then, numerous studies have been carried 
out to discover the etiology of the disease. In 1944, Dr. Howard realized a survey of two families 
with high mortality due to CF suggesting possible heterozygous inheritance 12. Two years later, a 
study guided by Drs Andersen and Hodges on 113 families led to the conclusion that "the disease, 
although hereditary, requires more than one factor for the expression" 13.  
A great discovery for CF diagnosis occurred in the 1950s during a heatwave in New York, when 
Dr. Paul Di Sant ‘Agnese observed an increase in the salt content in the sweat of CF patients, 
establishing the basis for the sweat chloride test still used in the diagnosis of CF 14. In 1955, modern 
treatment for CF was developed by Schwachman, consisting of diagnosis, early treatment, and 
adequate nutrition. In 1955, CF's first organization was founded; the US National CF Research 
Foundation, organizations specialized in diagnosis and therapy, began to emerge. The first 
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specialized clinics started to occur, the early prenatal diagnoses were defined, and a register was 
drawn up to enter all patients affected by this pathology. These records are still maintained today 
and find great use in the creation of guidelines in the treatment of CF, and at the same time, they 
are used by the same researchers to design new trials. 
During the 1980s, Paul Quinton realized research on the chloride (Cl-) impermeability in the sweat 
duct cells. This study has identified the primary defect in the apical membrane of epithelial cells 
with a decrease in chloride flow across the cells and an increase in sodium (Na+) transport 15. In the 
mid-1980s, using the analysis of restriction fragment length polymorphism (RFLP) was identified 
the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene. Finally, in 1989, several 
researchers' joint efforts as Lap Chee Tsui, Francis Collins, and Jack Riordan 16 have led to the 
cloning of the CFTR gene. The research resulting from positional cloning combined with 
identifying mutations in patients led to identifying a mutation in about 70% of the alleles of 
patients with CF 14. This mutation consists of a three bp deletion in exon 10 (NBD1), which results 
in the deletion of the phenylalanine amino acid at position 508 (F508del) 17.  
1.1.2 Aetiology  
CF is caused by a mutation in the gene that encodes the CFTR gene. The CFTR gene is located on 
the long arm of chromosome 7 18. Cystic fibrosis is an autosomal recessive disease, so the CF gene is 
not located on the sex chromosome, which means that both males and females can contract CF. CF 
occurs in people with two mutated CFTR genes located in trans, a mutation on each allele. Healthy 
carriers of the CFTR gene are widespread worldwide, with a ratio of 1:25. These people have only 
altered one pair of the CFTR gene, which means that they do not present the disease or its 
manifestations. The healthy gene compensates for the defective one (www.cff.org Cystic Fibrosis 
Foundation) 19. Therefore, when both parents are carriers and transmit a CF-related mutation to 
the child, none of the genes works appropriately, and the child will have CF.  
When both parents carry a CF gene mutation, each baby has a:  
• One in four (25 %) chances of not being a carrier and not having CF. 
• Two in four (50%) chances of being a carrier but not having CF. 
• One in four (25 %) chances of having CF. 
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To date, the only way to identify a healthy carrier is to perform a DNA test. However, it is a 
complex analysis since there are numerous rare mutations and others still unknown. Several 
genetic tests identify CFTR gene mutations on the DNA. The more straightforward tests identify 
the most frequent mutations and are called "first-level tests.” The more complex ones identify the 
rarer mutations and are called "second and third level tests."   
1.2 DIAGNOSIS  
The enormous clinical variability and symptom diversity make the diagnosis of infant CF a 
complicated problem. Therefore, providing prenatal diagnosis and voluntary termination of 
pregnancy for couples with previously ill children or relatives is another strategy to control CF in 
the community 20.  
 1.2.1 Prenatal test 
The first step in prenatal screening is to test the mother for CFTR gene mutations through a blood 
test. If the infant presents a non-mutated CFTR gene, the child will not have CF, but it can still 
inherit a mutated CFTR gene from the father, who may be a healthy carrier. If the mother is a 
carrier of a mutated-CFTR gene, the father should also perform the test. In this latter case, if the 
father also has a CFTR mutation, the child will have a 25% (1 in 4) chance of having CF. Once 
confirmed that both parents carry the mutated-CFTR gene, amniocentesis or chorionic villus 
sampling is performed.  
1.2.2 Newborn screening  
Newborn screening has been recommended for the initial diagnosis of CF. All babies are screened 
for CF soon after birth. Newborn screening is performed on blood samples collected from the heel. 
These blood samples are stored as blood "stains" on a special filter paper. Dried blood stains are 
tested for a variety of diseases, including CF. 
In this case, various screening algorithms are used that usually involve two tiers, starting by 
measuring the IRT on dried blood spots. Immunoreactive trypsinogen is a precursor of pancreatic 
enzymes found in the blood and is generally elevated in CF. In CF, its abnormal secretion in the 
pancreatic duct seems to enhance its release into the circulation. Therefore, regardless of the 
predicted or actual pancreatic adequate state, the serum IRT level of CF newborns increase. The 
second level of screening includes a second IRT analysis about 1-2 weeks after the initial 
measurement (IRT / IRT) or a CFTR mutation analysis for newborns with a higher initial IRT 
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concentration more remarkable than the predefined threshold (IRT / DNA). Then, the babies 
whose newborn screening results positive are referred to a diagnostic test, specifically to sweat 
chloride test or molecular genetic test of the CFTR gene21,22,23.  
1.2.3 Sweat chloride test  
CFTR regulates chloride flux in the sweat ducts.  In the presence of CFTR dysregulation, Cl- 
concentration is very low, as well as its reabsorption. As a consequence, the levels of NaCl in the 
sweat of CF patients are increased 24. Current strategies used to collect the sweat, using filter 
paper, gauze, or the Macroduct ® system put on to an extremity to gather sweat. QPIT is the 
preferred technique for sweat testing and also the sole legitimate practice recognized by CFF. The 
sweat test is often used as the primary CF diagnostic tool 14. 
The sweat test is based on Darhling's observation that CF patient's sweat is very salty under 
certain stimuli. There are four primary steps to sweat testing: pilocarpine iontophoresis to induce 
sweat production, sweat collection, quantification of the sweat gathered up by volume or weight, 
and the sweat chloride concentration 25,26. In the usual tests, pilocarpine applied through the skin 
can stimulate sweating, causing a potential gradient to the sweat glands. Collected sweat 
produced lead to determine the Cl- concentration and sometimes the Na+ one 20. The aim of the test 
should be reduced to patients showing any clinical symptoms other than respiratory dysfunction. 
In this context, The Clinical Laboratory Standards Association has published guidelines on the 
adequate performance of the QPIT. To ensure a sweat rate of 1 g per square meter per minute 
within a collection time of 30 minutes, when using gauze or filter paper, the minimum sweat 
weight required by the QPIT is 75 ml, or the minimum volume of sweat using a microporous tube 
is 15 µl. However, for the latter, if the sweat volume is less than 50 µL, the analytical system must 
be validated. The chloride concentration in sweat> 60 mEq/L in two different cases can be led to 
diagnosed CF. This test is positive for 98% of individuals tested with CF. Sweat chloride 
concentrations in newborns <30 mEq/L or older children and adults <40 mEq/L are considered 
within the normal range (average population value ≤3 SD). Current newborn screening guidelines 
indicate that 30-59 mEq/L is a marginal result, and the test should be repeated in the future 27.  
There are many possible reasons for false-positive sweat tests, despite that these people are 
generally distinguished from those with CF 28 29. Other potential sources of error in sweat testing 
usually include insufficient sweat collection or mistakes in sweat electrolyte analysis30. 
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1.2.4 Transepithelial nasal potential difference 
In addition to measuring the NaCl concentration in sweat, a second diagnostic test can also be 
performed: measuring the potential difference in the nasal mucosa cells (NPD), particularly useful 
when sweat tests give uncertain results 31. Respiratory tract epithelial cells regulate ion transport 
and control the airways' fluid surface content through the active transport mechanism. Non-
functional CFTR on the apical membrane surface leads to changes in chloride efflux and sodium 
transport, resulting in an abnormal potential difference across the epithelial surface. The 
procedure for measuring NPD in people over six years of age is well described, standardized, and 
safely performed in many professional CF centers32. This potential difference can be measured by 
placing an electrode on the surface of the nose. After the electrode is positioned on the nose's 
surface is bathed in a series of solutions that contain different salts. These solutions are projected 
to change the flow of ions across the cell surface in a predictable way. These solutions contain (1) a 
Ringer's saline solution (a particular salt solution used to obtain the baseline NPD), (2) amiloride, 
which blocks sodium channels, (3) a chloride-free solution, and (4) isoproterenol, which stimulates 
CFTR. 
The solutions are always administered in the same order during the NPD testing. Individuals with 
CF after the NPD tests have specific results. First of all, the basal NPD is higher (more negative), 
reflecting greater sodium absorption through a relatively chloride-impermeable membrane. There 
is a significant NPD change during the nasal mucosa's perfusion with amiloride, an epithelial 
sodium channel inhibitor. Finally, in response to perfusion with amiloride / low chloride / beta-
agonist, the NPD change is minimal as a measure of defective cAMP-mediated chloride transport 
by CFTR 27.  
1.2.5 Genetic test 
Several mutation detection techniques are handy in genetic counseling, prenatal diagnosis, and 
carrier screening, especially in complex clinical cases. As the number of mutations identified in the 
CFTR gene continues to increase, this analysis is usually limited to the most common mutations 
present in a specific region or country. Consensus diagnostic criteria presume that patients should 
have one or more characteristic clinical features. These include a sibling history of CF or a positive 
neonatal screening result followed by laboratory evidence of CFTR dysfunction 33. Moreover, 
clinical applications of CFTR molecular genetic testing include diagnosing symptomatic 
individuals and the search for carriers of at-risk individuals and their reproductive partners. 
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Prenatal genetic diagnosis is suitable for pregnancy with an increased risk of CF. In some 
symptomatic individuals, only one or both pathogenic mutations are detected; in some carriers, 
the pathogenic mutation cannot be identified 27.  
Currently, this analysis is performed by sequencing the complete coding sequence of the CFTR 
gene. This test can identify two variants; however, as most mutations are infrequent, the mere 
discovery of two variants in the CFTR gene alone cannot be considered a confirmed diagnosis. 
 
1.3 CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR: CFTR 
STRUCTURE AND FUNCTION 
1.3.1 CFTR structure  
CFTR belongs to the C subfamily of the ABC transporter superfamily of membrane proteins, and 
for this reason, it is known as ABCC7 34 35. Among the ABC transporters, CFTR is unique in that it 
functions at low conductance (6-10 pS). Other ABC transporters utilize the energy derived from 
ATP hydrolysis to transport substrates across the plasma membrane actively. Instead, CFTR is an 
ATP-regulated anion-selective channel with channel gating regulated by ATP binding at the NBD 
domains and through phosphorylation of consensus phosphorylation sites located within the R 
domain 36 37. CFTR regulates fluid flux across epithelial membranes, mainly by regulation of Cl- 
secretion, which creates adequate electrochemical and osmotic driving forces for the movement of 
ions and molecules such as Na+ and H2O38. 
Furthermore, CFTR facilitates HCO3- secretion, which plays an essential role at this level. It has an 
antibacterial role and participates in the physiochemical properties of the mucosal layer 39 40. In the 
airways, CFTR interacts with the Na+ epithelial channel (ENaC). The abnormal function of CFTR 
can affect the lung's innate immune response.  
CFTR has many structural similarities to other members of the ABC transporter family. CFTR 
forms a highly symmetric protein with two transmembrane domains (TMD1 and 2); each domain 
consists of six transmembrane helices (TM1-12). Together they constitute the transmembrane pore 
of the protein and two cytoplasmic binding domains (NBDs) 41. NBDs contain two ATP binding 
sites, each formed by the Walker A (WA) and Walker B (WB) sites on the 'head' of an NBD and the 
ABC specific signature sequence (LSGGQ) located on the tail of the opposite NBD 37. 
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The regulatory domain (RD) is unique for CFTR in the ABC transporter family and consists of a ~ 
200 a.a. and a region that connects the C terminal of NBD1 with the N terminal of TMD2. RD 
contains consensus protein kinase A (PKA) phosphorylation sites, as well as sites for 
phosphorylation by protein kinase C (PKC) and activated protein kinase 5 'adenosine 
monophosphate (AMPK) 16 42 43 (Fig.1). 
 
Fig.1. Schematic representation of CFTR structure. Two cytoplasmatic domains NBD1 (purple) and 
NBD2 (light blue); two transmembrane domains: TMD1 (orange), TMD2 (green), and one regulatory 
domain R (grey)44. Picture from Kleizen, B. et al. J Cyst Fibros. 2020;19 Suppl 1:S19-S24. 
The CFTR gene has approximately 180,000 base pairs and can be found on the long arm of 
chromosome 7. This gene encodes 1,480 amino acids that form the CFTR protein. To CFTR 
functions correctly should be synthesized, folded, and transported to the apical membrane of the 
cells. The pathway from the nucleus to the plasma membrane requires many other proteins that sit 
in various compartments on this path. During this process, the CFTR protein must pass rigorous 
quality control checking to eliminate any misfolded proteins2. 
The first step to form a fully functional CFTR protein starts at the nucleus level, where the CFTR 
gene is transcribed into the mRNA. When the transcription is completed, the mRNA leaves the 
nucleus, and once achieved, the ribosome binds to the ER, and then the translation continues until 
the CFTR protein is translated. As CFTR is a membrane protein, its process folding is complicated 
because the membrane domains and the cytoplasmic domains should be adequately assembled for 
the protein's correct functioning. The entire folding process follows two standard folding rules. 
The first rule is based on a hydrophobic interaction, while the second rule requires that the CFTR 
protein folded into a double-layered structure in the ER 45. 
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The folding process also requires help from other proteins called chaperones that are important for 
the correct folding and aggregation prevention. One of the essential cytoplasmic chaperone 
belongs to the heat shock protein families; Hsp70 guides CFTR to bend correctly 46.  
A co-chaperone called HDJ-2 reduces the aggregation in the early stages of the folding of CFTR 
recruiting Hsc70 47. Another important co-chaperone is calnexin48. It is present in the ER and 
possesses two regions that allow it to interact with the immature CFTR allowing its correct 
folding49. When the protein is misfolded, it is targeted for degradation, and in this case, the 
ubiquitin plays a crucial role bind covalently to the lysine residues on CFTR. The ubiquitilination 
process requires three enzymes: the ubiquitin E1 activates the enzyme, ubiquitin E2-binding 
enzymes, and the ubiquitin E3 ligases. The ubiquitilination process begins with the activation of 
E1 by the hydrolysis of ATP. In this way, the ubiquitin is activated and then transferred to an 
active E2 site. Hence, the E3 ligase covalently binds the activated ubiquitin to a lysine on the 
protein. Once the misfolded CFTR is polyubiquitinated, it is removed from the ER membrane and 
sent in the cytoplasm for degradation 50. 
Two separate systems detect the CFTR misfolded during the folding process. One system acts at 
the cytoplasmic level, while the other system works at the ER membrane. In this context, ERAD 
(endoplasmic reticulum-associated degradation) is a further complex that represents a rigorous 
system to detect malfunctioning CFTR channels and avoid them reaching the plasma membrane 
even if they can still function. The CFTR protein folded properly inside the ER reaches the Golgi 
apparatus. This transfer requires the Coating Protein Complex II (COPII) presence at the level of 
the membrane of the endoplasmic reticulum. COPII helps to maintain the correct structure of the 
CFTR. At the Golgi apparatus level, the mannose-enriched side chain of CFTR is replaced with the 
mature complex oligosaccharide's sidechain. So, the protein's maturation process is completed, 
and it is transferred to the apical membrane through clathrin-coated vesicles. 
The half-life of CFTR in the plasma membrane is approximately 12-24 hours, and then it is 
internalized by the clathrin-coated endosomes. The last quality control system is at the plasma 
membrane level that can detect the defective CFTRs. The recognized defective proteins are finally 





1.4 CLASSES OF MUTATIONS 
Over a thousand different mutations of the CFTR gene have been discovered that can lead to 
the cystic fibrosis phenotype. These mutations have been found in various locations, such as 
the CFTR and mRNA splice signals' coding sequence. CF-causing mutations have 
traditionally been classified into six groups according to their effect on channel production, 
processing, function, and membrane stability 51.  
The purpose of this classification system (Fig. 1.1) was to group CF-causing mutations 
according to potential therapeutic strategies to develop mutation-specific personalized 
therapies 52. Some mutations can be well classified into only one of these classes; however, 
other mutations can cause multiple defects and belong to more than one group. For this 
reason, it may be more appropriate to consider mutations according to their phenotype when 
developing therapeutic strategies 53.  
 




Class I mutations are caused by deletions, frameshifts, and nonsense mutations leading to a 
prematurely truncated CFTR. Class I mutations result in defective channel production 
leading to a complete absence or severe reduction in the amount of CFTR proteins produced 
55 53. R553X and G542X are the most relevant mutations within class I.  
Class II mutation includes changes that result in defective channel processing and biogenesis. 
A most common example of class II mutation is F508del, which results in protein misfolding 
and premature degradation through the endoplasmic reticulum quality control system 
(ERQC). Class II mutation results in a reduction in mature CFTR availability, leading to a 
deficit in the amount of active CFTR expressed at the cell membrane 55 53.  
Class III mutations lead to a defective channel regulation, primarily affecting channel gating 
and typically resulting in reduced channel activity by producing channel closures and 
decreasing the percentage time that channels occupy the stable open conformation 55 53.  
Class IV mutations affect the ion permeability pathway through the CFTR protein, resulting 
in decreased channel conductance and a reduction in the overall rate of cellular anion efflux 56 
57.  
Class V mutations reduce CFTR expression levels, for example, by affecting promoter 
sequences or splice mutations. Class V mutations reduce CFTR expression levels, for 
example, by affecting promoter sequences or splice mutations. 
Class VI mutations lead to a destabilization of CFTR in the post-ER compartments or at the 
PM by decreasing conformational stability  71. 
Mutant classes I, II and III, lead to the most severe phenotypes because there is little or no 
channel activity associated with these mutations 50. Also known as a residual function (RF) or 
minimal function (MF), classes IV-VI causes less severe CF. Some proteins are usually able to 
survive and maintain some level of homeostasis. 
1.4.1 The two most common CF-causing mutations: F508del and G551D 
The most common CF-causing mutation is F508del-CFTR, and it has been estimated that 90-
95% of patients have at least one allele with this mutation  59. Furthermore, it is also 
responsible for two-thirds of diagnosed CF cases 60. F508del results from the deletion of a 
phenylalanine at position 508 in the NBD1 domain. It was found that cells with F508del failed 
to produce fully glycosylated CFTR proteins; the CFTR is not fully processed and is degraded 
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by the UPS before it reaches the apical membrane. A small amount of F508del-CFTR proteins 
can bypass the ERAD system and reach the membrane; however, the proteins are unstable 
and malfunctioning due to endocytosis and degradation by the UPS 49. The F508del-CFTR 
occurs within the NBD1 domain of CFTR. It has been found that the backbone structure and 
thermodynamic stability of F508del-CFTR are similar to those of wild-type CFTR 61. However, 
the F508del can cause kinetic and thermodynamic folding defects within NBD1.  
During the folding process, CFTR employs a cooperative folding mechanism. This process 
implies that NBD1 wild-type folding energy is stabilized by a coupled domain folding, but 
this coupled domain folding is impaired in the F508del-NBD1. Due to this impairment, the 
interface assembly between NBD1 and MSDs is impaired, which destabilizes the 
conformations of MSD1 and MSD2 62.  
The second most common CF mutation is G551D, which is found in the population at a 
frequency of about three percent 63. This mutation is caused by a substitution of aspartic acid 
(D) for glycine (G) at position 551 within NBD164. As a result, the NBD1 domain is unable to 
bind and hydrolyze ATP. The protein folds appropriately go to the plasma membrane, and 
the R region is correctly phosphorylated, but the NBD1 domain cannot dimerize with NBD2 
because it cannot hydrolyze ATP65. Therefore, the protein rarely opens because it cannot bind 
to the energy source it needs to open the gate, making this mutation a class III mutation.  
These two mutations are just a sample of the many mutations responsible for CF. Currently, 
about 2000 different mutations in the CFTR have been discovered that can cause the disease 
phenotype. Compared to the F508del mutation, the other mutations are infrequent and not 
widely discussed 63. Currently, only 22 mutations have been classified as occurring with a 
frequency of over 0.1%. The other mutations are typically seen in only one or a few 
individuals 66.  
The classification mentioned above has become well established over the past decades. 
However, these classifications have some limitations, mainly because many of the most 
common and severe mutations that cause CF, including F508del, can cause defects that apply 
to multiple classes. As such, the system is frequently under review, and a more combined 





1.5. THERAPIES IN CYSTIC FIBROSIS 
1.5.1 Treatment of cystic fibrosis: an overview 
Current treatments for cystic fibrosis, particularly those used for F508del-CFTR, can treat the 
symptoms but not CFTR's aetiological defects. These therapies include antibiotics, mucolytics 
(such as DNAse), anti-inflammatory drugs, hypertonic saline spray, and lung transplantation. 
Compounds that restore normal CFTR function in the apical epithelium of cell membranes to 
chlorine permeability are very promising. In this context, many theories attempt to explain 
the correlation between dysfunction in CFTR and cystic fibrosis. 
One theory is that cystic fibrosis lung defect decreases the secretion of chloride, bicarbonate, 
and fluid in the airways' submucosal glands. This process forms an acidic liquid airway 
surface (ASL), promoting bacterial colonization, damaging the mucociliary clearance and 
bactericidal capability. Another theory is that cystic fibrosis's primary defect is the 
overactivity of the epithelial sodium channel (ENaC), which involves the CFTR-ENaC 
interaction, in which excessive absorption of sodium on the airway surface can lead to ASL 
dehydration. For this reason, some studies regarding ENaC inhibitors are in development. 
Up to now, the treatments for CF can be divided into three main categories: 
- Symptomatic treatment: The first is the downstream treatment. These efforts treat the 
symptoms of CF. A high-calorie, high-fat diet can compensate for malabsorption. It can be 
combined with the appropriate use of pancreatic enzymes and gastro protectors to combat 
pancreatic insufficiency. The goal is to remove sputum (also known as mucus) from the lungs 
through airway clearing techniques to control and prevent bacterial infections with 
antibiotics and reduce lung inflammation. Together, these therapies can improve lung 
function, but they are not without drawbacks. For many years, these downstream therapies 
have been the only option to help CF patients, and each new advancement and discovery has 
added years to CF patients' lives. It should be a complete and thorough treatment plan to 
treat CF's damages, whose purpose is to treat all clinical symptoms related to the disease. 
Besides, respiratory physiotherapy is the primary method to eliminate respiratory secretions 
and allowing for better ventilation. Using osmotic compounds can be helpful in hydrating 
mucus. These compounds recall water from the inside of the cell to the outside, allowing the 
mucus' hydration and favoring a better respiratory tract's clearance. Antibiotic treatment of 
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lung infections is almost always inevitable due to multiple infections. In many cases, lung 
transplantation is required if the respiratory system is severely damaged  
- Gene therapy: After cloning the CFTR gene in 1989, gene therapy was developed to treat 
cystic fibrosis. More than 25 gene therapy studies have been conducted using various viral 
and non-viral gene transfer reagents. Several vector systems have been tested in human 
studies, including adenovirus vectors, adeno-associated viruses, and cationic lipids. 
However, even if the in vitro studies have obtained good results, various experimental 
projects conducted in vivo have not confirmed these results. 67 68 69. 
- Therapies directed to the primary genetic defect: this approach includes small molecules, 
called modulators directed to correct or improve the CFTR protein function. These 
modulators are grouped into five classes: amplifiers, stabilizers, readthrough agents, 
correctors, and potentiators  70. 
 
1.5.2 Symptomatic therapies 
Current therapies treat disease symptoms and include antibiotics, anti-inflammatory agents, 
mucolytics, hypertonic nebulized saline formulations, pancreatic enzymes, and lung 
transplantation71 72.  
Nutrition and maintenance of body weight are essential in CF, establishing an 
epidemiological link between good nutritional status and improved lung function and 
survival 73. Optimizing body weight through proper nutrition, mineral and vitamin 
supplementation, and replacing digestive enzymes, and controlling CF-related diabetes 
(CFRD) is essential. In CF patients, the energy requirement is more significant due to lung 
infections and decreased intestinal absorption, even when there is an adequate intake of 
pancreatic enzymes. The diet must be high calorie (equal to 120-150% more than the levels 
usually recommended for subjects of the same sex and age), hyperlipidic and hyperproteic. 
The proportion of carbohydrates must facilitate the intake of starches with a percentage of 
carbohydrates for rapid absorption not higher than 10%. It is necessary to ensure an adequate 
supply of mineral salts and sodium (particularly in the summer season or during 
gastroenteritis), fat-soluble vitamins, and vitamin B12 in subjects who have had extensive 
intestinal resections. There is evidence that there is a correlation between optimal 
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nutrition/body mass index (BMI) (defined as the ratio of weight in kilograms to the square of 
height in meters) and decreased lung function 74 75. A decrease in blood glucose is also 
associated with poor lung function, a longer duration of lung disease 76 77, and lung function 
improvement after insulin therapy initiation. 
Use of gastro-protected pancreatic enzymes: the administration of digestive enzymes is 
aimed at patients with pancreatic insufficiency. Doses are calculated to allow adequate 
absorption of ingested fats and are based on the subject's degree of pancreatic insufficiency.  
Respiratory physiotherapy: aims to keep the lungs free of secretions. Removing thick, 
viscous mucus from the airways reduces the chance of infections; moreover, keeping the 
bronchi and lungs clear of secretions improves breathing and helps drugs perform their 
activities in the best possible way. Respiratory physiotherapy is recommended 1 to 4 times a 
day. After each lung segment has been drained, the patient is encouraged to cough, blow, and 
make force expirations. Voluntary coughing and repeated forced expiratory maneuvers with 
positive expiratory pressure (PEP-mask) can also help eliminate mucus. 
 rhDNase: Bioengineering product Dornase alfa (Pulmozyme®) is a recombinant human 
deoxyribonuclease (rhDNase) administered by a nebulizer that works by decomposing 
extracellular DNA released by neutrophils in sputum, making it thinner and more 
comfortable to spit. There is evidence that its use in CF can significantly improve long-term 
lung function and reduce lung deterioration. Short-term use (24 weeks) can improve FEV1 by 
5.8% and reduce the risk of aggravation78. Long-term use for 12 months can improve FEV1 by 
up to 7% 79. It has also been shown to reduce airway inflammation progression, and the ICL 
improves in young children, 80. rhDNase is now the standard of care in CF. 
Antibiotic therapy: is aimed at eradicating the first infection. It is indicated in the 
prophylaxis for the treatment of exacerbations in patients presenting chronic infections and in 
the treatment of exacerbations. The drug treatment schedule varies from short intermittent 
courses with a single antibiotic to almost uninterrupted administration of one or more 
antibiotics. Some of them are often 2 to 3 times higher than the recommended dose for minor 
infections, as patients with CF have proportionally more lean mass and a faster clearance rate. 
Also, it is difficult for many antibiotics to obtain adequate drug levels in respiratory 
secretions. These can be applied directly to the airways' surface (nebulized or inhaled) or 
taken systemically (oral and intravenous antibiotics). Antibiotics used in "maintenance" 
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therapy are designed to inhibit or prevent infection, maintain stable lung function, and 
reduce the frequency of pulmonary exacerbations81. 
Anti-inflammatory therapy: administering oral corticosteroids is indicated in infants who 
have protracted bronchiolitis forms or in patients with refractory bronchospasm, allergic 
bronchopulmonary aspergillosis, and complications due to multiple inflammations. 
Prolonged corticosteroid therapy can slow down lung function deterioration; it is not 
recommended as a routine treatment due to steroid complications. The use of non-steroidal 
anti-inflammatory drugs (NSAIDs) has been studied: researchers report that administration 
of regular high-dose of ibuprofen (with specific activity against neutrophil chemotaxis) can 
reduce the rate of decline in lung function, with the reduction of acute lung attacks 82. Its 
characteristics side effects limit its use in clinical practice. Continued administration of 
ibuprofen appears to reduce the rate of deterioration of respiratory function. 
Nocturnal oxygen therapy and support with Non-Invasive Ventilation (NIV): it is necessary 
for patients with advanced lung disease who undergo nocturnal hypoxemia and 
hypercapnia, especially during broncho pneumopathy exacerbations. 
 Airway surface osmotic agents: Both the nebulized hypertonic saline and the inhaled dry 
powder mannitol work by creating an osmotic gradient to pull water into the airway lumen, 
thereby replenishing mucus and improving defects in MCC. In a randomized controlled trial, 
after 48 weeks of HTS treatment, lung function FEV1 enhanced by 3.2% (not significant), and 
statistically, the exacerbation of lung disease was also reduced 83. 
Maintenance of inhaled antibiotic therapy: The purpose of applying regular or cycling 
antibiotics directly to the airway surface through nebulization or inhalation is to inhibit the 
number of bacteria, and mainly for chronic airway infections caused by Pseudomonas 
aeruginosa. In this context are used in clinical practice, three main types of nebulized 
antibiotics: (i) colistimethate sodium (colistin), (ii) tobramycin, and (iii) aztreonam lysine. 
Recent advances in drug delivery have shown that the introduction of colistin and 
tobramycin dry powder inhalers reduces patient administration times and improves 
treatment compliance. Although it has been used as a first-line nebulized antibiotic, there is 
no evidence to demonstrate nebulized colistin's clinical benefit. In contrast, the 
aminoglycoside tobramycin has become the "standard" for new topical antibiotics. It is an 
administration in which continuous administration is alternated for one month and 
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suspension for the following month; after six months of treatment with nebulized 
tobramycin, FEV1 improved by approximately 7%, and the risk of hospitalization to 
pulmonary aggravation was also reduced 84. In a head-to-head study, nebulized Aztreonam 
showed a better effect than tobramycin: FEV1 improved by 2.7% after alternate month cycles, 
and pulmonary deterioration was reduced 85. 
1.5.3 Therapies aimed to correct the genetic basic defect 
Currently used therapy for CF is mainly based on controlling the disease's symptoms without 
treating the underlying genetic defect; this approach reduces the disease's progression by 
improving the patient's quality of life. 86  
The discovery of CFTR modulators provides a breakthrough for CF treatment because these 
molecules can improve or potentially correct CFTR function by limiting the complications 
caused by this disease (Table. 1.1) 87. The rapid development in drug discovery, with the help 
of high-throughput-screening (HTS), has made it possible to study the activity of thousands 
of small molecules simultaneously in a short period, thus accelerating the identification of 
compounds that can improve the function of defective CFTR proteins88. Some small 
molecules that control the CFTR malfunctioning are currently used in the clinical field, and 
many others are undergoing clinical trials. One of the potential strategies in treating CF is to 
act at the mRNA level or the CFTR protein to correct the gene dysfunction. 
According to the mechanism of action, modulators are divided into five groups: amplifiers, 
readthrough agents, stabilizers, correctors, and potentiators. Briefly, the potentiators keep the 
CFTR channel open at the membrane surface 87. Correctors can be used as molecular 
chaperones to prevent CFTR's misfolding in the ER and transport it to the plasma membrane 
87. The amplifiers increase the amount of CFTR protein produced by cells 89. There are three 
ways to improve the CFTR activity: by increasing the number of CFTR channels on the 
plasma membrane, increasing the opening channel's time, or increasing the size or 
conductance of the channel90. Modulators can improve CFTR function in the cells by 
increasing any of these variables. There are currently four CF modulators therapies available 
to patients: Ivacaftor, Lumacaftor/Ivacaftor, Tezacaftor/Ivacaftor, and 
Elexacaftor/Tezacaftor/Ivacaftor. Ivacaftor was the first drug approved by the FDA to treat 
CF patients with the G551D mutation on January 31, 2012 (FDA, 2012). Ivacaftor is a 
potentiator that increases the time of CFTR opening and can be used for various mutations. 
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Lumacaftor, Tezacaftor, and Elexacaftor are all correctors, mainly used to correct the 
mutation F508del CFTR. When combined with Ivacaftor, these drugs form a combination 
therapy. The corrector is responsible for the folding of CFTR so that CFTR can be transported 
to the plasma membrane, and Ivacaftor increases the possibility of channel opening. The 
latest addition to these drug therapies is Trikafta (Elexacaftor / Tezacaftor / Ivacaftor), which 
the FDA approved on October 21, 2019, the first second-generation triple modulator therapy 
(FDA, 2019). 
Table 1.1. The pipeline of current CF modulators in clinical trials and the market. 
Name Function Development 
stage 
Company 






































PTI-801 Correctors Phase III Proteostasis Therapeutics 
VX-659 Correctors Phase III Vertex Pharmaceuticals 
PTI-808 Potentiators Phase III Proteostasis Therapeutics 
25 
 
PTI-428 Amplifiers Phase III Proteostasis Therapeutics 
ELX-02 Read-through 
agents 
Phase II Eloxx Pharmaceuticals 
ABBV-2222 Correctors Phase II Abbvie/Galapagos 
ABBV-2737 Correctors Phase II Abbvie/Galapagos 
FDL169 Correctors Phase II Flately Discovery Lab. 
VX-121 Correctors Phase II Vertex-Pharmaceuticals 
VX-152 Corrector Phase II Vertex. Pharmaceuticals 
VX-440 Corrector Phase II Vertex Pharmaceutical 
VX-561 Potentiator Phase II Vertex- Pharmaceuticals 
ABBV-974 Potentiator Phase II Abbvie/Galapagos 
ABBV-3067 Potentiator Phase II Abbvie/Galapagos 




1.5.4 CFTR structure and its role in the development of new modulators 
For many years, the lack of a high-resolution CFTR structure has been a significant obstacle in 
CF research91. In the beginning, X-ray crystallography allowed the determination of the 
structure of NBDs at the atomic level 92 93. However, until progress was made in cryo-EM, 
TMD's resolutions and the R domain remained insufficient. Previously, the best structural 
approximations of CFTR were obtained via the high-resolution structures obtained for related 
ABC transporters, including the P-glycoprotein (Pgp) multiple resistance transporter 94, the 
bacterial transporter Sav186695, and bacterial lipid flippase MsbA 96. These homologs pave the 
way for designing a series of CFTR in-silico models that could be used to investigate CFTR 
structure-function correlations 97 98 99 100. 
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The first high-resolution structure of the entire CFTR protein was obtained using the 
zebrafish CFTR ortholog in the ATP-free, non-phosphorylated inactive (closed) state 101, 
followed shortly after that by the human CFTR structures (Fig. 1.2) 41. Despite sharing only 
55% amino acid identity, these two CFTR orthologs' resulting structures were mostly similar. 
These structures result in many unique features that homology models cannot predict. One 
such feature is the presence of an interface motif named the "lasso motif" that could be 
involved in the mediation of protein-protein interaction 102. Furthermore, a secondary 
structure breakdown of TM8 was observed, which may allow primary chain residues to 
interact with ions and water within the channel pore 103. Despite these important discoveries,  
the cryo-EM models did not show consistent structural features attributable to RD, which 
may be due to the domain's disorganization, which cannot be resolved in cryo-EM images 101. 
 
Fig.1.2. Structure of human CFTR. (A) hCFTR in dephosphorylated, ATP-free conformation (PDB: 
5UAK). Picture from Liu F. et al. Molecular structure of the human CFTR ion channel. Cell. 2017, 169, 
85-95. (B) hCFTR in phosphorylated, ATP-bound conformation (PDB: 6MSM). Picture from Zhang, 
Z. et al. Molecular structure of the ATP bound, phosphorylated human CFTR.  Proc Natl Acad Sci U S A. 
2018, 115, 12757-12762. 
Recently, cryo-electron microscopy (cryo-EM) revealed structures formed by the N-terminal 
region of TMD1, called the lasso motif (LM), similar to a lasso that appears perpendicular to 
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the TM helix of TMD1 101 41. This motif's functional importance is still unclear, although there 
is evidence that the interaction between LM and NBD1 is involved in the regulation of 
ATPase activity 104. The TMD transmembrane helices are connected by four intra and six 
extracellular loops. Among these, the ICLs are more extensive and extend below the plasma 
membrane, enter the cytoplasm, forming coupling helices with NBDs. ECLs are much smaller 
than ICLs. However, ECL4 is larger than the others and undergoes co-translational N-
glycosylation at two sites N894 and N900 105. 
An alpha-helix region within the channel pore's intracellular vestibule between the ICLs has 
been determined, and it seems to correspond to a part of the RD. Finally, another cryo-EM 
model of CFTR has been disclosed representing the protein in its closed-phosphorylation 
ATP-bound state and bounded with the potentiator Ivacaftor and the modulator GLPG1837. 
These findings paw the way to identify hotspots for drug-binding and the application of 
rational design for a new generation of modulators.58.  
 
1.5.5 Correctors and potentiators 
The CFTR corrector can correct abnormal folding and processing of class II (and possibly V) 
CFTR mutation channels (such as F508del), thereby increasing the number of successfully 
processed channels and then expressed on PM 107. CFTR mRNA is translated in the ER, and 
most of the tertiary folds are co-translated at this stage 108. Wild-type (WT) CFTR undergoes 
further post-translational folding and is transported to PM via the Golgi apparatus. Before 
expressing the mature channel, the glycans that were added to the CFTR channel were 
further modified109 110. However, class II mutations (such as F508del) can misfold the protein 
during co-translational folding 111. Therefore, CFTR corrective compounds can act through 
multiple mechanisms. They can primarily act as pharmacological chaperones by binding to 
the same developing CFTR protein because it translates in the ER and promotes proper 
folding, thus preventing targeting to ERAD. 112 113. Second, they can interact after translation 
with incorrectly folded CFTR to correct the folded structure. Alternatively, they can act as 
regulators of protein stability, interact with non-CFTR proteins belonging to the CFTR 
interaction group, and determine the correct protein folding and transport of CFTR to the 
Golgi proteasome 114.  
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Lumacaftor is a corrector that is thought to interact with residues in TMD1 to stabilize mutant 
CFTR and correct folding early in biogenesis 115 7. To date, F508del is the most common CF 
mutation, and about 70% of patients are homozygous for the disease variant 116. Therefore, the 
development of small molecule therapies that prove useful for F508del patients is the key. In 
WT-CFTR, the F508 residue is located on NBD1 at the interface between NBD1 and ICL4 of 
TMD2 98. Although F508del affects the structural folding of NBD1, the correct folding of 
NBD2 also depends on the integrity of NBD1. Therefore, this mutation indirectly affects 
proper NBD2 folding, leading to misfolded CFTR recognition, which is subsequently 
degraded by ERQC 111. WT-CFTR is a protein with a relatively low folding efficiency. 
Depending on the cell type, only about 30-50% of the protein successfully reaches the PM 112. 
Since CF is an autosomal recessive genetic disorder and the heterozygous F508del mutation is 
asymptomatic, it is believed that a 50% recovery of CFTR expression should be sufficient to 
deliver enough CFTR protein to the PM for its normal functioning. 
The relatively low information for adequately managing CF provides a strong reason for 
combining correctors and potentiators to treat patients with F508del-CFTR mutation. 
Orkambi, which the FDA approved in 2015, is one such combination therapy, the purpose of 
which is to combine ivacaftor and lumacaftor to achieve this 117. It has been shown that only 
lumacaftor can correct F508del-CFTR processing to levels 14% of wild-type  118. Theoretically, 
this level should be sufficient to restore the patient's near-normal CFTR function combined 
with potentiators. 
However, for F508del homozygous patients, lumacaftor itself has no clinical benefit. Besides, 
the benefits of Orkambi shown by FDA approval are relatively limited for F508del 
homozygous CF patients 90.  
In 2018, the FDA approved Vertex Pharmaceuticals Symdeko's dual combination therapy, 
which combines ivacaftor with the corrector tezacaftor (VX-661) combined with an additional 
dose of ivacaftor 119. Compared with Orkambi, the combination of ivacaftor with tezacaftor 
instead of lumacaftor resulted in a similar recovery level of FEV1 but an increased level of 
tolerance119. 
However, using multiple corrector compounds with different mechanisms of action or 
binding sites, the relatively low level of improvement in FEV1 caused by these dual therapy 
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strategies can be improved using a triple combination of MCG1516A, RDR1, and VX- 809.  
These three corrector compounds interact with different sites on NBD1 120. 
Additionally, results from two recent Phase II clinical trials for this type of therapy (involving 
the combination of VX-659 or VX-445 with ivacaftor and tezacaftor) showed that FEV1 
increased by 13.3%. (VX-659) and 13.8% (VX-445). For G551D patients, this level of response 
exceeds ivacaftor's level, and it is hoped that the level of tolerance of these therapies is 
comparable to that of Symdeko121. 
Abbvie/Galapagos has developed novel classes of correctors, including the molecules GLPG-
2222, GLPG-2737, GLPG-2851, GLPG-3221, and GLPG-3748 are the most promising. GLPG-
2222 has a similar structure to the Tezacaftor and Lumacaftor (Fig. 1.3). A phase IIa clinical 
trial demonstrates improving the sweat chloride concentrations but did not ameliorate 
ppFEV1 in F508del-homozygous patients. Up to now, there are other clinical trials to test the 
safety and efficacy of GLPG-2222 in combination with other modulators.  
 
Fig. 1.3. Chemical structure of GLPG-2222. 
CFTR potentiators enhance the CFTR activity present in PM by promoting the stable open 
state of the channel and are targeted for the treatment of class III and class IV mutations 52. 
The CFTR potentiator ivacaftor (VX-770; Kalydeco® from Vertex Pharmaceuticals) is the first 
CFTR small molecule modulator approved by the FDA 122 123. Ivacaftor was initially approved 
to treat the third most common type III mutation (G551D) that causes CF, causing severe 
gating defects 124. However, its use has expanded to cover more than 38 mutations, including 
S549R and G1349D and the class IV mutation R117H 125.  
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The CFTR potentiators rely on the existing pool of CFTR proteins that already exist on PM. 
Therefore, unless used combined with other compounds, they are not suitable for patients 
with mutations affecting CFTR expression (including F508del). So far, although many 
patients have benefited from it, combination therapies (such as Orkambi and Symdeko) have 
not successfully demonstrated the efficacy of ivacaftor for class III mutations (such as 
G551D). 
Therefore, it is still necessary to develop CFTR potentiators with greater efficacy. So far, there 
are many drug candidates in clinical trials, including QBW251 (Novartis), CTP-656 (Concert 
Pharmaceuticals), and GLPG1837(AbbVie / Galapagos) 107. The obstacle to developing such 
compounds is that there is currently little understanding of existing potentiators' mechanisms 
(including ivacaftor). 
A better understanding of existing CFTR potentiators' mechanisms may help develop new 
potentiators compounds with greater efficacy against a broader range of mutations. When 
these modulators are used in combination with other compounds (such as correctors), they 
may also be more effective. Identifying potentiators that act through different CFTR protein 
regions (e.g., through TMDs rather than NBDs) can improve efficacy. Additionally, 
identifying multiple CFTR potentiators with different sites of action can help develop 
combinations that can be used in conjunction with correctors for mutations such as F508del. 
1.5.5.1 Ivacaftor 
Ivacaftor, also known as Kalydeco ® or VX-770 (Fig.1.4), was initially approved for patients 
with at least one G551D allele. Since its first FDA approval, Ivacaftor has been approved for 
more than 33 mutations, including gated mutations. Ivacaftor, developed by Vertex 
Pharmaceuticals, is a small organic molecule initially discovered via High-throughput-
screening (HTS) studies. 
 
Fig. 1.4. Chemical structure of VX-770 (Ivacaftor ®).  
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Ivacaftor's effect was tested using human bronchial epithelial cells (HBE) from CF patients 
with the G551D mutation, F508del mutation, and non-CF cells' control. Studies have shown 
that ivacaftor increases the possibility of CFTR channel opening and in wtCFTR cells 
increases chloride secretion to approximately 50% of normal chloride secretion122. 
Furthermore, Ivacaftor can prevent ASL dehydration and increase cilia beating. After this 
promising result, Ivacaftor proceeded for human clinical trials. For individuals with at least 
one G551D allele, ivacaftor produced significant results in both changes in ppFEV1 and 
changes in sweat chloride levels. Ivacaftor acts by binding directly to the CFTR protein and 
causes the spontaneous opening of the ATP-dependent channel 126 127. 
When Ivacaftor binds to the protein, phosphorylation of the CFTR regulatory region is 
required, but ATP is not needed to dimerize the NBD1 and NBD2 domains. This problem can 
correct the G551D mutation, which does not respond to ATP and is therefore rarely activated. 
Ivacaftor has little effect on the homologous F508del because Ivacaftor only increases the 
possibility of opening existing CFTR channels on the plasma membrane, while F508del CFTR 
never reaches the plasma membrane 128. 
Since Ivacaftor also increases the possibility of opening the wtCFTR channel, it has been 
approved for 33 different mutations, including gating, residual function, splicing, and 
conduction mutation. Although Ivacaftor can only cause clinical changes in some mutations 
representing a small percentage of total CF patients, Ivacaftor is the gold standard for 
modulating therapy (FDA, 2017).  
1.5.5.2 Lumacaftor 
Lumacaftor (VX-809) (Fig.1.5) was the second modulator developed by Vertex 
Pharmaceuticals. It has been designed to prevent the misfolding of F508del-CFTR. 
Concerning this function, it falls within the class of corrector-type modulators. Lumacaftor 
acts cotranslationally. It alters the protein conformation of the MSD1 domain, which allows 
the establishment of a more stable connection between the MSD1 and NBD1 domains, only 
partially correcting the F508del mutation129. As for the clinical studies conducted on 
Lumacaftor, the first study was carried out using only the Lumacaftor corrector in patients 
with CF, homologous for the F508del mutation. This study showed that Lumacaftor used 
alone has no clinically relevant effects on ppFEV1 or sweat chloride levels. These results 
could be explained by the fact that the F508del-.CFTR mutation also has gating defects as well 
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as misfolding 130. From these studies' data, Lumacaftor was combined with Ivacaftor to create 
a dual modulator therapy that led to the re-establishment of a specific function of CFTR. 
Lumacaftor would facilitate the correct bending of the CFTR canal. At the same time, the 
Ivacaftor would increase the opening time of the channel. 
 
 
Fig.1.5. Chemical structure of VX-809 (Lumacaftor ®).  
The Lumacaftor / Ivacaftor combination, also known by the trade name of Orkambi, has some 
clinical benefits for homozygous F508del patients but does have an effect on F508del 
heterozygous patients131. Compared to the impact that Ivacaftor has on the G551D mutation, 
the Lumacaftor / Ivacaftor combination therapy results in a much more modest lung function 
improvement. However, Lumacaftor / Ivacaftor significantly reduces the decline rate of 
FEV1, allowing for stabilization of ppFEV1 132. For this reason and the proven improvement 
in lung function, albeit modest, the combination therapy with Lumacaftor / Ivacaftor was 
approved by the FDA in 2015 (FDA, 2015)  
1.5.5.3 Tezacaftor 
Tezacaftor (VX-661) (Fig. 1.6) has a similar structure to that of the previous corrector. 
Tezacaftor is a CFTR corrector with a broader action than Lumacaftor, enabling cell 
production and facilitating the trafficking of many mutated forms of CFTR, including 
F508del-CFTR 133. Since Tezacaftor does not induce CYP3A4 enzymes, there are fewer drug-
drug interactions than those found using Lumacaftor. It follows that Tezacaftor, from a 
clinical point of view, has a better safety profile. Clinical studies conducted combining 
Tezacaftor with Ivacaftor have shown that this combination results in changes in ppFEV1 and 
sweat chloride levels similar to those produced with treatment with the Lumacaftor / 
Ivacaftor combination modulator therapy. Based on these clinical trials, the therapy Symdeko 
(Tezacaftor / Ivacaftor) was derived, which was approved by the FDA in February 2018 for 
patients with one allele of F508del and a residual function allele that responds to Ivacaftor 
(FDA, 2018). For homologous F508del patients, similar clinical benefits were found with both 
33 
 
Lumacaftor / Ivacaftor and Tezacaftor / Ivacaftor treatment, but the latter dual combination 
has been shown to have fewer side effects 134. 
 
Fig.1.6. Chemical structure of VX-661 (Tezacaftor ®). 
 
1.5.5.4 Trikafta 
The next step in modulator development was to design a triple combination of modulators 
known as second-generation modulators. Heijerman and colleagues theorized that adding a 
second corrector with a complementary mechanism of action to the Tezacaftor / Ivacaftor 
combination would better restore CFTR function 135. Furthermore, the goal was to develop a 
modulator capable of providing therapy to patients with CF who are heterozygous for 
F508del and a minimal function mutation. Minimal functional mutations include nonsense, 
insertion/deletion, splicing, and several severe protein misfolding mutations121. Therefore, the 
final aim was to correct the CFTR function by restoring the only F508del allele regardless of 
the mutation carrying the second allele. In this context, Vertex Pharmaceuticals had initially 
identified two very similar modulators to combine with Tezacaftor / Ivacaftor. The drug 
candidates in this study were VX-659 and VX-445 (Fig. 1.7). Separate phase 2 and phase 3 
studies were carried out on these two compounds. Both were found to have a corrective 
function as they reduce CFTR misfolding by promoting CFTR trafficking from the ER to the 
plasma membrane. They also have an additive effect on Tezacaftor. Clinical studies have 
shown that both VX-659 and VX-445 triple combination therapy provide dramatic lung 
improvement in homozygous and heterozygous patients 121. 
After conducting parallel phase 3 clinical trials on both VX-659 and VX-445, Vertex 
Pharmaceuticals decreed that compound VX-445 (Elexacaftor) was the most effective drug of 
the two candidates. Both parallel clinical trials included 24-week tests for heterozygous 
patients carrying one F508del mutation and one MF mutation and 4-week tests for F508del 
homozygous patients. Both programs met their primary and secondary endpoints, and both 
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triple combinations were generally well tolerated with a low amount of adverse effects 136. 
Based on the data collected, Vertex submitted Elexacaftor in combination with Tezacaftor / 
Ivacaftor for FDA approval. On October 21, 2019, Trikafta (Elexacaftor / Ivacaftor / 
Tezacaftor) was approved by the FDA for patients with at least one F508del mutation 137. This 
drug is a significant step forward in the search for modulators for CF. It is available to 
patients who previously could not access previous modulatory therapies, demonstrating a 
noticeable improvement in lung efficiency over the modulators mentioned above. It is 
important to note that Trikafta is not the definitive cure for CF. If a patient cannot continue 
therapy, they return to their previous treatments 138.  
 
 
Fig. 1.7. Chemical structures of VX-445 (Elezacaftor) (left) and VX-659 (Bamocaftor) (right).  
1.5.5.5 Stabilizers 
Stabilizers are compounds that anchor CFTR at the PM, so avoiding its degradation by 
lysosomes 139. 
Despite Lumacaftor demonstrated to bail out the functional expression of F508del-CFTR in 
cells, it does not provide long-term stability at the PM surface (He et al., 2013). For this 
reason, new treatments are explored to extend the residence time of CFTR at the PM. In this 
scenario, the Hepatocyte growth factor (HGF) was proved to abet CFTR at the PM in F508del-
expressing cells as it induces the CFTR interaction with Na+/H+ exchanger regulatory factor 1 
(NHERF1) 140. Other adopted strategies involved administering vasoactive intestinal peptide 
(VIP) 141 or the use of S-nitrosoglutathione reductase inhibitors 142.  
The first stabilizer tested in a clinical trial was Cavosonstat (N91115; Nivalis) (Fig. 1.8). A 
phase I clinical trial showed reduced sweat chloride concentration in F508del-CFTR 
homozygous patients but not showing any further improvement in lung function and sweat 
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chloride levels in phase II clinical trial 140. For this reason, the clinical development of 
Cavosonstat has been terminated for CF. 
 
 
Fig.1.8. Chemical structure of N91115 (Cavosonstat). 
1.5.5.6 Readthrough agents 
A significant portion of CF-related mutations is in-frame nonsense, frameshift, and splice 
variants introducing a premature stop codon (PTC) into CFTR mRNA, eliminating CFTR 
protein synthesis, or producing shortened or truncated forms of CFTR. 
Readthrough agents are compounds that perform a ribosomal over-reading of a premature 
stop codon and allow the insertion of an amino acid at that point allowing translation to 
continue until a standard final transcript is produced144. The so-called readthrough effects 
were first found in aminoglycoside antibiotics, such as gentamicin. This drug is used in CF 
patients to eradicate P. aeruginosa infections. Although in numerous studies conducted on 
cell lines, these compounds have been shown to increase full-length CFTR expression, they 
cannot be used in clinical practice since their use over long periods causes nephrotoxicity and 
ototoxicity 145. 
In this context, Ataluren (Fig. 1.9) (also known as PTC124; PTC Therapeutics) identified by 
HTS studies has shown that it can restore the expression and function of CFTR transgenic 
mice. Despite the results observed in phase II clinical trials, treatment with Ataluren did not 
demonstrate a significant trend in improving the ppFEV1 of CF patients. against this, its 
clinical development as a CF drug has been halted. However, it has been approved to treat 





Fig.1.9. Chemical structure of PTC124 (Ataluren). 
 
1.5.5.7 Amplifiers 
CFTR amplifiers are modulators that increase immature CFTR protein expression. These 
compounds act synergistically with correctors and potentiators, increasing therapeutic benefit 
146. Up to now, there are known two types of amplifiers devised both by Proteostasis 
Therapeutics. These drugs, named PTI-428 (fig. 1.10) and PTI-CH, passed the pre-clinical and 
clinical studies with promising results 147. 
 In vitro studies conducted on PTI-428 demonstrated double CFTR activity when used in 
combination with other modulators. in these latter cases, a clinical trial supported by 
Proteostasis Therapeutics showed that the patients who received PTI-428 in co-treatment 
with Orkambi improved lung function. However, there are no changes in the levels of sweat 
chloride. 
 





























CHAPTER 2  
STRUCTURE-BASED DRUG DESIGN 
2.1 Molecular docking studies of correctors as modulators of F508del-CFTR 
During my Ph.D., I performed docking studies of a library of F508del-correctors, such as the 
in-house series VX-809-AAT hybrids and modulators described in the literature (Fig.2.1). All 
the compounds possess variable chemical features (see Appendix A1-A3)148. 
 
Fig.2.1. Chemical structures and biological activity of the examined F508del-CFTR correctors. 
Firstly, these calculations have been performed on the human F508del-CFTR NBD1 (PDB 
code:4WZ6) domain starting from the several experimental efforts described in the literature 
that affirmed that the NBD1 domain plays a key role for the corrector's activity at this domain 
of channel 149,150,151,152. Since the data derived from calculations performed only on the NBD1 
domain are partial, our research group decides to perform molecular docking studies on the 
whole protein. Given the absence of crystallographic data of the CFTR mutant protein, our 
research group modeled the whole protein superimposing the cryoelectron microscopy 
available data of the wild type protein (PDB code: 6MSM) 153 and that of the mutant NBD1 
domain (PDB code: 4WZ6) (Fig.2.1.2). Furthermore, I align our in-house model of F508del-
CFTR onto the cryoelectron microscopy data of the wild-type protein (PDB code: 6MSM) to 





Fig.2.1.2. Superimposition of the modeled F508del-CFTR (cyan) onto the mutant NBD1 domain 
(PDB code:4WZ6) (magenta). At the right, a focus on the zone that contains ATP (C carbon 
orange) and Mg2+ (green).  
 
Fig.2.1.3. Superimposition of the modeled F508del-CFTR (cyan) onto the WT-CFTR structure 
(PDB: 6MSM) (red). The two superimposed structures show a strong similarity.  
Molecular docking studies on VX-809 and related analogs were performed considering the 
putative binding site proposed by the site finder module implemented in the MOE 
software. This software module identifies tight atomic packing regions to filter out sites that 
are “too exposed” to solvent. This approach allows removing protrusions that are unlikely 
to be good active sites. The derived preliminary sites are then classified based on their 
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hydrophobic or hydrophilic profile. The generation of alpha spheres on these sites is made 
by collecting sets of points using a modified Delaunay triangulation method to derive different 
spheres displaying different radii. All the collected sites are ranked according to their 
Propensity for Ligand Binding (PLB) score, which is based on the pocket's amino acid 
composition as described in the literature160 (Table 2.1). 
Table. 2.1. Top ten best-ranked scored sites identified with Site Finder at the modeled F508del-
CFTR.  
Site Aminoacidic residues 
1 L165 K166 S168 S169 R170 L172 D173 K174 S176 I177 G178 Q179 G253 
S256 E257 V260 S263 E264 I266 E267 N268 I269 Q270 S271 A274 Q378 
E379 Y380 K381 T382 L383 E384 Y385 N386 A399 F400 W401 E402 
E403 G404 F405 E407 T438 V440 A457 G458 S459 T460 G461 A462 
G463 K464 T465 S466 M469 M470 I471 M472 G473 E474 L475 E476 
P477 S478 I482 K483 H484 S485 G486 R487 I488 F490 S492 Q493 N494 
S465 W496 I497 M498 P499 G500 T501 E504 N505 I506 I507 G508 V509 
S510 Y511 D512 R515 E527 D528 K531 F532 A533 E534 K535 V539 
L540 G544 I545 T546 L547 S548 G549 G550 Q551 R552 A553 R554 R559 
Y562 D564 D571 S572 P573 F574 G575 Y576 L577 L580 E582 L601 V602 
T603 S604 K605 H608 A654 E655 R657 N658 L661 T662 V956 M961 
L964 N965 T966L967 K968 A969 G970 I972 L973 P1050 T1053 H1054 
V1056 T1057 L1059 K1060 G1061 L1062 W1063 T1064 L1065 R1066 
A1067 F1068 G1069 R1070 Q1071 Y1073 F1074 L1077 K1080 A1081 
L1084 K1218 Y1219 G1223 N1224 I1226 L1227 G1224 R1245 T1246 
G1247 S1248 G1249 K1250 S1251 T1252 L1254 S1255 L1258 L1260 
L1262 V1288 P1290 Q1291 K1292 V1293 F1294 I1295 F1296 S1297 
G1323 L1324 S1326 V1327 Q1330 F1331 V1340 D1341 G1342 G1373 
C1344 V1345 L1346 S1347 H1348 G1349 H1350 K1351 Q1352 L1353 
D1370 Q1371 P1372 A1374 H1375 L1376 D1377 V1379 T1380 I1383 
C1400 H1402 V1415 I1416 E1417 E1418 N1419 K1420 R1434 S1435 
L1436 F1437 R1438  
2 L88 E92 K95 Q98 P99 L102 F131 R134 L138 H139 I142 H146 I175 G178 
Q179 L180 V181 S182 L183 S185 N186 N187 L188 N189 K190 F191 
E193 G194 A196 L1987 F200 Q207 R242 M244 M245 K246 R248 D249 
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R251 A252 G253 I255 S256 L259 R289 E292 T296 R303 N306 S307 F310 
F311 F337 I340 S341 I344 V345 R347 M348 A349 R352 Q353 P355 W356 
Q359 T360 Y362 D363 S364 G366 A367 L370 D373 F374 K377 Y913 
V920 G921 V922 A923 D924 S977 K978 D979 A981 I982 D984 D985 
L989 T990 F992 D993 L997 I100 V1001 A1004 K1041 S1045 R1048 
W1092 L1093 L1096 R1097 F1099 Q1100 I1103 E1104 F1107 V1108 
F1111 M1137 N1138 I1139 S1141 T1142 Q1144 W1145 N1148 S1149 
I1151 D1152 S1155 L1156 R1158 S1159 R1162 
3 A274 Y275 C276 W277 I1203 W1204 P1205 L1258 Q1281 R1283 A1285 
F1286 G1287 V1288 L1304 D1305 P1306 Y1307 E1308 Q1309 W1310 
E1314 K1317 V1318 E1321 R1358 S1359 V1360 L1361 S1362 K1363 
A1364 K1365 I1366 L1367 A1391 F1392 A1393 D1394 C1395 
4 F229 V232 L233 F236 L240 Y304 F305 S308 A309 F312 G930 F931 
5 F994 L998 V1001 I1002 I1005 A1006 F1016 I1023 F1026 I1027 R1030 
L1143 A1146 V1147 S1150 
6 E282 I285 G286 R289 Q290 L293 S945 K946 I947 H949 H950 K951 L953 
H954 
7 I70 L73 R74 F77 F78 F81 M82 M152 F191 L195 W361 S364 I368 
8 M1 L34 I37 L967 K968 G971 N974 R975 L1043 E1046 G1047 S1049 
P1050 L1084 A1087 N1088 R1162 F1166 
9 L6 V11K14 L15 F17 W19 V43 R80 Y84 P140 F143 G144 H147 I148 Q151 
10 K273 C276 W277 E278 E279 A280 L957 Q958 T1171 E1172 G1173 








Finally, I consider the best-ranked site by Site Finder for the following molecular docking 
calculations in these studies (Fig.2.1.4). 
 
Fig.2.1.4. Representation of the first ‘best-ranked binding site identified by Site Finder on the 
modeled F508del-CFTR.  
The obtained scoring functions (see appendix A4-A5) proved to be in accordance with the 
experimental activity, supporting the docking protocol at the two putative binding sites. The 
most promising tetrahydropyridopyrimidines and cyanoquinolines (featuring pEC50 > 5.5) are 
supplemented by score values at the NBD1 domain lower than -20 kcal/mol. On the other 
hand, the most effective hybrids (pEC50 > 6.0) exhibited scoring values spanning from -20 to -
25 kcal/mol. For all chemotypes investigated, the poorly activity correctors presented score 
values higher than -20 kcal/mol.  
Regarding molecular docking at the modeled F508del-CFTR, the same promising hybrids 
experienced score values spanning from -22 to -30 kcal/mol, while the 
tetrahydropyridopyrimidines above and cyanoquinolines showed variable scores spanning 
from -20 to -30 kcal/mol.  
Firstly, I investigated the putative docking mode of VX-809 and its related analogs ALK-809  
and SUL-809, selected as reference compounds 149. These two derivatives bore an amide and a 
sulfonamide function as a substitute for VX-809 carboxylic moiety, missing the possibility to 
display a negatively charged group155.  
Regarding VX-809, it demonstrates to assume two putative docking positioning within the 
NBD1 domain, namely POS1 and POS2 (Fig.2.1.5).  
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Notably, in POS1, the oxygen atom of the carboxamide group of VX-809 is H-bonded to the 
N659 sidechain. In contrast, the carboxylic group exhibits one salt-bridge with K464 and 
further H-bonds with T460 and G461 (Fig.2.1.5). The corrector's biaryl portion was enclosed 
by S573, G576, V603, and A655, presenting Van der Waals contacts. The benzodioxole ring is 
near Y577 and E656. Concerning POS2 (Fig. 2.1.5), the two oxygen atoms of the benzodioxole 
core detected two H-bonds with K464 and T465. At the same time, the negatively charged 
carboxylic group and the carbamide moiety of VX-809 are H-bonded to the backbone of E656 




Fig.2.1.5. Selected docking pose of VX-809 within the hNBD1 domain as POS1 (A) and POS2 (B). 
 Molecular docking studies performed on the related analogs ALK-809 and SUL-809 revealed 
a unique positioning according to the POS2 of VX-809. The two analogs engage the 
(solfon)amide moiety in one H-bond with the E656 backbone, and the amide group 
positioned on their central core makes an H-bond with N659 (Fig.2.1.6). Again, as shown for 
VX-809, the benzodioxole ring of ALK-809 and SUL-809 featured polar contacts with K464 
and T465 through its oxygen atoms. In this scenario, POS2 could be considered the possible 
bioactive conformation considering the comparable potency experienced by VX-809 and by 







Fig.2.1.6. Selected docking pose of ALK-809 (A) (C atom; magenta) and SUL-809 (C atom; yellow) 
(B) within hNBD1 domain together with VX-809 (C atom; dark cyan).  
The putative binding site herein identified is supported by other computational studies 
presented in the literature performed by Odolczyk151.  
 Odolczyk and colleagues have identified four derivatives acting as F508del-CFTR correctors 
using molecular docking and virtual screening strategies. Thanks to these approaches, they 
disclose two different pockets within the NBD1 domain, describing the proposed 
compounds' corrector ability. Performing molecular dynamic simulations, they reported the 
NBD1 pocket1 and pocket2, including the first one, Q493, N659, and Y577. The research 
group conceived their work been aware that data reported in the literature highlighted NBD1 
as a key anchoring point for CFTR modulators156. These findings suggested considering the 
related binding site as plausible even if an unwanted way to achieve corrector ability. 
Proceeding, with molecular docking calculations performed at the mutant protein model, 
showed VX-809 highly stabilized within the protein crevice via polar contacts with R552, 
K1060, and K1292. The acid moiety displayed salt-bridges with R552 and K1292, while the 
two oxygen atoms of the benzodioxole were H-bonded to K1060. In this conformation, VX-
809 exhibits a further H-bond with the carboxamide nitrogen atom and K1060. The terminal 
carboxy-substituted phenyl ring was projected to F494 and K1060, detecting cation- and − 
stacking while the pyridine ring was in − contact with W496. Ultimately, the cyclopropyl 





Fig.2.1.7. Selected docking pose of VX-809 (C atom; dark cyan) within the modeled F508del-CFTR. 
The analogs ALK-809 and SUL-809 mentioned above show a comparable positioning (Fig 
2.1.8). Their benzodioxole portion oriented towards a polar cavity delimited by E264, E267, 
N268, R552, K1292, V1293, and K1351, detects H-bonds with I1295 and V1293, respectively. 
The two correctors' central carboxamide moiety showed one H-bond with K1351 while the 
terminal one was H-bonded to L1062, W1063 and K1060, L1062, T1064, respectively. This 
positioning moved the bulkier and lipophilic groups of the modulators in the hydrophobic 






Fig.2.1.8. Selected docking posed of ALK-809 (C atom; magenta) and SUL-809 (C atom; yellow) 
within the modeled F508del-CFTR.  
Subsequently, to in-depth investigate the in-house hybrids series and other chemical series 
like tetrahydropyridopyrimidines and cyanoquinolines and their positions at the F508del-
CFTR NBD1 domain and both at the entire modeled protein, I performed molecular docking 
calculations (see Appendix A1-A3). 
 
Fig.2.1.9. Chemical structures and biological values of the examined series of F508del-CFTR 
correctors. 
At the first observations, it is thought that all of them share a positioning highly related to 
that previously discussed for VX-809 and its related analogs. Regarding the hybrids that do 
not have a substitution in position 5 of the thiazole ring, the presence of a p- substituted 
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phenyl ring tethered to position 4 of the main thiazole ring was privileged to the m-
substituted analogs, leading to compounds featuring higher potency values. On the other 
hand, the m-substitution was more effective when a methyl group or ester moieties decorate 
position 5 of the AAT. Furthermore, the concomitant substitution on positions 4 and 5 of the 
thiazole ring plays a beneficial role in terms of corrector activity157.  
Firstly, I analyze the binding mode of the in-house hybrid series on the NBD1 domain. Among 
the hybrids series, derivatives 2-4 proved to be the most potent; the derivatives 3-4 presented 
an ester moiety linked to position 5 of the thiazole, while the promising analog 2 (pEC50 = 
7.06) displayed a benzoyl group at the same position.  
In agreement with molecular docking calculations, all these compounds present the two 
oxygen atoms of the benzodioxole substituent H-bonded to K464 and T465, moving the 
carboxamide moiety to N659 detecting one H-bond.  
The 2 docking mode was in good agreement with VX-809 (POS2) and SUL-809 binding mode. 
(Fig.2.1.10). Indeed, the carboxamide moiety was in proximity of N659 detecting H-bonds. 
Simultaneously, the corrector's benzodioxole ring proved to mimic the POS2 of the prototype 
VX-809, displaying the same interactions, being the two oxygen atoms of the benzodioxole 
ring H-bonded to K464 and T465. The benzoyl and the phenyl ring of 2 showed the same 
hydrophobic interactions showed by the benzoic group of VX-809, including − stacking 
with Y577, while the oxygen atom of the benzoyl group interacts with the E656 sidechain, as 
described for the two reference compounds.  
 
Fig.2.1.10. Selected docking pose of compound 2 (C atom; pink) within the hNBD1 domain with 
VX-809 (C atom; dark cyan).  
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The presence of the quite flexible ester group tethered to position 5 of the thiazole core, in the 
case of 3 (pEC50 = 6.52) and 4 (pEC50 = 6.25) derivatives, result in a different position within 
the NBD1 domain on the concomitant m- or p- substituted phenyl ring connected to the 
position 4 of AAT. Indeed, 3 and 4 present an H-bond with Y577 sidechain or the E656 
backbone via the carbonyl group's oxygen atom, respectively. Based on the two correctors' 
high corrector ability, it is thought that H-bonding N659, K464, and T465 represents a critical 
anchor point for the correctors. At the same time, the interactions with E656 or Y577 residues 
could efficiently stabilize the compound at the protein domain.  
Then I performed molecular docking calculations of the hybrid compounds on the F508del-
CFTR model. The data derived from estimates highlighted important H-bonds between the 
oxygen atom of the benzodioxole group and K1060, the nitrogen atom of the carboxamide 
moiety and S495, and the ester oxygen atom and W1063 (Fig.2.1.11). In particular, the 
benzodioxole group interacts through cation- contacts and − stacking with R552 and F494, 
while the phenyl ring at position 4 of the thiazole showed − contacts with W496 and 
W1063. 
 
Fig.2.1.11. Selected docking pose of compound 2 (C atom; pink) within the modeled F508del-
CFTR. 
On the other hand, the ester group was projected towards C1344 and W1063, in agreement 




The introduction of a smaller group at position 5 of the thiazole, such as methyl group 
instead of the ester or carbonyl moiety, led to compounds 6-10 (pEC50 = 5.5-6.0) less potent 
than the previously cited analogs 2-5.  
Thus, they maintained the positioning previously described at the NBD1 domain, but they 
lost H-bonds with Y577. Within these less potent derivatives, compound 10 (pEC50 = 6.05) is 
the most interesting; it presents a p-F-phenyl ring and a methyl substituent at positions 4 and 
5 of the thiazole, respectively. These substitutions increased its hydrophobicity and allowed it 
to make − stacking and hydrophobic interactions that improve its corrector ability. In this 
context, the benzodioxole moiety maintains the same interactions assumed by the prototype 
VX-809, featuring H-bonds with T465, K464, while the carboxamide moiety is H-bonded with 
the N659 side chain. 
Regarding the binding mode assumed by the 6-10 derivatives within the entire CFTR model, 
they maintain the overall positioning so far discussed for the other derivatives but display 
different H-bonds involving I1295 and K1351 thanks to the benzodioxole and carboxamide 
oxygen atoms. In contrast, the main − stacking and van der Waals contacts were 
maintained. Indeed, the benzodioxole and the phenyl ring exhibited lipophilic contacts with 
F494, V1293, and W496, W1063, respectively. Notably, the overall positioning of 6 highly 
resembles ALK-809 but lacks H-bonds with L1062 and W1063.  
Leaving unsubstituted the position 5 of the thiazole core diminished the compounds' 
corrector ability, as shown for 11-13 (pEC50 = 5.08-5.53), featuring lower pEC50 values than the 
methyl-substituted analogs 6-8 (pEC50 = 5.53-5.72). 
Compound 11 was the most interesting because it shares a comparable position with its 
analog 6.  Despite this, the methyl group's presence is supposed to be related to the proper 
conformational and steric requirements that allow the corrector to bind NBD1, exhibiting the 
most effective overall shape. Conversely, the introduction of electron-withdrawing and 
hydrophobic substituents such as a halogen atom allowed the detection of hydrophobic 
interactions and − stacking with Y577 and several contacts with the surrounding 
residues S573, Q493, E656 at the NBD1 domain.  
At the same time, at the level of the entire CFTR model, these introductions led the 
compounds to detect hydrophobic interactions with W496, for example, observing the 
docking position of compound 7 compared to 6. This kind of substitution proved to be more 
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effective than halogens' replacement with other electron-withdrawing groups lacking 
hydrophobic properties, such as the carboxylic group of 20 (pEC50 = 5.30) and 21, with the 21 
the most promising (pEC50 = 5.53). Interestingly, the related docking pose was endowed with 
comparable contacts with those previously proposed for VX-809. Conversely, the presence of 
polar substituents with electron-donor properties such as the hydroxyl function improved the 
modulators' potency, as shown for 16-19 (pEC50 = 5.4-5.9). 
In particular, at the NBD1 domain, compound 16 (pEC50 = 5.74) was more effective than 17 
(pEC50 =5.64), thanks to additional H-bonds involving the hydroxyl group and E656.  
Simultaneously, their congeners 18-19 (pEC50 = 5.92-5-40) bearing the methyl group at 
position 5 of the thiazole maintained a comparable docking mode. While pointing attention to 
these derivatives' binding mode on the model CFTR, compound 18 was H-bonded to K1060, 
keeping all the other contacts exhibited by compound 6.   
Another series investigated concerning the tetrahydropyridopyrimidines 30-56 (pEC50 = 4.00-
6.70) that present variable substituents onto the positions 2 and 4 of the central core and at the 
nitrogen atom of the tetrahydropyrido portion. 
The most effective compounds feature a 2-pyridine substituent at position 2, while 
substitution with a 3-pyridine or 4-pyridine groups led to less potent compounds. 
In fact, the benzyl-6 substituted tetrahydropyridopyrimidines 31-33 (R3 = 2-pyridine; pEC50 = 
5.51-5.85) displayed higher potency than the related analogues 35-37 (R3 = 3-pyridine;pEC50 = 
4.00) and also then 39-40 (R3= 4-pyridine; pEC50 = 4.00).  
The presence of benzyl group in R1 without any substitution was similar both with a 
secondary (33, pEC50 = 5.51) and a tertiary (30, 32-34; pEC50= 5.55-5.82) amine group directly 
tied to position 4 of the tetrahydropyridopyrimidine ring as R2.  
On the contrary, in the presence of a 4-F or 4-methoxy-benzyl ring in R2, the presence of a 
secondary amine appears to be favored, as confirmed by the higher potency of 50,51 (R2= 
ethylamine-containing chain; pEC50 = 6.70) and 45 (pEC50 = 6.70), if equated to 42 (R2= 
piperazine-containing chain; pEC50= 4.00) and 41 (pEC50 = 4.00), respectively. 
Moreover, 41 and 42 were weakly active in relation to the unsubstituted analog 34 (pEC50 = 
5.82). The unsubstituted- benzyl-based derivatives can be further effective than analogs, 
including H-bonding functions in the para position. Therefore, the isostere 52 (pEC50 = 6.70) 
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displaying a thiophene ring exhibited much-elevated potency than the analog 34. With this, 
the introduction of branched or cyclic alkyl groups in R1, 53,54 (pEC50 = 6.52-6.70) supports 
hydrophobic groups' development tethering the position 6 of the 
tetrahydropyridopyrimidine core.  
The docking calculations of the mentioned compounds, 50,51 (pEC50 = 6.70), showed a 
comparable binding position within the NBD1 domain. In detail, the pyridine nitrogen atom 
was involved in one H-bond with T465, as the protonated nitrogen atom of the 
tetrahydropyrido group established polar contacts with S573. Both the nitrogen atoms of the 
R2 substituent were H-bonded to Q493. Lastly, the 4-F benzyl ring was projected near F575, 
V603, T604, and A655, detecting hydrophobic interactions and − stackings. Regarding the 
4-methoxy-benzyl derivatives, the most promising 45 (pEC50 = 6.70) presented two H-bonds 
with T604 and S505 via its methoxy group. Simultaneously, the nitrogen atom of the 
pyrimidine core was involved in polar contacts with T465 and K464. The imidazoyl group in 
R2 at the end of the aminoalkyl chain permitted to compound 45 to show additional H-bonds 
involving N659 (Fig.2.1.12).  
 
Fig.2.1.12. Selected docking poses of 45 (A) (C atom; purple) and  50 (B) (C atom; green) within the 
hNBD1 domain.  
These discoveries sustain the compound's highest potency regarding the analogs, 41, 44, 46, 
47 (pEC50 = 4.00-6.52), due to the amino-alkyl spacer, which showed the correct distance 
between the central core of the compound and the terminal H-bonding features. In contrast, 
the introduction of the strict linker in R2, for instance, a piperidine or piperazine-containing 
groups, guided to compounds 41, 43, 44, 46 (pEC50 = 4.00-6.40) that show a different docking 





Among them, 43,46 detected several contacts inside the same channel cavity, involving 
interactions with G461 and K464 through their methoxy group, keeping modest F508del-
CFTR corrector ability. Likewise, the two correctors formed via piperazine ring further 
interactions with S573. In compound 43, the hydroxyl group on the piperazine ring made an 
H-bond with N659, while compound 46 was H-bonded to the T604 residue.  Ultimately, for 
both compounds, the interactions of the piperidine moiety with the E656 sidechain remain 
stable. The only exception is characterized by compound 41 (pEC50 = 4.00) placed in a distinct 
crevice of the biological target, missing all the significant interactions so far discussed and 
preserving only one H-bond with N659. 
 The docking results obtained on the F508del-CFTR model show how the compound 43 was 
highly stabilized at the biological target due to salt-bridges, including the protonated 
piperazine and the hydroxyl moiety with D1341. The methoxy group's presence at the R1 
substituents guided the corrector near to V1293, featuring one H-bond, while the pyridine 
ring was engaged in − stacking with W496 and W1063. 
These findings support the highest potency of 45 and 50 bearing a flexible linker in R2, for 
most of the analogs designed with a rigid spacer, such as 41-44 and 46 and 47, with 45 and 50 
endowed with the proper distance between the main core of the compound and the terminal 
H-bonding features, which allowed us to interact with G1342 and V1293. The docking 
calculations on the F508del-CFTR model have been finding a common positioning for both 45 
and 50, as shown in Fig 2.1.13. In detail, the terminal amide and imidazoyl groups of 50 and 
45 were involved in one H-bond with V1293, resembling the same contacts previously 
mentioned for SUL-809. The nitrogen atom of the secondary amine was H-bonded to G1342, 
while the protonated nitrogen atom of the tetrahydropyrido moiety was engaged in a salt-
bridge with D1341. While the R1 substituent of both correctors was employed in polar 




Fig.2.1.13. Selected docking poses of 45 (C atom; purple) and 50 (C atom; green) within the 
modeled F508del-CFTR. 
Along with the unsubstituted benzyl-based derivatives, at the NBD1 domain, compound 31 
(pEC50 = 5.85) was engaged in one H-bond between the nitrogen atom of the 
tetrahydropyrido moiety and the N659 sidechain. Simultaneously, the pyridine ring was 
involved in polar contacts with G461 and K464. The oxygen atom of the amide function 
experienced on H-bond with Y577 and the benzyl moiety was oriented to the F875, A655, 
S576, T604, and G576 residues, finding hydrophobic and − interactions. The same contacts 
were also held by compound 34 (pEC50 = 5.82). Introducing a more flexible linker in position 4 
of the main bicyclic core reduced the corrector ability (33; pEC50= 5.51). This substituent led 
the corrector's main core in a different region of the NBD1 domain, missing the 
aforementioned key contacts with the biological target. 
 
Cyanoquinolines derivatives (57-80; pEC50 = 4.00-5.82) consist of different compounds 
containing the main bicyclic core tethered to a terminal (hetero)aryl-containing amide group 
by a flexible or rigid spacer. In particular, cyanoquinolines 57-68 (pEC50 = 4.00-5.82) and 69-74 
(pEC50 = 4.00-5.52) show the diaminoethyl- and the diaminopropyl-chains, while 
cyanoquinolines 75-80 (pEC50 = 4.00) exhibited a piperazine linker. Within these compounds, 
the existence of an H-bonding function at the para position of the terminal (hetero)aryl ring 
led to several most active compounds (59, 64, 65, 67; pEC50 = 5.38-5.82). Though 59, 64, and 65 
exhibited a benzamide portion in R, compound 67 was characterized by the picolinamide 
group (pEC50 = 5.57).  
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According to our docking calculations at the NBD1 domain, these compounds preserved a 
comparable docking positioning, being the linker's carboxamide in H-bonds with S573 and 
N659. At the same time, the methoxy group on the terminal aromatic group shifted in 
proximity to T465, G461, and K464, detecting H-bonds. The docking positioning associated 
with compound 59 (pEC50 = 5.52) underlined several H-bonds, including the N659-side chain 
and G461 and K464, through the methoxy group. The flexible spacer permitted the 
compound to be well-suited in the domain pocket, finding hydrophobic contacts with the 
surrounding Y577 and A655. Compound 67 occupied the channel crevice placing the 
quinoline core towards Y577, A655, G576, being H-bonded to the backbone of E656 residue 
(Fig.2.1.14). In this way, the compound displayed a similar positioning to that previously 
reported for the reference compound VX809. Indeed, the amide group was involved in H-
bond with S573 and N659, while the methoxy group behaves like a hydrogen acceptor 
function to T465. These conclusions were in good agreement with the higher potency trend 
noticed for the 4-substituted 59 and 67 compared to the unsubstituted 63 and 60 (pEC50 = 
4.00), respectively. 
 
Fig.2.1.14. Selected docking poses of 59 (C atom; cyan) and 67 (C atom; yellow) within hNBD1. 
While moving the 4-methoxy substituent onto the ortho position of the (hetero)aryl group led 
to the modest corrector 58 (pEC50 = 4.96), the 3,4-dimethoxy benzamide-based analog 65 
(pEC50 = 5.82) proved to be the most potent within this series. Compound 65 was H-bonded to 
G461, K464, and T465 thanks to the dimethoxy-substituted phenyl ring, while the 
carboxamide moiety exhibited two H-bonds with S573 and N659. The cyanoquinoline main 
core was projected towards Y577, featuring − interactions. Therefore, the overall 
positioning of the derivative assures a comparable docking mode with that previously 
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discussed for the reference compound VX-809 as well as for the other chemotypes acting as 
CFTR correctors. 
The unsubstituted pyridine-containing analogs 60-62 (pEC50 = 4.00-5.57) experienced a 
relatively similar positioning related to their previously described congeners but missing key 
interactions with N659 at the expense of corrector ability. The introduction of the 1,3-diamino 
propyl tether guided to the methoxy substituted benzamide-based compounds 49-51 (pEC50 = 
4.0-5.37) pyridine-containing 52-54 (pEC50 = 4.00-5.52), which proved to be less potent than 
the previously mentioned analogs carrying the diaminoethyl chain.  Indeed, 69-71 and 72-74 
featured lower pEC50 values if compared to 57-59 (pEC50 = 4.96-5.66) and to 61-63 (pEC50 = 
4.00-5.57). Among them, compound 73 (pEC50 = 5.52), featuring the nicotinamide portion as a 
terminal substituent, was placed within a specific crevice of the channel interacting with key 
residues involved in the corrector binding. The quinoline core's nitrogen atom was engaged 
in H-bonds with K464 and G461, while the cyano group detected polar contacts with N659.  
The nitrogen atom of the secondary amine group and the carboxamide function displayed 
contacts with S459 and T604. 
Finally, the nicotinamide ring was correctly projected towards F575, S605, V603, N659, and 
A655. Choosing a rigid spacer tethering the bicyclic main core with the terminal aromatic ring 
deeply impaired the compounds' corrector ability, as shown by 75-80 (pEC50 = 4.00), being 
folded within the NBD1 domain and maintaining only interactions with E565 through the 
nitrile function.  
At the whole protein, docking results highlighted the two derivatives' common positioning, 
with the CN-group H-bonded to L1062 and W1063, while the two nitrogen atoms of the 
linker were involved in H-bonds with K1060 and D1341. This type of positioning ensures the 
appropriately hydrophobic contacts and − stacking with C1344 and W1063, F494, W496. 
Remarkably, the methoxy group of the R substituent was engaged in contact with I177. These 
results are in good agreement with the higher potency trend observed for the 4-substituted 59 
and 67 if compared to the unsubstituted 63 and 60 (pEC50 = 4.00), respectively. The 4-methoxy 
substituent's presence on the ortho-position led to modest corrector 58 (pEC50 = 4.96), while 
the 3,4-dimethoxy benzamide-based analog 65 (pEC50 = 5.82) is the most potent within this 





Fig.2.1.15. Selected docking poses of 59 (C atom; cyan) and 67 (C atom; yellow) within the 
modeled F508del-CFTR.  
 The most promising 73 (pEC50 = 5.52) highly imitated the docking mode of 65 with assured 
key contacts between the CN- and the spacer nitrogen atoms with L1062, W1063 with K1060, 
D1341, respectively.  Also, the nicotinamide portion as terminal substituent was H-bonded to 
I177.  
2.1.2 Discussion  
In this study, I performed two series of molecular docking calculations regarding different 
chemotypes of F508del-CFTR correctors. Plausibly, based on the mean value of the docking 
scores (Score mean) derived by the two approaches, VX-809 and related analogues (1-29; 
NBD1 Score mean = -21.04; modelled CFTR Score mean = -23.54) 
tetrahydropyridopyrimidines (30-56; NBD1 Score mean = -17.60; modelled CFTR score mean 
= -26.67) and cyanoquinolines (57-80; NBD1 Score mean = -18.64; modelled CFTR Score mean 
= -25.56) were predicted to bind at the NBD1:ICL4 interface. These findings indicate that 
docking calculations at the modeled F508del-CFTR are more helpful in investigating the 
putative mechanism of action of CFTR correctors compared to visual examination centered at 
the only NBD1 domain.  
Molecular docking results revealed a common positioning featured by the F508del-CFTR 
corrector VX-809, which is the most applied and investigated drug for treating cystic fibrosis. 
Regarding the molecular docking result of VX-809 at the modeled CFTR, two salt-bridges, 
including R552, K1292, and H-bonding to K1060, resulted in support of the mechanism of 
action of this corrector. The well-known corrector is further stabilized at the NBD1-ICL4 
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interface by − stacking and van der Waals contacts with F494, W496, and W1063. 
Moreover, calculations performed onto the analogs ALK-809 and SUL-809 revealed one H-
bond with K1351 and further H-bonds to L1062, W1063 K1060, W1064, respectively. This kind 
of positioning allowed arranging the hydrophobic terminal chains of the two correctors in the 
hydrophobic cavity delimited by W496, L1059, L1063, C1344, and L1346. 
Along with this, similar results were achieved for hybrids 2-29 (pEC50 = 5.08-7.06) and other 
chemotypes endowed with CFTR corrector ability, such as tetrahydropyridopyrimidines 30-
56 (pEC50 = 4.00-6.70) and cyanoquinolines 57-80 (pEC50 = 4.00-5.82). 
On the whole, mandatory interactions are experienced by all the correctors, suggesting a 
pivotal role played by proper polar features within the chemical structure of the molecule. 
Tetrahydropyridopyrimidines were able to detect most of the key contacts showed by SUL-
809. Furthermore, these derivatives show additional contacts between the protonated 
nitrogen atom of the tetrahydropyrido moiety and D1341. The cyanoquinolines correctors 
experienced the aforementioned key contacts thanks to the main scaffold's CN- group, 
exhibiting H-bonds with L1062 and W1063. Simultaneously, the two nitrogen atoms of the 
spacer were engaged in H-bonds with K1060 and D1341.  
2.1.3 Material and methods 
The compounds 1–80 were manually built through the “MOE Builder” software and then 
were parameterized with AM1 partial charges as the calculation method. The energy 
minimization was made through the “Energy Minimize Program” using MMFF94x 
forcefield, and RMS (= root mean square) equal to 0.0001 Kcal/mol/A
2 of the MOE compute 
module to create a single low-energy conformation for every ligand. Molecular docking of all 
the analyzed compounds was performed on the crystallographic structures of the NBD1 
domain of the F508del-CFTR (PDB code: 4WZ6)154, which was prepared through the 
“Structure Preparation” program of the Molecular Operating Environment158, and on the in-
house model of F508del-CFTR protein. This model was “built” based on the 
superimposition of the whole protein (PDB code: 6MSM)153 obtained by cryoelectron 
microscopy, with that of the mutated NBD1 domain (PDB code: 4WZ6)154. The modeled 




Molecular docking studies on VX-809 and related analogs were performed considering the 
putative binding site proposed by the site finder module implemented in the MOE 
software. 
Site Finder aims to calculate possible active sites in a receptor from the receptor's 3D atomic 
coordinates. MOE’s Site Finder falls into geometric methods, considering the relative 
positions and accessibility of the receptor atoms based on a rough classification of chemical 
type. The Site Finder methodology works on the Alpha Shapes represented by convex hulls 
developed and described in the literature 159. This software module identifies tight atomic 
packing regions to filter out sites that are “too exposed” to solvent. This approach allows 
removing protrusions that are unlikely to be good active sites. 
The derived preliminary sites are then classified based on their hydrophobic or 
hydrophilic profile. This primary classification of chemical type is used to split water sites 
from the more likely hydrophobic sites. The generation of alpha spheres on these sites is made 
by collecting sets of points using a modified Delaunay triangulation method to derive different 
spheres displaying different radii. The collection of alpha spheres is pruned by eliminating 
those that correspond to the receptor's inaccessible regions and those exposed to solvent. 
A d d i t i o n a l l y , only the small alpha spheres are retained since they correspond to tight 
atomic packing locations in the receptor. 
Then, alpha spheres are classified as either “hydrophobic” or “hydrophilic,” depending on 
whether the sphere is in the right hydrogen bonding spot in the receptor. 
Clustering the alpha spheres using a double-linkage clustering algorithm leads to a 
collection of sites where each site consists of one or more alpha spheres, at least one of which 
is hydrophobic. All the collected sites are ranked according to their Propensity for Ligand 
Binding (PLB) score, which is based on the pocket's amino acid composition as described in 
the literature160. 
I consider the best-ranked site by Site Finder for the following molecular docking 
calculations in these studies. Then, I performed docking calculations using LeadIT 2.1.8 
software suite (www.biosolveit.com) starting from the hNBD1-VX-809 complex previously 
derived from automatic docking with MOE software. The docking algorithm is a state-of-
the-art fragment docker: Ligands are divided into fragments, and an initial fragment is 
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placed into several sites in the pocket and scored applying a rapid pre-scoring scheme. The 
ligand is built from the n solutions set, fragment by fragment, and the temporary solutions 
are scored against each other. The best scored passes the analysis and is delivered to the 
user. The preliminary idea correlates to the FlexX algorithm, but many advancements have 
been made over the years, such as the “Single Interaction Scan” (SIS) placement that 
discovers solutions when there are very few polar groups in a compound. The SIS algorithm 
utilizes virtual lines between protein and ligand interaction spots. It is trimmed for a high-
speed rotation around these lines, generating solutions quickly for more hydrophobic 
character ligands. The final docking poses were highlighted by the score values of the lowest 
energy pose of the compounds docked to the protein structure. All ligands were refined and 
rescored by assessment with HYDE, included in the LeadIT 2.1.8 software. The HYDE 
module considers dehydration enthalpy and hydrogen bonding 161. Briefly, HYDE was 
formulated to reflect the experimentally observed binding contributions due to hydrogen 
bonding and the hydrophobic effect in a very accurate way. HYDE works on new terms for 
the dehydration of idealized polar and nonpolar functional groups. It provides a simple 
explanation for inter-molecular interaction's main characteristics in aqueous solution, 
including the hydrophobic effect, dehydration penalties, and hydrogen bonding. Because the 
hydrophobic effects are quantitatively described as the free dehydration enthalpy of a 
nonpolar function, the noncovalent contributions to intermolecular interactions in aqueous 
solutions and ∆Gbinding can be calculated by considering only two main terms: (i) the 
dehydration of the interacting molecular interfaces, ∆Gdehydration, and (ii) the vacuum hydrogen 
bond energies between interacting hydrogen bond functions.   
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2.2 Molecular docking studies of potentiators as modulators of F508del-CFTR 
For the studies of the binding mode of F508del-CFTR potentiators, I take into account 
different series of modulators, with variable chemotypes and potency, to explore the key 
features turning in more effective potentiators (A7-11)162. 
 
Fig.2.2.1. Chemical structures and biological values of the examined series of F508del-CFTR 
potentiators. 
I considered the X-ray crystallographic structure of VX-770 in complex with CFTR (PDB code 
= 6O2P, resolution = 3.30 Å)163 as well as of GLPG1837 (PDB code = 6O1V, resolution = 3.20 Å) 
163.In particular, VX-770 was deeply investigated in the literature, enhancing the open 
probability (Po) of wild-type (WT) and mutant CFTRs in membrane patches, proteoliposomes 
planar lipid bilayers. Because the potentiation by VX-770 necessitates phosphorylation of 
CFTR by protein kinase A (PKA) being independent of ATP, it is believed that this 
potentiator might directly target CFTR.  Not long ago, the new potentiator GLPG1837 has 
been discovered to display better efficacy than VX-770. Indeed, when the ATP concentration 
is saturated, the Po of phosphorylated WT- CFTR has risen from 0.23 to 0.54 upon the 
addition of 10 µM GLPG1837. 
Therefore, I proceed to perform a re-docking of the co-crystallized ligands to evaluate the 
molecular docking protocol's reliability to be used in the subsequent modeling studies of the 
potentiators series. Both the two potentiators were adequately predicted within the CFTR 
channel, being the selected docking poses in good accordance with the experimental data 
(VX-770-RMSD = 0.8352 Å). Evaluating the two proteins, VX-770 and GLPG1837 occupied the 
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same channel crevice as the CFTR's backbone highly overlapped (RMSD = 0.182 Å) (Fig.2.2.2). 
The two potentiators were involved in − stacking with F931 and F312 through their main 
bicyclic core and their hydrophobic substituents; at the same time, the carboxamide moiety 
was H-bonded to Y304 and S308.  
 
Fig.2.2.2. Superimposition of X-ray crystallographic data of hCFTR complexed with VX-770 (PDB 
code = 6O2P) (C atom; green) (helix; blue) and hCFTR complexed with GLPG1837 (PDB code = 
6O1V)(C atom; orange) (helix; yellow).  
These computational studies have been done contemplating the experimental data 
concerning VX-770, selected as a reference potentiator, being one of the CFTR modulators 
used in therapy. The obtained CFTR-VX-770 complex was refined by energy minimization 
within the MOE software's OPLs force field 158.  
The quinoline ring of VX-770 is stabilized in a hydrophobic pocket surrounded by F236, Y304, 
F305, S308, A309, and F312, making numerous − stacking and van der Waals interactions. 
Furthermore, the potentiator's carboxamide moiety was H-bonded to F931. The potentiator's 
hydroxyl group displayed one H-bond with R933. At the same time, the tert-butyl 
substituents and the phenolic ring were projected in the direction of F931 and F932, forming 
hydrophobic contacts. The most relevant binding conditions discovered within the collected 
potentiator's database were suggested based on evaluating the obtained docking pose with 




Fig.2.2.3. Selected docking pose of VX-770 (C atom; orange) within hCFTR. 
Adopting this method, I investigated the most effective chemotypes that imitate the bioactive 
conformation and interactions experienced by the reference potentiators VX-770 (pEC50 = 
6.63). 
The GLPG1837 analogs (1-26; pEC50 = 6.10-9.26) involving thiophene-based compounds 
represent the most active potentiators within the CFTR modulators series examined.  
Most of them assume the same docking positioning within the CFTR channel, featuring key 
contacts with F931, such as earlier described for VX770. Overall, compounds showing the 
5,5,7,7-tetramethyl-4H-thieno[2,3-c] pyran scaffold (6-26; pEC50 = 6.33-9.26) displayed higher 
potency than the analogs with less hydrophobic bicyclic cores, as well as 1-4 (pEC50 = 6.10-
7.88). Among the 5-carboxamide pyrazole-containing analogs 10-12, 22-26 (pEC50 = 6.86-8.69), 
compound 11 (pEC50 = 8.52) exhibited two H-bonds between the two oxygen atoms of the 
carbonyl moieties and the F931 backbone together with polar contacts with S308 and − 
stacking including the same residue F931 and F932 and the pyrazole substituent (fig 2.2.4). 
Additionally, the pyrazole substituent and the potentiator primary amide group were H-
bonded to the R933 and Y304 sidechain. At the same time, the thienopyran-based core was 
projected towards F236, F305, and F312, detecting − stacking and van der Waals contacts, 
comparably to VX770. Therefore, whereas the thienopyrane ring was bioisosteres of the 
quinoline ring of VX-770, the presence of the carboxamide moieties and the pyrazole ring 
allowed 11 to improve the stability at the biological target, making 11 (pEC50 = 8.52) more 



















Fig.2.2.4. Selected docking poses of 11 (C atom; cyan) and VX-770 within hCFTR. 
This type of positioning was well retained by most docking poses collected for those analogs 
featuring a CH3 or a Cl- substituent on position 3 of the pyrazole 22-23 (pEC50 = 8.69), then 
exhibiting comparable potency values to compound 11. On the contrary, the docking poses 
analyzed for the 3-substituted pyrazole containing (25-26; pEC50 = 7.88-8.52) derivatives 
missing any H-bond with R933, generating lower pEC50 values than the 4-substituted analogs 
(22-23; pEC50 = 8.69). The introduction of a 4-carboxamide- as a substitute of a 5-carboxamide-
pyrazole substituent tethered to the main bicyclic moiety, such as 10 (pEC50 = 6.90) compared 
to 11 (pEC50 = 8.52) or the introduction of methylene tethered to the pyrazole core to the 
amide moiety of the potentiator, (see 12 (pEC50 = 6.86)) reduced the potency profile of the 
derivatives. This decrease in potency was influenced by the absence of any H-bonds with 
R933 for all the related docking poses. 
Selecting a triazole moiety as a replacement for the pyrazole led to compound 9 (pEC50 = 
6.33), exhibiting two H-bonds via the carbonyl oxygen atoms to the F931 sidechain. At the 
same time, the primary amide group detected one H-bond with Y304. Remarkably, the 
triazole ring proved to simulate the hydroxyl group of the reference potentiator VX-770 but 
presents a limited number of hydrophobic interactions within the protein cavity. The triazole 
ring also proved to mimic the behavior of 10 and 12, displaying comparable potency levels. 
Moving from the aforementioned five-membered ring derivatives (9-14; 22-26; pEC50 = 6.33-
8.69) to the six-membered ones (4-8; pEC50 = 6.72-8.39), permitted the conservation of the 



















key contacts with F931 and Y304. Even if they cannot interact with R933, these potentiators 
were effectively stabilized within the biological target thanks to cation- contacts with the 
same residue.  
On the contrary, the pyridine analog 7 (pEC50 = 6.72) or the sulfone amide-substituted 
benzoyl derivatives 8 (pEC50 = 6.83) were characterized by a lower potency than that of 
prototype 6 (pEC50 = 8.39), perhaps for the absence of any contacts with R933 as well as with 
F932. 
The importance of an H-bond donor group decorating the benzoyl moiety linked to the 
carboxamide functions was determined by the adequate potentiator ability, as exhibited by 
those derivatives bearing an alcohol group 15-21 (pEC50 = 6.89-9.26), sometimes showing 
comparable interactions with those indicated for VX-770 and the analog 11. 
The compound 20 (S enantiomer) (pEC50 = 8.56) exhibited one H-bond between the hydroxyl 
group and the R933 side chain imitating the role played by the VX-770 hydroxyl group or by 
the pyrazole group of 11 (Fig.2.2.5), while the 19 (R enantiomer) (pEC50 = 6.89) not show this 
contact. Concerning the compound 21 racemic mixture (pEC50 = 9.26), the S enantiomer was 
expected to be more effective than the R enantiomer, providing H-bonds with R933, S308, 
Y304, F932 via the alkoxy group and the two carboxamide moieties. The high number of 
interactions with the biological target guarantees a high potency level, 21 more effective than 
11.  
 



















The deletion of any H-bond donor group from the amide group tied to the main bicyclic core 
complemented by less hydrophobic R substituents led to compounds 1-3 (pEC50 = 6.10-6.18), 
displaying a thiophene ring with loss of potency as F508del-CFTR potentiator. Compound 3 
only mimics the positioning of VX-770, is characterized by a limited number of hydrophobic 
contacts and H-bonds with F931 and F932. 
The second class evaluated involves cyanoquinoline-containing derivatives.  
All these compounds show a low potency profile as F508del-CFTR potentiator compared to 
the first-class discussed above. Specifically, compounds 27-56 (pEC50 = 4.25-5.92) include 
cyanoquinoline-containing derivatives, exhibiting a moderate potency as F508del-CFTR 
potentiators if compared to the above-mentioned series of thienopyran -based compounds (1-
26; pEC50 = 6.10-9.26). Following the molecular docking calculations, this potency range might 
be clarified through the ability of cyanoquinolines to interact only with F931 and sometimes 
with R933, missing any contacts with S308 or Y304. Certainly, the most potent 
cyanoquinolines 29,33-56 (pEC50 = 4.25-5.92) bore a 5,7-dimehtylquinoline-3-carbonitrile main 
core,  being more effective than the analogs characterized by a monomethyl-substituted 
quinoline ring, such as analogue 27 (pEC50 = 4.82) and the 6-methylquinoline-3-carbonitrile 
derivative 28 (pEC50 = 4.82). Nevertheless, the potentiator potency trend modestly improved 
with the 6-methoxyquinoline-3-carbonitrile ring, as shown by 30-32 (pEC50 = 4.95-5.33). The 
computational study derived that the compounds 30-32 displayed a relative positioning 
moving the benzoyl moiety towards L233, F236, and A309 and the main cyanoquinoline core 
near F305, F312 detecting − stacking. The 32 methoxy group's oxygen atom was H-bonded 
to F931 backbone nitrogen atom, while the piperazine tying the main core with the benzoyl 
substituent was involved in van der Waals contacts with F236. 
The presence of a rigid linker between the bicyclic core and the terminal aromatic ring 
permitted to derive effective derivatives even within the 5,7-dimethylquinoline-3-
carbonitrile-containing cyanoquinolines, as confirmed by the promising potency values of the 
methoxybenzoyl substituted 45-47 (pEC50 = 5.88-6.00). 
The piperazine ring of the potentiator 45 moved the terminal benzoyl group in the proximity 
of R933, detecting H-bonds and cation- contacts. The piperazine ring shows many 
hydrophobic contacts in agreement with that displayed for the reference compound VX-770. 
In contrast, the nitrogen atom of the quinoline ring exhibits H-bonds with the key residues 
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F931. The 5,7-dimethylquinoline main core relatively imitated the hydrophobic contacts and 
− stacking featured by the VX-770 quinoline core, while the nitrogen atom of the bicyclic 
core of the potentiator 45 was correctly H-bonded to the F931 backbone. Hence, the potency 
profile shown for 45 (pEC50 = 6.00) was quite lower than that of VX-770 (pEC50 = 6.63) 
(Fig.2.2.6). 
 
Fig.2.2.6. Selected docking poses of 45 (C atom: magenta) with VX-770 (C atom; orange) within 
hCFTR. 
On the contrary, the isosteric substitution on the benzoyl group with a pyridine ring impaired 
the potency within the piperazine-containing 5,7-dimethyl-3-carbonitrile cyanoquinolines, 
missing the contacts mentioned above, as confirmed by the lower pEC50 of 48 (pEC50 = 5.13) 
and by inactive analogs 49-51. 
The significance of the methoxy benzoyl substituents, perhaps in terms of balanced 
hydrophobic-hydrophilic properties and of the related ligand positioning, is confirmed 
within the cyanoquinolines bearing the 1,2-ethylendiamine 33-35 (pEC50 = 5.22-5.63), being 
more 33-35 more potent than the unsubstituted benzoyl congener 39 (pEC50 = 5.00) and the 
dimethoxy benzoyl substituted analogs 40,41, 44 (pEC50 = 4.25-4.93). 
The flexibility of the spacer of 34 allowed the benzoyl group to make one H-bond with R933; 
the nitrogen atom of the quinoline core was H-bonded to F931. This type of positioning 
ensures the same contacts for 45 and 34 at the CFTR protein, except for cation- contacts 


















potentiator. Interestingly, the substitution of the benzoyl moiety with the 2-carboxamide 
pyridine ring led to the optimized derivative 36 (pEC50 = 5.92), making one H-bond between 
the quinoline nitrogen atom and F931 and further contacts with Y304 and F305. The other 
pyridine-based analogs 37 and 38 (pEC50 = 4.87-5.00) exhibited a similar positioning even with 
a loss of potency. 
The extension of the linker employing the introduction of the 1,3-propylendiammine chain 
allowed the yield of potentiators 51-53 (pEC50 = 4.55-5.33), decorated with a methoxybenzoyl 
ring which presented an adequate F508del-CFTR potentiator potency, whereas the related 
pyridine analogs 54-56 (pEC50 = 4.79-5.21) were in some way endowed with lower pEC50 
values. Within these compounds, the docking mode of 53 (pEC50 = 5.30) was comparable with 
that described for 34 (pEC50 = 5.63), hence exhibits similar potency. Compound 53 was H-
bonded to the R933 side chain while the quinoline nitrogen atom to F931. Several − 
stacking, including the Y304, F305, and F312, were detected by the quinoline mentioned 
above the core. 
An additional series of F508del-CFTR potentiators that I considered comprises the 
tetrahydropyridoindole-based compounds (57-69; pEC50 = 4.52-5.69), that were endowed with 
lower pEC50 values than the GLPG analogs (1-26; pEC50 = 6.10-9.26) and with comparable 
potency to cyanoquinoline derivatives (33-56; pEC50 = 4.25-5.92). 
Along with them, the benzyl-substituted derivatives 57-59 (pEC50 = 5.00-5.69) and 61-63 
(pEC50 = 4.52-4.88) were more potent than 64-69 (pEC50 = 4.52), featuring benzoyl rings or 
other alkyl-based substituent onto the indole portion. Consequently, the related docking 
poses allowed the enlightenment of the main role of a quite flexible aromatic group tethered 
to the basic nitrogen atom as R1 substituent, which is the potentiator engaged in hydrophobic 
contacts and  − stacking with F236, Y304, F305, A309. 
Additionally, in the most promising compound 58, its protonated nitrogen atom showed 
cation- interaction with F931, having a key role in stabilizing the ligand at the CFTR channel, 
while the methoxy group in R3 was H-bonded to R933. Therefore, the 2,4-di-F derivatives 58 
(pEC50 = 5.69) and 59 (pEC50 = 5.58) display similar docking poses and higher potency values 
than their mono-substituted analog 57 (pEC50 = 5.00) or the isostere 60 (pEC50 = 5.29), having a 
thiazole ring as a substitute of the benzyl ring (Fig.2.2.7). The studied positioning of the 
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analog 57 (pEC50 = 5.00) disclosed only one H-bond involving the methoxy group at the R1 
substituent and R933 while no cation- stackings were detected. 
 
Fig.2.2.7. Selected docking pose of compound 58 (C atom; blue) and compound 59 (C atom; green) 
within hCFTR. 
Eliminating any halogen atom from the benzyl moiety and also the methoxy group on the 
indole core led to the modest potentiator 61-63 (pEC50 = 4.79-4.88), perhaps for the limited 
number of hydrophobic contacts and polar interactions with the aforementioned key 
residues, especially lacking H-bonds with R933. The insertion of an additional H-bonding 
acceptor group as the carbonyl moiety in place of the benzyl group in compounds 65-67 
(pEC50 = < 4.52) quite reduced the efficacy of the potentiators.  
The compounds 64 and 67 maintained one H-bond with R933 using the methoxy group, but 
the R1 substituent was unable to exhibit cation- contacts with F931.  
As regard compound 64, the cyclohexyl group in R1 impaired π-π stacking with the 
surrounding aromatic residues.  
About the series of pyrazolo-quinolines 70-80 (pEC50 = 4.52-6.52), the presence of lipophilic 
and electron-withdrawing groups at positions 2 and 4 of the aromatic ring (R3 substituent) 
led to potent derivatives 74 (pEC50 = 5.61) and 78 (pEC50 = 5.76), by correctly increasing the 
hydrophobic contacts with the biological target.  
Compound 74 was able to mimic the tert-butyl motifs decorating the terminal phenyl ring of 



















In this way, many Van der Waals contacts were detected, stabilizing the ligand at the protein 
channel.  
Interestingly, the two nitrogen atoms of the 74 tricyclic core demonstrated to be adequately 
superposed on the two oxygen atoms of the reference compound, being one of them H-
bonded to the F931 backbone. Also, the primary amine group exhibited H-bonds with Y304 
and S308 (Fig2.2.8). 
 
Fig.2.2.8. Selected docking pose of 74 (C atom; magenta) and VX-770 (C atom; orange) within 
hCFTR. 
 The compound 78 could mimic the carboxamide-substituted quinolone-based ring of VX-770 
and, thanks to the primary amine group, detects H-bonds with S308 and M929. The pyrazole 
portion of the tricyclic core of 78 and the nitro group was H-bonded to F931 and R933, 
respectively. The − stackings were maintained, such as with F236, Y304, F305, and other 
ones with F312, while the cation- contacts with R933 and Van der Waals interactions with 
A309, F312 were weaker or lacking.  
These data agreed with the quite lower potency experienced by 78 (pEC50 = 5.61) if compared 



















Accordingly, 74 and 78 proved to be more potent than those analogs featuring polar groups 
or electron-donor moieties in R3 such as 71 (R3 = 4-pyridine; pEC50 = 4.52), 73 (R3 = 3,4,5-
methoxyphenyl; pEC50 = 4.52), and 75 (R3 = 3-methyl 4-nitrophenyl; pEC50 = 4.52).  
The consistency of these computational data is also in agreement with the higher potency 
values exhibited by compound 80 (pEC50 = 6.52), bearing a bulky, aromatic, and hydrophobic 
portion interacting with R933, a key residue for the potentiator binding, as well as the high 
number of interactions involving the R3 substituent and Y304, F305, A309, F312, F316.   
The aminoarylthiazoles derivatives (AATs) represent the last examined series herein 
investigated. Specifically, I consider compounds 81-90 (pEC50 = 4.14-5.71), featuring F508del-
CFTR potentiator ability, that our research group recently reported and discussed 164,165. 
The insertion of a 4-substituted phenyl ring at position 4 of the thiazole ring or a bicyclic ring 
led to the most promising compounds (82, 89-90; pEC50 = 4.56-5.71) to 3-substituted derivative 
83 (pEC50 = 4.27).  
Compound 82 (pEC50 = 4.56) oriented the 4-F-phenyl group in the proximity of the tert-butyl 
portion of VX-770, detecting the same hydrophobic contacts with F931 and F932.  
The main thiazole core was a bioisostere of the VX-770 carboxamide function while the 
aminoaryl moiety of 82, exhibiting the lipophilic thiomethyl substituent, overlapped onto the 
quinolone group of VX-770. This arrangement allowed the compound to involve Van der 
Waals contacts and π-π stacking with F236, F305, and F312. More interestingly, this type of 
positioning assures H-bond to the F931 backbone and Y304 sidechain through the thiazole 
nitrogen atom and the amine group, respectively.  
A 4–CN group as a replacement for the 4-F substituent onto the terminal phenyl ring quite 
switched the docking mode maintaining π-π stacking with F931 and one H-bond with S308 
through the amine group. This was in agreement with the lower potency of 81 (pEC50 = 4.46) 
in comparison to 82 (pEC50 = 4.56).  
The benzoxazolone ring at position 4 of the thiazole ring led to the most potent AAT 
potentiator 84 (pEC50 = 5.19), characterized by the key H-bond with the R933 side chain and 
the oxygen atom of the carbamate portion.  
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This kind of positioning allowed the compound to involve a higher number of hydrophobic 
contacts, with CFTR being the nitrogen atom of the carbamate moiety H-bonded to F305. On 
the other hand, the thiazole ring interacts with the F931 backbone through its nitrogen atom 
while the thiomethyl group mimics the tert-butyl substituents onto the prototype VX-770 also 
involved in hydrophobic interactions with F931 and F932 (Fig 2.2.9) 
 
Fig.2.2.9 Selected docking poses of 84 (C atom; green) and VX-770 (C atom; orange) within 
hCFTR. 
 
The most promising derivative 89 (pEC50 = 5.71) exhibited a comparable docking mode if 
compared to 84, being endowed with higher hydrophobic contacts played by the indolinone 
moiety with respect to the benzoxazolone one of the congener 84.  This binding mode 
allowed mimicking the tert-butyl portion of VX-770 better. 
The replacement of the phenyl ring at position 4 of the thiazole of 81-83 (pEC50 = 4.27-4.56) 
with a five-membered ring, such as 86-88 (pEC50 = 4.23-5.00) left unvaried the potentiator 
binding ability, which showed comparable docking mode and potency trend.  
Among them, compound 86 (pEC50 = 5.00) experienced two H-bonds with F931 and Y304 




















 A preliminary visual inspection of the X-ray crystallographic data reported by Liu et al. 21 
suggested a high number of hydrophobic contacts and Van der Waals interactions and − 
stacking with residues F236, Y304, F305, S308, A309, and F312 together with H-bonds to S308 
and F931. The quinolone moiety of VX-770 detected these interactions as well as the most 
promising series of potentiators previously discussed. This binding mode could allow the 
potentiator to assume an adequate arrangement within the channel crevice. The subsequent 
refined docking calculations highlight H-bonds' key role with Y304, F305, and R933 residues, 
detecting with the last residue not only H-bonds but also cation- contacts. It is thought that 
the potentiator is stabilized within the protein cavity need of hydrophobic contacts or − 
stacking and additional polar interactions involving Y304, S308, and F305. 
Mainly, H-bonds with F931, R933, S308, and Y304 led to derivatives exhibiting higher 
potency as CFTR potentiators, as illustrated for most of the GPLG1837 analogs (series 1-26). 
The other series of potentiators presented many of these contacts showing a variable potency 
ability.  
To validate the whole computational approach applied, I proceeded by choosing from the 
literature and evaluating in silico compounds 91-139 (see Appendix A12-A14); only five are 
modest CFTR potentiators while the other ones proved to be completely inactive.  
These compounds have been examined through molecular docking calculations applying the 
same docking protocol previously discussed for the potentiators 1-90.  
Conformity to our docking calculations, some of the thiazoles 91-106 exhibited a comparable 
docking mode. Two H-bonds contacts characterize them; one H-bond involves one oxygen 
atom of the ester moiety and R933, while the second  H-bond involves the oxygen of the 
carboxamide function and F931. Thiazoles 107-111 presented only two weak H-bonds with 
Y304 and F931, missing any contact with R933. For instance, the di-substitution at the R 
substituent with electron-withdrawing groups is supposed to impair the aromatic ring's 
ability to be involved in cation- contacts with R933.  
It is important to note that the most effective potentiators explored above featured at least 
two contacts with F931 and another one with S308 or Y304, and several H-bonds or cation- 
contacts with R933. All of them were considered key points for the potentiator.   
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Regarding 91-106, the examined poses were variable even if preserving these two 
interactions, except for the congeners 100 and 101. Indeed, both of them were well stabilized 
at the biological target thanks to two H-bonds with R933 and two others with F931. Only 100 
and 101 were considered putative potentiators on this foundation, being in good agreement 
with the biological assays reported in the literature. 
The docking mode of 100 and 101 showed two H-bonds with R933 and F931 thanks to the 
ester moiety and the carboxamide and thiazole nitrogen atom. This kind of positioning 
allowed the compounds to be well attached at the binding site projecting the ester chain and 
the phenyl ring towards the hydrophobic crevice surrounded by F931, F932, and L233, F236, 
F305, respectively.  
Consequently, the two hydrophobic cores partially imitated the quinolone ring and the tert-
butyl substituent of VX-770, while the tertiary amide chain was involved in Van der Waals 
contacts with F931 and F305.  
Compounds 112-139 were designed as hybrid derivatives of the F508del-CFTR corrector VX-
809, showing comparable or higher potency ability. Only 127, 128, and 139 were endowed 
with a modest CFTR potentiator activity, while all other analogs are entirely inactive. 
Consequently, the docking poses obtained for 127 and 128 highlighted two H-bonds and 
cation- contacts between the benzodioxole group and R933, one H-bond between the oxygen 
atom of the carboxamide moiety and F931, and an additional H-bond involving the m-OH-
phenyl ring and F305. The predicted positioning of the hybrid 139 was adequately 
superposed on that of the reference VX-770, maintaining − stacking and Van der Waals 
contacts with Y304, F305, F236, F312, and L233, A309, respectively, thanks to the 139 
quinoline moiety. Also, the two oxygen atoms of the benzodioxole ring guarantee H-bonds 
with R933. 
 
2.2.2 Material and methods 
The compounds were manually built by the ‘MOE Builder’ tool and then were parameterized 
with AM1 partial charges as calculation method, and the energy minimization was 
performed using the ‘Energy Minimize Program’ with MMFF94x forcefield and RMS ( = root 
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mean square) equal to 0.0001 Kcal/mol/A2 of the MOE compute module, to produce a single 
low-energy conformation for each ligand 158.  
Molecular docking of all the explored compounds was performed within the X-ray structure 
of human CFTR in complex with the potentiator VX-770 (PDB code = 6O2P) and GLPG1837 
(PDB code = 6O1V) 163, which were prepared through the ‘Structure Preparation’ program of 
the MOE software.  
Docking calculations were performed thanks to the LeadIT 2.1.8 software suite 
(www.biosolveit.com). In particular, the FlexX scoring algorithm is employed by LeadIT 
2.1.8, relying on binding free energy calculations considering the Gibbs-Helmholtz equation. 
The docking approach is centered on a spherical search space, defined detecting the binding 
site as a radius of 6 Å far from the co-crystallized ligand.  
The docking algorithm is a state-of-the-art fragment docker: Ligands are divided into 
fragments. An initial fragment is placed into multiple places in the pocket – and scored using 
a very fast pre-scoring scheme. From the n solutions placed, the ligand is built up, fragment 
by fragment, and the intermediate solutions are scored against each other. The best-scored 
poses pass the process, and those are delivered to the user. The initial idea relates to the FlexX 
algorithm; many advances have been made over the years, such as the "Single Interaction 
Scan" (SIS) placement that finds solutions when there are few polar groups in a compound. 
The SIS algorithm uses virtual lines between protein and ligand interaction spots. The 
calculated docking poses were ranked by the score values of the lowest energy pose of the 
derivatives docked to the macromolecule. All compounds were refined and re-ranked by 








CHAPTER 3: LIGAND BASED APPROACH 
3.1. QSAR studies applied on correctors as F508del-CFTR modulators 
 
In preceding work performed by our research group QSAR analyses on a dataset of sixty-
three F508del-CFTR correctors featuring the thiazole, tetrahydropyridopyrimidines, and 
cyanoquinolines scaffolds have been described. This research allowed the discovery of eight 
descriptors describing the corrector ability range of the collected library, being five and three 
of them 2D and 3D descriptors. These included parameters correlated to atoms and bound 
counts (b_single, a_IC, and a_nH) and surface area descriptors (Vsurf_DD12 and Vsurf_W8). 
The connectivity-based descriptor chi1, the distance matrix parameter weinerPol, and the 
potential energy descriptor E_nb were also maintained164. 
These studies supported the design of branched scaffolds enriched with flexible substituents 
and quite polar moieties within overall limited and bulky conformations. Considering the 
prediction achieved with the model, several hybrids endowed with a promising CFTR rescue 
ability have been designed and synthesized.  
During my Ph.D., I refine the previous QSAR model, including the chemical structure and the 
related corrector profile of the in-house hybrid correctors in the newly developed dataset. The 
optimized QSAR model aims to expand the SAR information of this potent series of CFTR 
modulators148.  
The utilized dataset consists of eighty compounds (1-80; see Appendix A1-A3), being 
compounds 1 (pEC50 = 5.59), the corrector VX-809, and derivatives 2-29, the hybrids 
mentioned above. Compounds 30-80 relate to the tetrahydropyridopyrimidines and 
cyanoquinolines considered in the literature as F508del-CFTR correctors 167.  
The new predictive mathematical model was calculated separating compounds 1-80 into a 
training set (3-13, 15-18, 23-27, 30-32, 37-47, 49, 50, 54-63, 65-68, 70, 71, 73-80) to create the 
QSAR model, and into a test set containing twenty derivatives (1, 2, 14, 19-22, 28, 29, 33-36, 
48, 51-53, 64, 69, 72), in order to estimate the reliability of the mathematical relationship. 
Specifically, the obtained statistical tool was produced by using non-cross-validated PLS 
analysis to provide a cross validated r2 (r2cv) = 0.80 a non-cross validated r2 (r2ncv) = 0.84, a root 
mean square error (RMSE) = 0.333 and a test set r2 (r2pred) = 0.78. The predicted and 
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experimental rescue ability for all the derivatives is listed as tables together with the collected 
descriptors, as shown in supplementary data (see Appendix A15-16).  
To develop QSAR analyses, three hundred molecular descriptors (including 2D- and 3D- 
parameters) were analyzed using MOE software.  
2D molecular descriptors are distributed in seven subsets that represent physical properties 
(2D-I), subdivided surface areas (2D-II), atom and bond counts (2D-III), connectivity-based 
descriptors (2D-IV), partial charges descriptors (2D-V), pharmacophore features descriptors 
(2D-VI) and the so-called Adjacency and Distance Matrix Descriptors (2D-VII).  
3D-descriptors contain five groups, such as potential energy descriptors (3D-I), MOPAC 
descriptors (3D-II), Surface Area (3D-III), Volume and Shape Descriptors (3D-IV), and 
Conformation-Dependent Charge Descriptors (3D-V). 
The statical method used to perform the studies is the same as our research group's previous 
work.   
A limited cluster of descriptors was chosen utilizing the QSAR-Contingency module 
implemented in MOE. Firstly, the top-fifty best-ranked parameters were maintained based on 
the contingency scoring function. Then they were further filtered by re-iterative partial least 
square (PLS) analyses, involving only those parameters displaying the highest relative 
importance (RI) values.  
Following this method, I identified six descriptors related to the collected library's rescue 
ability profile, mostly 3D descriptors (see Table3.1). Indeed, two descriptors drop in the 3D-I 
cluster, three in the 3D-V series, and only one in the 2D-VI. Descriptor E_nb was the only one 





Table.3.1. Selected descriptors and corresponding relative values (RI) based on the derived 
model. 
 
The obtained model was developed, choosing the training set and test set compounds 
manually, taking into account the biological activity trend and structural variations. 
All the 3D selected descriptors describe the correctors' polarity profile, lengthened along the 
molecular surface, considering the ligands' conformational disposition. Conversely, these 
characteristics also turn in specific and adequate prerequisites assisting the 
hydrophilic/hydrophobic balance onto the overall surface extent, as verified by the vsa_pol 
descriptor. This information is indicated for a suitable overall dimension and shape of the 
ligand, turning in favored branched and flexible substituents over rigid, planar, and much 
more extended groups. This data agrees with the whole need for a significant polarity profile 
to be solved along with a branched chemical structure.  
Quantitatively, the corrector ability of the compounds examined is described by the following 
equation Eq. (1): 
Eq. (1): pEC50 = 12.91882-0.10591 * E_nb -0.01931 * ASA-0.04699 * vsa_pol+0.00260 * 
CASA+0.00658 * CASA-0.02034 * E_ang 







Fig.3.1.2 Schematic representation of the model's high performance when predicting modest to 
promising F508del-CFTR correctors (4.50 < pEC50 < 6.00), being the corresponding residual values 
near to zero. In (A) is represented the distribution of the predicted (Pred. pEC50) and experimental 
(Exp. pEC50) potency values of the training set compounds (violet crosses). The residual values 
have calculated the difference between the Exp.pEC50 and the Pred.pEC50. In (B) is represented the 
distribution of the predicted (Pred.pEC50) and experimental (Exp.pEC50) potency values of the test 
set compounds (magenta crosses). Residual values are calculated as the difference between the 
Exp.pEC50 and the Pred.pEC50.  
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Considering this information, E_nb and CASA+ are the most important molecular descriptors 
concerning the biological activity trend of the VX-809 hybrids, of the tetrahydropyridopyrimides, 
and the cyanoquinolines (Table 3.1), presenting RI values > 0.6. The E_nb mean value among the 
hybrid series changes from 35 to 40 (Kcal/mol) for the quiet and more promising correctors.  
Rising in E_nb occurs with the introduction of a polar electron-donor group linked to the meta 
position of the phenyl ring rather than a bulky and hydrophobic group at the same position. In 
fact, the 5-methyl thiazole 9 (pEC50 = 5.80; E_nb = 37.62 Kcal/mol) presented a lower E_nb value 
than the congener m-OH-phenyl substituted 18 (pEC50 = 5.92; E_nb = 38.13 Kcal/mol). In addition, 
compound 18 experienced an elevated E_nb value than the m-Cl-phenyl substituted 8 (pEC50 = 5.64; 
E_nb = 37.86 Kcal/mol). Curiously, the ideal value regarding this descriptor (E_nb = 40 Kcal/mol) 
was exhibited by those hybrids presenting the ester moiety at the position 5 of the AAT. This was 
in accordance with the promising corrector ability of 5 (pEC50 = 6.05; E_nb = 39.97 Kcal/mol), 3 
(pEC50 = 6.52; E_nb = 40.20 Kcal/mol) and 4 (pEC50 = 6.26; E_nb = 40.07 Kcal/mol) if compared to the 
non-substituted analogues 11 (pEC50 = 5.54; E_nb = 37.21 Kcal/mol), 12 (pEC50 = 5.31; E_nb = 37.43 
Kcal/mol) and 13 (pEC50 = 5.09; E_nb = 37.21 Kcal/mol), respectively. 
Conceivably, it is believed that deep changes of E_nb value occur in the presence of branched or 
flexible substituents tethered to the central scaffold of the corrector, leading to useful intra-
molecular contacts as well as intra- hydrogen bonds and hydrophobic interactions. This type of 
conformation is experienced within the tetrahydropyridopyrimidines, presenting the most potent 
E_nb values spanning from 70 to 100 Kcal/mol, while the less active analogs experience E_nb 
higher than 100 Kcal/mol.  
Tetrahydropyridopyrimidines with flexible chains in R2 in conjunction with H-bond acceptor 
functions (such as 45 and 50; pEC50 =6.70) might be involved in intramolecular H bonds with the 
protonated nitrogen atom of the tetrahydropyridine ring, presenting proper levels in E_nb (45, 
E_nb = 84.29 Kcal/mol; 50, E_nb = 74.34 Kcal/mol).  
Conversely, more rigid tetrahydropyridopyrimidines with a piperazine ring linked to the main 
bicyclic core led to less promising derivatives displaying too high levels in the E_nb descriptor, 
over 100 Kcal/mol. This data is supported by the poor potency values of the piperazine-containing 
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38 (pEC50 = 4.00; E_nb = 153.96 Kcal/mol), 40-42 (pEC50 = 4.00; E_nb = 153.73- 158.42 Kcal/mol), 55-
56 (pEC50 = 4.00; E_nb = 123.08- 132.29 Kcal/mol).  
The most interesting cyanoquinolines show a E_nb value between 50 and 65 Kcal/mol, while the 
less potent analogs exhibit higher values of E_nb. According to  these information, CQs featuring 
basic and flexible ethylene diamine spacer, such as 65-68 (pEC50 = 5.17-5.82; E_nb = 57.02 – 63.47 
Kcal/mol) presented lower E_nb than the modestly active analogues bearing a propylene diamine 
spacer in R1, such as 73-74 (pEC50 = 4.88-5.52; E_nb = 52.39 – 54.52 Kcal/mol) and the poorly active 
piperazine-containing 75-80 pEC50 = 4.00; E_nb = 65.90 – 71.22 Kcal/mol). 
Regarding CASA+, the whole electropositive profile experienced by hybrids such as by 
cyanoquinolines was extremely comparable, disclosing a mean value for the most promising 
derivatives around 1100 Å
2
. The introduction of an electro-donor moiety such as the ester function 
at the position 5 of the thiazole rises the CASA+ descriptor values, with an increase of the 
corrector ability of the compounds. Hence, 5 (pEC50 = 6.05; CASA+ = 1154.36 Å
2
), 3 (pEC50 = 6.52; 
CASA+ = 1154.36 Å
2
) and 4 (pEC50 = 6.26; CASA+ = 1153.63 Å
2
) are endowed with higher potency 
values than the analogues unsubstituted at the same position of the five-membered ring 11 (pEC50 
= 5.54; CASA+ = 728.87 Å
2
), 12 (pEC50 = 5.31; CASA+ = 708.34 Å
2




These results sustenance the high effectiveness of those hybrids bearing the hydroxyl group 
linked to the phenyl ring at the position 4 of the thiazole if compared with the chlorine substituted 
analogues ( compare 16 (pEC50 = 5.74; CASA+ = 890.95 Å
2
), 17 (pEC50 = 5.64; CASA+ = 893.51 Å
2
), 25 
(pEC50 = 5.89; CASA+= 804.04 Å
2
) and 18 (pEC50 = 5.92; CASA+ = 966.20 Å
2
) with 11 (pEC50 = 5.54; 
CASA+ = 728.87 Å
2
), 13 (pEC50 = 5.09; CASA+ = 743.19 Å
2
), 27 (pEC50 = 5.40; CASA+ = 662.58 Å
2
) 







Fig.3.1.3. Distribution of the Experimental (Exp.pEC50) potency values of the training set compounds 
based on the CASA+ descriptor (Å
2
) of hybrid derivatives.  
 
 Regarding the cyanoquinolines series, the substitution onto the terminal aromatic ring with a 
methoxy- or dimethoxy- group allowed the increase of CASA+ descriptor supplemented by a 
whole increase in terms of corrector ability. Similarly, the presence of benzamide moiety 
generates more promising compounds than the picolinamide or nicotinamide moieties. The 
reliability of this information is verified by the higher pEC50 and by the CASA+ descriptor profile 
when the methoxy-substituted 57–59 (pEC50 = 4.96–5.66; CASA+ = 911.40-923.78 Å
2
) are compared 
to the unsubstituted heteroaryl-based analogues 60–62 (pEC50 = 4.00–5.57; CASA+ = 774.53–789.39 
Å
2
) and to the benzamide analogue 63 (pEC50 = 4.00; CASA+ = 709.99 Å
2
). This information is 
maintained within the series of cyanoquinolines, presenting the dimethyl spacer and the 
diaminopropyl- and the piperazine-containing analogs. Indeed, the methoxy-substituted 71 
(pEC50 = 5.37; CASA+ = 880.84 Å
2






Fig.3.1.4. Distribution of the Experimental (Exp.pEC50) potency values of the training set compounds 
based on the CASA+ descriptor (Å
2
) of cyanoquinolines.  
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The most promising tetrahydropyridopyrimidines were characterized by a value of CASA+ 
descriptor spanning from 1600 to 2300 Å
2
, presenting the preponderance of the less potent 
(higher) values of this parameter. Conceivably, this evidence can be clarified based on the 
prominent polarity of this corrector series’ main scaffold, being very enriched of nitrogen atoms 
and basic features. 
Within them, the tetrahydropyridopyrimidines 50, 51 (pEC50 = 6.70; CASA+ = 1729.20 Å
2
) exhibit 
adequate CASA+ values thanks to their flexible basic chain in R2 as well as the methoxyphenyl-
based analogue 45 (pEC50 = 6.70; CASA+ = 2102.26 Å2), also endowed with basic features 
(Fig.3.1.5). 
 
Fig.3.1.5  Distribution of the Experimental (Exp.pEC50) potency values of the training set compounds 
based on the CASA+ descriptor (Å
2
) tetrahydropyridopyrimidines.  
 
3.1.2 Discussion 
The information achieved by QSAR analyses agreed with those of docking results discussed in 
chapter 2, disclosing a consistent number of descriptors explaining the correctors' polarity profile. 
E_nb and CASA+ have been previously considered the most relevant parameters concerning the 
three CFTR modulators' series. Beyond these descriptors, the potency trend of hybrids was 
positively affected by increasing values of E_ang, in agreement with the whole promising potency 
of the ester-containing analogs, as well as by a balanced electro-negative profile. 
These results were validated by the limited CASA- and ASA parameters exhibited by the most 
potent hybrids. Conversely, the pEC50 values of tetrahydropyridopyrimidines increased with these 
two descriptors, maybe because of the high polarity of the main core of this corrector series 
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featuring several nitrogen atoms and basic groups. Consequently, the vsa_pol descriptor was also 
positively correlated to this chemical series's corrector ability, supporting the need for a corrector 
shape endowed with a quite flexible and polar molecular surface to reach corrector behavior. 
Therefore, the most potent cyanoquinolines were accompanied by increasing values of the vsa_pol 
parameter. 
3.1.3 Material and methods 
QSAR studies were performed based on calculations of three hundred molecular descriptors, 
including 2D and 3D parameters, using MOE software. 2D molecular descriptors are identified as 
numerical properties that can be determined from the connection table representation of a molecule. 
2D descriptors are not dependent on a molecule's conformation and are most proper for extensive 
database studies. They include descriptors associated with atom and bond counts, subdivided 
surface areas, physical properties, connectivity-based descriptors, pharmacophore feature 
descriptors, partial charges descriptors, and the Adjacency and Distance Matrix Descriptors. The 
3D-descriptors comprise potential energy descriptors, MOPAC descriptors, Surface Area, Volume 
and Shape Descriptors, and Conformation Dependent Charge Descriptors. 
Then, 302 molecular descriptors (2D and 3D) were calculated by MOE, and the resultant matrix 
was presented to the statistical analyses and quantitative structure-activity relationships (QSAR). 
Also, QuaSAR-Contingency was used for pruning molecular descriptors, while the QSAR 
analysis module of MOE software was utilized to create the final mathematical models. 
To perform quantitative structure-activity relationship (QSAR) studies, sixty correctors were 
included in the training set for generating the model. The other ones into the test set for the 
validation of the model. The compounds were divided manually into the training and the test set 
to generate the mathematical model, based on representative criteria of the overall biological 
activity trend and structural variations. QSAR was done by employing various iterations of 
partial least-squares (PLS) multivariate analysis, taking into account the molecular descriptors as 
independent variables and corrector pEC50 values as dependent variables. For each iteration, the 
relative importance of every single descriptor in influencing corrector ability was calculated. 
Hence, the less important ones were discarded in the following PLS analysis until the final linear 
regression model generation. At every PLS, the Leave One Out method was utilized to verify the 
derived models' internal predictability. 
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The predictive ability of the derived model was evaluated for the test set compounds (expressed 
as r
2
pred) by using the following Equation (2): 
r
2
pred = (SD−PRESS)/SD (2) 
SD is the sum of the squared deviations between the test set molecules' biological activities. The 
mean activity of the training set compounds, and PRESS, is the sum of the squared deviations 
between the observed and the test set compounds' predicted activities. 
 
3.2 QSAR studies applied on F508del-CFTR potentiators 
To explore the main features of the different potentiator abilities exhibited within the chemo-types 
1-90, I considered it interesting to proceed with a QSAR analysis. The derived QSAR model is 
supposed to deepen the SAR knowledge of this series of CFTR modulators162. 
 Firstly, this study was administered based on different descriptors referring to 2D- and 3D- 
parameters (three hundred molecular descriptors), which were calculate thanks to the MOE 
software. As for the QSAR analysis performed on the corrector series previously discussed also in 
this case, the 2D molecular descriptors can be divided into seven sub-series, related to physical 
properties (2D-I), subdivided surface areas (2D-II), atom and bond counts (2D-III), connectivity-
based descriptors (2D-IV), partial charges descriptors (2D-V), pharmacophore features descriptors 
(2D-VI) and the so-called Adjacency and Distance Matrix Descriptors (2D-VII). At the same time, 
3D-descriptors are classified into five different sub-groups, including potential energy descriptors 
(3D-I), MOPAC descriptors (3D-II), Surface Area (3D-III), Volume and Shape Descriptors (3D-IV), 
and Conformation-Dependent Charge Descriptors (3D-V). 
The dataset used to conduct the studies included seventy-five compounds (1,3,4,6-12,22-41, 43-48, 
51-69, 71-90) selected from the whole dataset, deleting the completely inactive compounds and 
those presenting a chiral carbon atom.  
Thus, a final data matrix of 75 objects (compounds/ molecules) and 306 rows (molecular 
descriptors) was obtained. 
The chemometric package PARVUS168 was applied to check the constant predictors, dividing the 
data into training and test sets, removing the non-informative descriptors, and extracting 
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meaningful QSAR models to recognize the most important predictors accounting for the 
potentiator ability of the compounds in terms of pEC50 values.  
Following this method, has been identified 20 relevant descriptors, five of them belong to the 2D 
subdivided surface area (Table 3.2.1; SlogP_VSA4, SlogP_VSA5, SlogP_VSA9, 
SMR_VSA2,SMR_VSA4) four to the 2D Adjacency and Distance Matrix Descriptors (Table 3.2.2; 
BCUT_SLOGP_1, BCUT_SMR_1, BCUT_SMR_2 BCUT_SMR_3) two to the 2D Partial Charge 
Descriptors (Table 3.2.1; PEOE_VSA+5, PEOE_VSA-6) one to the 2D Pharmacophore Feature 
Descriptors (Table 3.2.2; a_hyd), one to the Physical Properties (Table 3.2.2; logS)  one to the 2D 
Atom Counts and Bond Counts (Table 3.2.2; b_1rotR). Regarding the selected 3D descriptors, four 
of them fall in the Surface Area, Volume, and Shape Descriptors (Table 3.2.3; vsurf_ID1, vsurf_ID7, 
vsurf_Wp2, vsurf_Wp3) while the other two were Conformation Dependent Charge Descriptors 
(Table3.2.39; dipoleY and ASA+). 
 
 
Table. 3.2.1 Selected 2D Subdivided Surface Area and Adjacency and Partial Charge descriptors and 





Table.3.2.2. Selected 2D Adjacency and Distance Matrix Descriptors, Pharmacophore Feature 
Descriptors, Physical properties, and Atom Counts and Bound Counts descriptors and corresponding 
importance values (RI).  
 
 
Table.3.2.3. Selected 3D Surface Area, Volume and Shape Descriptors and Conformation Dependent 
Charge descriptors and the related importance Values (RI).  
All the chosen 3D descriptors are associated with the modulators' polarity profile, extended along 
the molecular surface area, considering the ligands' conformational disposition. Instead, all the 2D 
ones indicate balanced hydrophilic/hydrophobic properties onto the whole surface extent.  
The final QSAR model was created, dividing the compounds into training and test sets applying 
the space-filling Kennard-Stone duplex design169, the most prevalent algorithm for selecting a 
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subset sample with distribution as much as possible to the uniform distribution. As a result, sixty 
objects were picked for the training set, and 15 molecules were allocated to the test set (20% of the 
total molecules).  
In details, the predictive model was calculated by including in the training set 1, 4, 7-10, 12, 22, 23, 
25-30, 31, 33, 34-37, 39, 41, 43-48, 51-54, 56, 58, 60-65, 67-69, 71, 73- 76, 78-83, 85-87, 89,90, which 
have been used to generate the QSAR model, and in the test set 3, 6, 11, 24, 32, 38, 40, 55, 57, 59, 66, 
72, 77, 84, 88 in order to evaluate the reliability of the mathematical relationship. Specifically, the 
final model was generated by using non-cross-validated PLS analysis to give a cross validated r2 
(r2cv) = 0.74 a non-cross validated r2 (r2ncv) = 0.90, root mean square error (RMSE) = 0.347, a test set r2 
(r2pred) = 0.86. The predicted and experimental rescue ability for all the derivatives are listed as 
tables together with the collected descriptors (A17, A18, A19, A20) 
Quantitatively, the potentiator ability of the compounds is explained by the following equation Eq. 
(1): 
Eq. (1): pEC50 = Potency = -2.51363 +1.87312 * BCUT_SLOGP_1 +1.58432 * BCUT_SMR_1 +0.09344 * 
BCUT_SMR_2 +1.48927 * BCUT_SMR_3 -1.39449 * b_1rotR -0.27817 * logS +0.25870 * dipoleY 
+0.01241 * a_hyd +0.00253 * ASA+ +0.00205 * PEOE_VSA+5 -0.02622 * PEOE_VSA-6 +0.00522 * 
SlogP_VSA4 -0.00628 * SlogP_VSA5 +0.00393 * SlogP_VSA9  -0.00921 * SMR_VSA2 -0.00440 * 
SMR_VSA4 +0.13782 * vsurf_ID1  +0.41705 * vsurf_ID7 +0.00211 * vsurf_Wp2 +0.00957 * vsurf_Wp3 
 
Fig.3.2.1. Representation of the developed model's high performance when predicting the potentiator 
ability of the in-house dataset (4.25 < pEC50 < 9.26). Representation of the predicted (Pred.pEC50) and 




Considering these results, the existence of quite flat groups substituted with polar moieties and 
endowed with limited flexibility should be favored for much more linear and flexible groups. This 
type of information agrees with the need for a limited number of rotatable bonds and hydrophobic 
atoms, as suggested by the B_1rotR and a_hyd descriptors. Therefore, the calculated mean values 
of the B_1rotR descriptor within the most potent thienopyrans (1-26; B_1rotRmean = 0,119343), and 
of the flat pyrazoloquinolines (70-80; B_1rotRmean = 0.131342), were lower than those of 
cyanoquinolines (B_1rotRmean = 0.182995), often displaying extended flexible chains (Table 3.2.4). 
Indeed, the promising thienopyrans 19, 22-24 (pEC50 = 8.52-8.69) featured branched moieties or 
small aromatic rings as R substituent as a substitute of a linear aliphatic chain, while the most 
potent pyrazoloquinoline 80 (pEC50 = 6.52) brings a thiophene-substituted quinoline as a planar 
group in R3. Concerning the less potent cyanoquinolines, the substitution of a piperazine spacer 
instead of diamino alkyl chain proved to be advantageous, as shown by 45-47 (pEC50 = 5.88-6.00) if 
compared to the diamino ethyl-based 33-35 (pEC50 = 5.22-5.63)  and to the diamino propyl-
containing 51-53 (pEC50 = 4.55-5.33).  Taking into account, the ideal number of hydrophobic atoms 
should fall in a range spanning from 15 to 20 atoms. Higher values of this parameter might worsen 
the compounds' potency profile, as reported within the pyrazoloquinoline series displaying an 
a_hydmean value > 21. 
Increasing values of the 3D descriptors Vsurf_ID7 and Vsurf_Wp3 turn in improved potency of the 
potentiators, favoring the key role of balanced polar and hydrophobic features at the molecular 
surface. It is possibly accompanied by differently substituted aromatic rings included in the 
potentiator's main structure, as the (at least) three quite co-planar aromatic rings of thienopyrans 1-
26 pyrazoloquinolines 70-80 and AATs 81-90.  
These results were validated by the related mean values (Table 3.2.4) and according to the higher 
potency profile experienced by thienopyrans than all the other potentiators' classes. Conversely, 
the ideal value for the SlogP_VSA9 of at least 150 is predicted to be accompanied by pEC50 values > 





Table 3.2.4. Mean values of the most important 3D descriptors and 2D descriptors were chosen as 
reference parameters within the different 2D subtypes. 
 
Beyond these five descriptors, ASA+, logS, and BCUT_SMR3 summarized the overall role of 
balanced hydrophobic and polar properties displayed by all the potentiators herein investigated.  
  
3.2.1 Material and methods 
Quantitative Structure-Activity Relationships (QSAR) studies were completed based on 
calculations of three hundred molecular descriptors, including 2D- and 3D parameters, through 
MOE software. 2D molecular descriptors are identified as numerical properties computed from the 
connection table representation of a molecule. 2D descriptors are not dependent on a molecule's 
conformation and are most suitable for extensive database studies. They include descriptors 
correlated to physical properties, subdivided surface areas, atom and bond counts, connectivity-
based descriptors, partial charges descriptors, pharmacophore features descriptors, and the so-
called Adjacency and Distance Matrix Descriptors. The 3D-descriptors consist of potential energy 
descriptors, MOPAC descriptors, Surface Area, Volume and Shape Descriptors, and Conformation 
Dependent Charge Descriptors. 
Then 306 molecular descriptors (2D and 3D) were calculated by MOE, and the resulting matrix 
was proposed to the statistical analyses and (QSAR) objects of the present work.  
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A final data matrix of 75 objects (compounds/ molecules) and 306 rows (molecular descriptors) 
was obtained. The chemometric package PARVUS168 was applied to handle such information, 
particularly for inspecting the constant predictors, splitting the data into training and test sets, 
discarding the non-informative descriptors extracting meaningful QSAR models able to recognize 
the most important predictors accounting for potentiator pEC50 value. 
Firstly, the CHECK module implemented in PARVUS was used to check the constancy of variables 
in five cancellation groups, and 283 molecular descriptors were retained after eliminating the 
constant predictors.  
The space-filling Kennard-Stone duplex design169 was used to split the data into representative 
training and test sets; this algorithm was applied using the first 10 principal components of the 
autoscaled data, considering the 90% of the total variance. Sixty objects were selected for the 
training set, and 15 molecules were assigned to the test set (20% of the whole molecules). 
Iterative stepwise elimination PLS (ISEPLS) was applied, as a variable selection method, to 
evaluate the selected predictors' relevance concerning the possibility of predicting the response 
variable y (pEC50). ISE is based on the importance of the predictors, defined as: 
 
where bv is the regression coefficient and sv the standard deviation of the descriptor v. In each 
elimination cycle, the descriptor with the minimum importance is removed. The model is 
computed again with the remaining predictors. The final model, with the maximum predictive 
ability in cross-validation, retained 20 relevant descriptors. 
QSAR was completed by applying various iterations of partial least-squares (PLS) multivariate 
analysis through MOE software, considering the molecular descriptors as independent variables 
and corrector pEC50 values as the dependent variable. At each iteration, the relative importance of 
every descriptor in influencing corrector ability was calculated. Therefore, the less important ones 











each PLS, the Leave One Out method was used to check the derived models' internal 
predictability.  
The predictive ability of the derived model was evaluated for the test set compounds (expressed as 
r2pred) by using the following equation:  
r2pred = (SD – PRESS)/SD 
SD is the sum of the squared deviations between the test set molecules' biological activities. The 
mean activity of the training set compounds, and PRESS is the sum of the squared deviation 
















CHAPTER 4. DISCOVERY OF NEW CORRETTORS USING 
COMPUTATIONAL APPROACHES, CHEMICAL SYNTHESIS, AND 
BIOLOGICAL ASSAYS 
Background 
In the last years, to find new drugs for CF treatment, our research group reported the rational 
design, chemical synthesis, and biochemical characterization of a novel library of 
aminoarylthiazoles (AAT) and VX-809 hybrid derivatives showing interesting properties as 
F508del-CFTR correctors1. 
This type of substitution proved to be efficient as shown by the related analogs of VX-809 
previously mentioned, such as the congeners ALK-809 and SUL-809150, VX-661 (Tezacaftor), 
successfully evaluated on patients in combination with VX-770, or a library of compounds 
synthesized coupling 1-(2,2-difluorobenzo[d] [1,3]-dioxol-5-yl)cyclopropanecarboxylic acid with 
various amine monomers, as described by Wang et al. 170. 
The in-house set of compounds has been called “hybrid compounds” since their structures were a 
“hybrid” between the AAT and the VX-809 scaffolds. Among them, several analogs have been 
identified featuring EC50 values in terms of CFTR rescue ability comprised between 0.09 and 0.2 
mM, with compound 2a being the most active (EC50 0.087 mM; pEC50 = 7.06). These data were very 
useful for designing and discovering a new library of optimized hybrids, exhibiting ameliorated 
potency values (EC50 values spanning from 0.02 to 0.1 M; pEC50 = 7.69-6.00) been obtained 
through the modification of some groups on the main core of the compounds. 
In particular, the molecular docking studies performed on the CFTR NBD1 to explore the putative 
binding mode of the hybrid compounds, previously in-depth analyzed in chapter 2 of this thesis, 
permitted to explore better the structure-activity relationship (SAR) within the hybrid series and to 
identified novel chemical substitutions on the thiazole ring. The mathematical QSAR model 
obtained in the previous study helps select the most promising compounds to be synthesized1. 
The following synthetic strategies united with the compounds' biochemical evaluation and the 
subsequent biological evaluation F508del-CFTR correctors validated the effectiveness of the hybrid 
core in the search for novel potent CFTR modulators. All results have offered novel SAR 
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information on hybrids as correctors and led to the identification of molecules with a particular 
ability to rescue F508del-CFTR. 
4.1 Rationale 
Our research group's previous QSAR analyses promoted the design of branched scaffolds enriched 
with flexible substituents and quite polar moieties within overall limited and bulky conformations. 
This information led to the design and synthesis of several hybrids endowed with a promising 
CFTR rescue ability, with 2a being the most potent. 
The subsequent step included preliminary docking studies at the NBD1 domain to guide the 
rational design of new analogs of the compound 2a. These calculations have been previously 
discussed in chapter 2 by exploring the putative docking mode of VX-809 and the two highly 
related analogs, ALK-809 and SUL-809, chosen as further reference compounds. Briefly, the two 
oxygen atoms of the VX-809 benzodioxole core detect two H-bonds with the K464 and T465 while 
the negatively charged carboxylic group and the carbamide moiety of the corrector are H-bonded 
to the backbone of E656 and N659, respectively. Concerning ALK-809 and SUL-809, both the two 
congeners were engaged in one H-bond between the (sulfon)amide moiety and the backbone of 
E656 being the two oxygen atoms of the benzodioxole near K464 and T465. In addition, the amide 
group on the main core of the derivatives was H-bonded to N659 while the aromatic rings and all 
the substituents were placed in proximity of G461, V603, A655, and N659 residues. 
Concerning the docking calculations performed on hybrid compounds revealed that for all of 
them, the carboxamide moiety is involved in one H-bond with N659, while the two oxygen atoms 
of the benzodioxole ring were H-bonded to K464 and T465. The most probable docking mode of 
the most potent compound 2a (EC50 0.087 M; pEC50 = 7.06) proved to agree with VX-809 (POS2) 
and SUL-809. 
The carboxamide moiety and the benzodioxole ring of the hybrid simulate the binding mode of 
VX-809 and for the related congener SUL-809, showing the same contacts. Overall, the thiazole 
ring proved to be good bioisosteres of the pyridine, maintaining the previously mentioned 
interactions with the biological target. Notably, hydrophobic interactions exhibited by the benzoic 
group of VX-809 and by the sulfonamide moiety of SUL-809 are experienced by the two aromatic 
rings tethered to the 2a thiazole core. In contrast, the benzoyl group's oxygen atom interacts with 
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the E656 side-chain, as reported for the two reference compounds. These findings allowed us to 
explore the role played by different substitutions on the benzoyl moiety of 2a and to clarify: (i) the 
relevance of hydrophobic and polar contacts, especially with Y577, (ii) the possibility of 
substitutions on the carbonyl function with other H-bond acceptor moieties tethered adequately to 
the thiazole core.   
The step forward is represented by the chemical synthesis and biological evaluation of 2a analogs 
concentrating on variations of the benzoyl core (compounds 7a-7z, 12a-12d, 24a-24c) (pEC50 = 4.86-
7.76), whose potency profile in terms of CFTR rescue ability have been predicted using the QSAR 
model that has previously built before synthesis.   
 
4.1.2 Synthesis of new F508del-CFTR modulators 
During my second year of my Ph.D., I continue my studies to research new F508del-CFTR 
modulators at the Center of Excellence of Biomedical Research (CEBR), under the supervision of 
Professor Enrico Millo. In this context, I applied the previous knowledge derived from 
computational studies to guide the synthesis of a library of 33 new hybrid derivatives (pEC50 = 
4.86-7.76). In particular I  synthesize ten hybrids, within the aforementioned cited thirty-three 
compounds (7e; 7o; 7s; 7v; 7w; 7x; pEC50 = 4.86-6.88 and 12a-12b; pEC50 = 5.59-5.89)171.  
For the synthesis of all the compounds has been applied a well-known synthetic route with 
appropriate modifications. To obtain the benzodioxole substituted portion has been used the 
cyclopropanation of active methylene compounds. The substituted aminoarylthiazoles are 
synthesized differently depending on the substituents at position 5 of the thiazole ring. 
For the general structures of (2-amino-4-arylthiazol-5-yl) (aryl) methanone derivatives, a 
convergent synthesis was established (Scheme 4.1) according to the Wang protocol apporting 
minimum variations. To obtain a selective introduction of the substituent groups on the thiazole 
ring, a protected carbamothioyl amide was conjugated with substituted -bromoketone. A mixture 
of 1- [4- (methoxy)phenyl]methanamine 1 and 4-(methoxy)benzaldehyde 2 was heated in refluxing 





Scheme 4.1. Reagents and conditions: (a)methanol, reflux, 3h; (b)NaBH4 0°C to rt, 10h; (c) 
benzoylisothiocyanate, acetone, 0°C, 1h;  (d) RCOCH2Br, N,N-DMF, 85 °C, 3h; (e) TFA 80°C, 36h (f) 
HATU,DIPEA, N, N-DMF, 50 °C, 24h.  
 
Protected carbamothioyl amide 4 was obtained by condensation of benzoylisothiocyanate and bis 
((4-(methoxy) phenyl) methyl) amine 3 in high yield. 
Condensation of protected carbamothioyl amide and -haloketone followed by deprotection 
afforded the thiazolic derivatives 5, which were then further condensed with 1-(benzo[d] [1,3] 
dioxol-5-yl) cyclopropanecarboxylic acid 6 to produce the desired analogs 7a-7z. This last synthetic 
step was reached by a 2-amino- thiazole reaction with the carboxylic group of cyclopropane 
carboxylic acid derivatives with uronium salt activation in anhydrous solvents.  
A different synthetic route was applied for compound 12a (Scheme 4.2). From ethyl 2-amino-4-
aryllthiazole-5-carboxylate 8, t-Boc protection at the aminic group was directed to minimize the 
thiazole ring's decarboxylation. To obtain the carboxamide derivative 10, the appropriate 2- amino-
thiazole-5-carboxylate 8 was treated with di-tert-butyl carbonate in the presence of 4-(N, N-
dimethylamino)pyridine in tetrahydrofuran to produce the corresponding tert-butyl carbamate 
that upon basic hydrolysis afforded the acid 9. Conversion of the carboxylic acid to its uronium 
salt using standard peptide coupling conditions and its subsequent treatment with aniline, in the 
presence of diisopropylethylamine in N,N-DMF gave the anilide derivative 10. Further 

















The final compound 12a was obtained by condensation with the carboxylic group of 
cyclopropanecarboxylic acid derivative 6 as previously described. 
 
Scheme 4.2. Reagents and conditions: (a) Boc2O, DMAP, THF, rt, 4h; (b) KOH 6 N, THF:EtOH = 1:15, 
55 °C, 4h; (c) HATU, DIPEA, N, N-DMF, rt, 5 min; (d) PhNH2, 40 °C, 2h; (e) TFA:DCM = 1:1, 0 °C, 4h; 
(f)6,  HATU,DIPEA, N, N-DMF, 50 °C, 24h.  
 
Another approach was used to prepare 12b. N-(2-amino-4-(4- methoxyphenyl) thiazol-5-yl) 
benzamide was prepared, performing two-step synthesis starting from alfa-aminoacetophenone 
derivative 14 (Scheme 4.3). The starting reagent was prepared from 4- methoxyphenacyl bromide 
13 following Delepine reaction (hexa- methylenetetramine in diethyl ether) as 4-
methoxybenzoylmethylammonium chloride salt. Acylation of the amino functionality with 
benzoyl chloride advanced efficiently to provide N-(2-(4-methoxyphenyl)-2-oxoethyl) benzamide 
15.  The low yield of this synthetic step is due to the difficulty of selectively monobromination of 
derivative 15 and isolating the respective unstable intermediate N-(1-Bromo 2-(4-
methoxyphenyl)-2-oxoethyl) benzamide. But there was an increase in yield with the one-pot 
condensation of N-(2-(4-methoxyphenyl)-2-oxoethyl)benzamide with thiourea and iodine using 
triethylamine as catalyst under mild conditions 172. The synthesis of amide derivatives of 2-
aminothiazole was made by the condensation reaction of the 2-amino-thiazole with the carboxylic 




Scheme 4.3. Reagents and conditions: (a)hexamethylenetetramine, diethyl ether, rt, 2h; (b)HCl conc, 
EtOH, reflux, 3h; (c) C6H5COCl, NaHCO3, THF, rt, 3h; (d)thiourea, I2, EtOH, TEA, 80 °C, overnight; (e) 
HATU, DIPEA, N,N-DMF, 50 °C, 24h.  
The synthesis of compounds 12c and 12d comprises a synthetic strategy hinged on a reaction 
between a substituted thiazole in position 5 and cyclopropanecarboxylic acid derivative. The 
functionalized thiazoles used for the substitution step were obtained, as shown in Scheme 44. 
Thiourea 17 was quantitatively activated as bis-thiazadiene 18 with an excess of N, N-
dimethylformamide dimethylacetal in methanol. The thiazole ring was formed after the addition 
of the corresponding alfa-bromoketones 19a and 19b in THF. Intermediates 20a-20b were 
deprotonated in situ, adding triethylamine. The second imine, used as a protecting group, was 
subsequently removed in situ with methylamine in water to form the expected products 21a and 
21b. The final products 12c and 12d were obtained by condensation of the 2-amino-thiazole with 




Scheme 4.4. Reagents and conditions: (a)N, N-Dymethyl formamide dimethyl acetate, DCM, reflux, 
4h; (b)THF, rt to reflux, 18h; (c), 33% ac CH3NH2, THF, rt, 24h; (d) HATU, DIPEA, N,N-DMF, 50°C, 24 
h.  
To synthesize derivatives 24a, 24b, and 24c have been applied the same synthetic route used in 
Scheme 4.1 but starting from aliphatic, heteroaromatic, and heterocycle haloketones 22a, 22b 22c 
(Scheme 4. 5). 
 
 
Scheme 4.5. Reagents and conditions: (a) N, N-DMF, 85 °C, 2 h; (b) TFA, 80 °C, 36 h; (c) 6, HATU, 




4.1.3  Structure-activity relationship analysis of the new series of F508del-CFTR 
modulators 
From the previous studies1, in which the thiazolic ring was modified at different positions, our 
research group has identified that the most active compound 2a (EC50 0.087 M; pEC50 = 7.06 ) was 
characterized by substitution at position 5 of the thiazole ring with benzoyl group and phenyl ring 
linked at the thiazole position 4. The substitution at position 5 of the thiazole ring is necessary for a 
good activity since the previous series's most active derivatives all contained a substituent at 
position 5. Indeed, the presence of a bulky substituent (benzoyl or ethyl acetate) at position 5 could 
be beneficial in increasing some pharmacokinetic characteristics, while the derivatives containing 
no substitution led to a reduction in corrector activity. First, removing the keto group present in 
the hit compound or substituting it with the amidic one led to a decrease in activity concerning the 
benzoyl analogs: compare 12a (EC50 1.26 M; pEC50 = 5.89) and 12b (EC50 1.76 M; pEC50 = 5.75) 
with 2a. 
For the comparative purpose, the phenyl ring at position 4 was kept intact. This substitution 
permitted the investigation of the substitutions at position 5 of the thiazole ring starting from the 
para position.  Although several different electron-withdrawing groups were anchored at this 
position, such as a   methylthio group 7a (EC50 0.10 M; pEC50 = 8.00) or bromine 7b (EC50 0.53 M; 
pEC50= 6.27), only the first was tolerated and represented one of the most promising hybrids within 
this series. Regarding the compounds containing ester, carboxylic or amidic moieties, only the 
ethyl ester derivative 7c maintains certain activity (EC50 =0.41 M; pEC50 = 6.38) while the 
carboxylic derivative 7d (EC50 = 7.31 M; pEC50 = 5.13) led to a decrease in activity and finally the 
presence of the amidic group is very detrimental for activity.   
To understand the para position's importance for F508del-CFTR rescue, electron-donating groups 
have been introduced in the same position. 
The presence in this position of an alkyl amino group (7f (EC50= 0.45 M ; pEC50 = 6.34) or an alkyl 
moiety ( 7g (EC50= 0.43 M; pEC50 = 6.36) were not seen to improve the activity in a similar way the 
introduction of a methoxy group in 7h not increase the activity (EC50 =0.45 M; pEC50 = 6.34)). A 
comparable result was obtained also with a trifluoromethoxy group 7i (EC50 = 0.36 M; pEC50 = 
6.44). Modifying the alkin chain's length to increase the hydrophobic portion led to derivative 7j 
that present in substitution of the methyl group a propyl one that ameliorates the activity by about 
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five times (EC50 =0.017 M; pEC50 = 7.76). Conversely, changing the propoxy group's position from 
para to meta position 7k (EC50= 0.165 M; pEC50 = 6.78) reduced the activity. This data suggest that 
there is a preference for hydrophobic groups. To further investigate this aspect has been used 
steric hindrance in the structures.  
Subsequently, three different compounds were designed and built with a second aromatic ring like 
thiophene for 7l (EC50 =1.06 M; pEC50 = 5.97)) or phenyl for 7m (EC50= 0.07 M; pEC50= 7.15) or 
hetero aliphatic ring 7n (EC50 =0.37 M; pEC50 = 6.43). In this context, compound 7m led to an 
increase in activity with an EC50 better than the reference compound 2a.  
On the other hand, moving the methoxy group from the para 7h to the ortho 7p and the meta 
position 7q led to a significant increase in activity (EC50 =0.14 M; pEC50 = 6.85 and EC50= 0.10 M; 
pEC50 = 7.00). 
Similar behavior was observed placing bromine in the meta position 7r (EC50= 0.18 M; pEC50= 
6.74), which was revealed better than the para position. The bromine substitution with fluorine in 
the meta position caused increased potency in 7s (EC50 =0.13 M; pEC50 = 6.88). 
Given the methoxy group's inclination for the meta/ortho substitution, two disubstituted analogs 
containing the methoxy group on the ortho position and the second one in the meta and para 
position, respectively (7t and 7u), have been synthesized. notably, the 4-substitution wasn’t well 
tolerated (EC50 =0.4 M; pEC50 = 6.39), but the inclusion of a 3’-OCH3 group afforded potent 
analogue (EC50= 0.11 M; pEC50 = 6.95). 
Indeed, evaluating the molecules containing 3, 4-substituted benzoyl groups like 7v (EC50 = 0.41 
mM; pEC50 = 6.38 or 7w (EC50= 0.28 M; pEC50 = 6.55), the substitution proved to be tolerated, 
especially with regard to the allyl moiety. Conversely, a high decline in activity was observed 
when one of these substituents was an amide group as in 7x (EC50 = 13.7 M; pEC50 = 4.86) and 
similarly with 7e.  
From the information furnished by this SAR, it was identified that an amide group was 
detrimental to activity.  
All the compounds in the dataset contain at the 5 position only a benzoyl derivative. The insertion 
of a different keto group using aliphatic like methyl 24a, heteroaromatic like pyridine 24b and 
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heterocycle, morpholine in this case, 24c in the same position proved that the only 24b (EC50= 0.79 
M; pEC50 = 6.10) had a certain activity while 24a (EC50 =2.72 M; pEC50 = 5.56) and overall 24c 
(EC50 =8.5 M ; pEC50 = 5.07) led to decreasing activity with respect to the progenitor (EC50 = 0.087 
M ; pEC50 = 7.06). 
4.1.4 Biological assays 
All designed compounds were then synthesized and tested to investigate the structure-activity 
relationships as correctors of F508del-CFTR.  
The biological assays to test the compounds were performed at the U.O.C medical genetics at the 
Giannina Gaslini Institute in collaboration with Dr. Nicoletta Pedemonte.  
This research group assayed the corrector's rescue ability F508del-CFTR using an 
electrophysiological technique: the transepithelial electrical resistance and potential difference 
measurements (TEER/PD). In this way, they proved the ability of the novel derivates to rescue 
F508del-CFTR on well-differentiated primary cultures of human bronchial epithelial cells 
from a CF patient homozygous for the F508del. 
The two most potent derivatives, 7a and 7m have been tested. Epithelia were treated for 24 h with 
test compounds at different concentrations: 7a (5-0.5-0.05 M), 7m (10 – 1-0.1 M), VX-809 1 M (as 
positive control), or vehicle alone (DMSO; negative control) and then assayed. Transepithelial 
electrical resistance was measured before and after stimulation with forskolin (20 M) plus 
genistein (50 M) to activate CFTR (Fig.4.1). Long-term treatment of CF primary epithelia with 7a 






Fig.4.1. Bar graphs representing the delta between the values of electrical resistance measured before 
and after CFTR inhibition. Compounds 7a and 7m rescue F508del-CFTR activity in primary bronchial 
epithelia. In detail, the graph reports the equivalent short-circuit current (calculated from TEER/ PD 
measurements) in F508del/F508del bronchial epithelia, treated for 24 h with test compounds at the 
indicated concentration, or VX-809 (1 mM), or vehicle alone (DMSO). 
Another assay used to analyze these compounds' structure-activity relationship is the YFP 
functional assay on F508del-CFTR CFBE41o- cells. This assay provides an incubation of 24 h at 
different concentrations to extrapolate the compounds' EC50 values as correctors of mutant CFTR. 
After incubation, the activity of F508del-CFTR in the plasma membrane was determined by 
measuring the rate of HS-YFP quenching caused by iodide influx. The activity was then compared 
to that of cells treated with vehicle alone (DMSO) or with the known corrector VX-809 (1 M). 
Then they evaluated the rescue of processing defect biochemically using the electrophoretic 
mobility of CFTR protein. In Western blots, CFTR protein is detected as two bands, named B and 
C.  Band B corresponds to partially glycosylated CFTR residing in the ER, while band C is the 
mature CFTR that has passed through the Golgi. The prevalent form in cells expressing wild-type 
CFTR is band C. To evaluate the effect of hybrid compounds on CFTR electrophoretic mobility, 
they treat F508del-CFTR/HS-YFP expressing CFBE41o-cells with DMSO (vehicle alone) or test 
compounds 7m and 7a (0.5 M) or VX-809 (1 M, as positive control). After an incubation of 24 h, 
cells were lysed, and lysates were subjected to SDS-PAGE followed by western blotting. Treatment 
of F508del-CFTR cells with corrector VX-809 significantly enhanced the expression of mature 
CFTR (band C), resulting in a change in the C band/B band ratio. Similarly, treatment with the 
compounds resulted in a significant increase in the C band/B band ratio, comparable to that 




Fig.4.2. Biochemical analysis of the F508del-CFTR expression pattern. (Left) Electrophoretic mobility of 
F508del-CFTR in 2 different preparations of CFBE41o-cells, treated for 24 h with vehicle or test 
compounds (0.5 mM) or VX-809 (1 mM). Band C represents the complex-glycosylated; Band B 
represents the core-glycosylated forms of CFTR protein. (Right) The bar graph reports the densitometric 
analysis of band C/band B ratio normalized to GAPDH.  
To characterize the biological activity of hybrid compounds, the compounds 7a, 7j, 7m were tested 
in combination with VX-809 and VX- 661 in CFBE41o-cells stably expressing F508del-CFTR using 
the YFP functional assay. Then, the cells were treated 24 h with single test compounds or their 
combinations and then assayed. No additive or synergistic effect was observed when combining 
7a, 7j, and 7m with VX-809 or VX- 661, supporting the hypothesis that all these compounds 
possibly share the same binding site. 
 
Fig.4.3. The F508del-CFTR activity was determined in CFBE41o− cells with the HS-YFP. Cells were 






CHAPTER 5. FINAL REMARKS 
The rational design and study of useful modulators for CF treatment is tough due to the limited 
structural and experimental information on the complete F508del-CFTR protein. Furthermore, the 
mechanism of action of the F508del-modulators still needs to be clarified. In chapters 2 and 3 of 
this thesis, I wanted to emphasize how QSAR analysis is more predictive than the structure-based 
approach. The series of correctors allowed a very accurate prediction of their biological activity 
(expressed in terms of pEC50) before their chemical synthesis. 
Regarding potentiators, the available data of X-ray of wild-type CFTR in complex with the 
potentiators VX-770 and GLPG1837 guaranteed the reliable and feasible structure-based approach.  
Conversely, the whole F508del-CFTR protein's limited experimental data quite impaired the 
reliability of the information coming from molecular docking approaches.  
In this contest, experimental mutagenesis and molecular dynamics are urgently needed to clarify 
the modulators' putative mechanism of action.  
The last chapter reported a new series of hybrids compounds, which their design has been helped 
by the computational studies mentioned above. Consequently, the second series of hybrids is 
synthesized from structural variations on the scaffold of the most active compound 2a.   
The following biological assays performed on all obtained compounds allowed us to verify the 
corrector ability as F508del-CFTR correctors and better explore their structure-activity 
relationships. Among these hybrids, the compounds 7j and 7m proved to be the most potent 
hybrids even if compared to the well-known corrector VX-809 (pEC50 = 5.59) and the compound 2a 
(pEC50 = 7.06).  
Finally, the computational approaches applied during my Ph.D. years will continue with a new 
QSAR analysis that comprehended the new second hybrid compound series. This way permits our 
research group to design new reasonable structures to be synthesized and evaluated through 
biological assays. Furthermore, the structure of F508del-CFTR will be modeled to perform a 
structure-based study on the entire protein. Then, this model will be validated with known 
correctors. Regarding the synthesis of new aminothiazole hybrid derivatives, the most active 
compounds of the new library will be substituted in position 4 of the thiazole ring to study how 
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the substitution in 4 could affect the bioactivity of the molecules. Furthermore, the compounds will 
also be studied in combination with other correctors approved for Cystic Fibrosis, such as VX-445 


















CHAPTER 6. EXPERIMENTAL SECTION 
6.1 CHEMISTRY 
Starting materials were purchased from Sigma Aldrich, Alfa Aesar, VWR, and Zentek. The 
analytical instrument used was Agilent 1260 high-performance liquid chromatography (HPLC). 
The analytical HPLC column was a Phenomenex C18 Luna. 
The preparative HPLC was Agilent 1260 Infinity preparative HPLC and the column used for 
preparative chromatography was a Phenomenex C18 Luna. The analysis of the intermediates and 
the raw products was performed by liquid chromatography-electrospray mass spectrometry 
(HPLC-ESI-MS) using an Agilent 1100 series LC/MD ion trap instrument.  
HRMS were performed using the Q Exactive Orbitrap instrument by Thermo Scientific.  
The nuclear magnetic resonance (NMR) spectrometer was performed by Dr. Bruno Tasso at the 
Department of Pharmacy (DIFAR) at the University of Genoa, using a Varian Gemini 200 MHz. 
The proton spectra were acquired at 200 MHz, while carbon spectra were acquired at 50 MHz, at 
room temperature. Chemical shifts are reported in  units (ppm) relative to TMS as an internal 
standard. Coupling constant (J) are reported in Hertz (Hz).  
All the raw powders obtained were purified with preparative HPLC using the following gradient: 
from 0 to 5 min at 20% eluent B, then from 5 to 40 min to 100% eluent B, from 40 to 45 min at 100% 
of eluent B. eluant A was water with 0.1% formic acid (FOA) and eluent B was acetonitrile with 
0.1% FOA. All analog submitted for testing were judged to be 95% or higher purity based on 
analytical HPLC/MS analysis. Compound purity was determined by integrating peak areas of the 
liquid chromatogram, monitored at 254 nm.  
 
 6.1.1 General procedure for the synthesis of the intermediate starting compound N-
(bis(4-methoxybenzyl) carbamothioyl) benzamide for the synthesis of 7e- 7o-7s-7v-7w-
7x derivatives. 
A mixture of (4-methoxyphenyl) methanamine (535 L, 4 mmol) and 4-(methoxy) benzaldehyde 
(595 L, 4.8 mmol) in methanol (2 mL) was heated to reflux for 3 h, then cooled to T = 0 °C, NaBH4 
(228 mg, 6 mmol) was added portion-wise to the reaction. The resulting mixture was stirred at 
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room temperature for about 10 h. The solvent was removed under reduced pressure, and the 
residue was partitioned between ethyl acetate (EtOAc) and H2O. The combined organic layers 
were washed with H2O and then dried over anhydrous Na2SO4. After filtration, the solvent was 
removed in vacuum to afford bis [4-methoxyphenyl]methylamine (962 mg, 94%) as a colorless oil 
used in the next step without further purification. ESI-MS: m/z 258.0 [M+H]+. 
To a solution of benzoylisothiocyanate (140 L, 1 mmol) in acetone (1 mL) cooled at T = 0 °C, bis [4-
methoxyphenyl]methylamine (257 mg, 1 mmol) in acetone (1 mL) was added at this temperature 
and stirred for an additional 1 h. The mixture was concentrated under reduced pressure to afford 
N-(bis(4-methoxybenzyl) carbamothioyl)benzamide (398 mg, 95%) as yellow sticky oil, which was 
used in the next step without further purification. ESI-MS: m/z 421.0 [M+H]+.  
6.1.2 (7e): 4-(2-(1-(Benzo[d][1,3] dioxol-5-yl)cyclopropanecarboxamido)-4-
phenylthiazole-5-carbonyl)-N-methilbenzamide  
A solution of 4-(2-bromoacetyl)-N-methyl-benzamide methylbenzamide (128 mg, 0.5 mmol) and 
N-(bis(4-methoxybenzyl)carbamothioyl)-benzamide (210 mg, 0.5 mmol) in N, N-
dimethylformamide (DMF) (3 mL) was stirred at T = 85 °C for 3h. After cooling to room 
temperature, the mixture was partitioned between EtOAc and H2O. The organic layer was washed 
with brine and dried over anhydrous Na2SO4. After filtration, the solvent was removed in vacuum, 
and the residue was stirred in trifluoroacetic acid (TFA) (4 mL) at T = 80 °C for 24-36 h until 
complete deprotection. Most of TFA was removed under reduced pressure. The residue was then 
neutralized with NaHCO3 1N, and then extracted with EtOAc for 3 times. The combined organic 
layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the solution was 
concentrated and further crystallized in acetonitrile to afford 4-(2-amino-4-phenylthiazole-5-
carbonyl)-N-methylbenzamide (110 mg, 65%) as a brown oil. ESI-MS: m/z 337.09 [M + H]+.  
Benzo [1,3]dioxol-5-yl-cyclopropanecarboxylic acid (20.6 mg, 0.1 mmol) was resuspended in 
anhydrous DMF (1 mL); HATU (38 mg, 0.1 mmol) and DIPEA (35 L, 0.2 mmol) were added. The 
reaction was vigorously stirred for 5 min and 4-(2-amino-4-phenylthiazole-5-carbonyl)-N-
methylbenzamide (68 mg, 0.2 mmol) in anhydrous DMF (500 L)was added. The reaction was kept 
at T= 50 °C until completeness (18-24 h) and then purified by preparative HPLC. The peak of 
interest was concentrated to obtain the title compound as brown oil with purity of >95% as 
determined by HPLC-MS (12 mg, 11%). 
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1H NMR (200 MHz, DMSO‑d6):  12.01 (s, 1H, broad, NH); 11.75 (s, broad, 1H, NH); 7.71e6.63 (m, 
12H, arom); 6.03 (s, 2H OCH2O); 2.43 (s, 3H, CH3N); 1.72e1.46 (m, 2H, CH2, cyclopr); 1.42e1.11 
(m,2H, CH2, cyclopr). 
13C NMR (50 MHz, DMSO‑d6):  187.8, 172.3, 167.8, 154.1, 146.8, 146.3, 136.6, 131.8, 130.3, 129.3, 
128.8, 128.1, 127.5, 123.2, 113.5, 110.2, 107.8, 100.6, 38.5, 30.3, 15.5. 
HRMS (ESI) calculated for C29H24N3O5S:[M + H]+ 526.14366; found 526.14343. 
6.1.3 (7o) N-(5-([1,1’- Biphenyl] -3-carbonyl)-4-phenylthiazol-2-yl)-1-(benzo[d] [1,3] 
dioxol-5-yl)cyclopropanecarboxamide 
A solution of 1-([1,1'-biphenyl]-3-yl)ethanone (196 mg, 1  mmol) was brominated with N-
bromosuccinimide (NBS) providing  [1,1’-biphenyl]-3-carbonyl bromide intermediate (202 mg, 
73%). The purity was verified by HPLC-MS without further purification.  
A solution of [1,1’-biphenyl]-3-carbonyl bromide  (130 mg, 0.5 mmol) and N-(bis(4-
methoxybenzyl)carbamothioyl)-benzamide (230 mg, 0.5 mmol) in N, N-dimethylformamide 
(DMF) (3 mL) was stirred at T = 85 °C for 3h. After cooling to room temperature, the mixture was 
partitioned between EtOAc and H2O. The organic layer was washed with brine and dried over 
anhydrous Na2SO4. After filtration, the solvent was removed in vacuum and the residue was 
stirred in trifluoroacetic acid (TFA) (4 mL) at T = 80 °C for 24-36 h until complete deprotection. 
Most of the TFA was removed under reduced pressure. The residue was then neutralized with 
NaHCO3 1N, and then extracted with EtOAc for 3 times. The combined organic layers were 
washed with brine and dried over anhydrous Na2SO4. After filtration, the solution was 
concentrated and further crystallized in acetonitrile to afford [1,1’-biphenyl]-3-yl(2-amino-4-
phenylthiazol-5-yl) methanone (60,5 mg, 34%)  ESI-MS: m/z 357.1 [M + H]+. 
Benzo [1,3]dioxol-5-yl-cyclopropanecarboxylic acid (20.6 mg, 0.1 mmol) was resuspended in 
anhydrous DMF (1 mL); HATU (38 mg, 0.1 mmol) and DIPEA (35 L, 0.2 mmol) were added. The 
reaction was vigorously stirred for 5 min and[1,1’-biphenyl]-3-yl(2-amino-4-phenylthiazol-5-yl) 
methanone (36 mg, 0.1 mmol)  in anhydrous DMF (500 L)was added. The reaction was kept at T= 
50 °C until completeness (18-24 h) and then purified by preparative HPLC. The peak of interest 
was concentrated to obtain the title compound as pale yellow oil with purity of >95% as 
determined by HPLC-MS (12.5mg, 23%).  
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1H NMR (200 MHz, DMSO‑d6):  12.01 (s, 1H, broad, NH); 8.27e6.82 (m, 17H, arom); 6.04 (s, 2H 
OCH2O); 1.69e1.42 (m, 2H, CH2, cyclopr); 1.41e1.03 (m, 2H, CH2, cyclopr). 
13C NMR (50 MHz, DMSO‑d6):  187.9, 171.8, 157.4, 153.3, 146.9, 146.3, 141.7, 137.8, 137.2, 131.3, 
129.4, 128.8, 128.1, 127.5, 123.1, 110.2, 107.8, 100.6, 30.3, 15.6. 
HRMS (ESI) calculated for C33H25N2O4S: [M +H]+ 515.15349; found 545.15331. 
6.1.4 (7s) 1-(Benzo[d] [1,3] dioxol-5-yl)-N-(5-(3-fluorobenzoyl)-4-phenylthiazol-2 
yl)cyclopranecarboxamide 
A solution of 2-Bromo-1-(3-fluorophenyl)ethan-1-one (108 mg, 0.5  mmol) and N-(bis(4-
methoxybenzyl)carbamothioyl)-benzamide (210 mg, 0.5 mmol) in N, N-dimethylformamide 
(DMF) (3 mL) was stirred at T = 85 °C for 3h. After cooling to room temperature, the mixture was 
partitioned between EtOAc and H2O. The organic layer was washed with brine and dried over 
anhydrous Na2SO4. After filtration, the solvent was removed in vacuum, and the residue was 
stirred in trifluoroacetic acid (TFA) (4 mL) at T = 80 °C for 24-36 h until complete deprotection. 
Most of the TFA was removed under reduced pressure. The residue was then neutralized with 
NaHCO3 1N, and then extracted with EtOAc for 3 times. The combined organic layers were 
washed with brine and dried over anhydrous Na2SO4. After filtration, the solution was 
concentrated and further crystallized in acetonitrile to afford (2-amino-4-phenyl-1,3-thiazol-5-yl)(3-
fluorophenyl)methanone (90 mg, 60%) as a brown solid. ESI-MS: m/z 299.06 [M + H]+. 
Benzo [1,3]dioxol-5-yl-cyclopropanecarboxylic acid (20.6 mg, 0.1 mmol) was resuspended in 
anhydrous DMF (1 mL); HATU (38 mg, 0.1 mmol) and DIPEA (35 L, 0.2 mmol) were added. The 
reaction was vigorously stirred for 5 min and (2-amino-4-phenyl-5-yl)(3-fluorophenyl)methanone  
(30 mg, 0.2 mmol) in anhydrous DMF (500 L)was added. The reaction was kept at T = 50 °C until 
completeness (18-24 h) and then purified by preparative HPLC. The peak of interest was 
concentrated to obtain the title compound as a white solid with a purity of >95% as determined by 
HPLC-MS (13 mg, 27%). 
1H NMR (200 MHz, DMSO‑d6):  11.93 (s, 1H, broad, NH); 8.01e6.74 (m, 12H, arom); 6.05 (s, 2H 
OCH2O); 1.73e1.44 (m, 2H, CH2, cyclopr); 1.42e1.08 (m, 2H, CH2, cyclopr). 
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13C NMR (50 MHz, DMSO‑d6):  188.0, 171.5, 158.7, 156.2, 146.9, 146.3, 137.0, 133.4, 131.1, 129.7, 
128.8, 128.2, 127.6, 123.2, 113.8, 110.2, 107.8, 100.6, 30.3, 15.5. 
HRMS (ESI) calculated for C27H20FN2O4S: [M + H]+ 487.11277; found 487.11243. 
6.1.5 (7v) 1-(Benzo[d][1,3] dioxol-5-yl)-N-(5-(3-chloro-4-methoxybenzoyl)-4-phenyltiazol-
2yl)cyclopropanecarboxamide  
 
A solution of 2-bromo-1-(3-chloro-4-methoxyphenyl)ethan-1-one (132 mg, 0.5  mmol) and N-(bis(4-
methoxybenzyl)carbamothioyl)-benzamide (210 mg, 0.5 mmol) in N, N-dimethylformamide 
(DMF) (3 mL) was stirred at T = 85 °C for 3h. After cooling to room temperature, the mixture was 
partitioned between EtOAc and H2O. The organic layer was washed with brine and dried over 
anhydrous Na2SO4. After filtration, the solvent was removed in vacuum and the residue was 
stirred in trifluoroacetic acid (TFA) (4 mL) at T = 80 °C for 24-36 h until complete deprotection. 
Most of the TFA was removed under reduced pressure. The residue was then neutralized with 
NaHCO3 1N, and then extracted with EtOAc for 3 times. The combined organic layers were 
washed with brine and dried over anhydrous Na2SO4. After filtration, the solution was 
concentrated and further crystallized in acetonitrile to afford (2-amino-4-phenyl-thiazol-5-yl)(3-
chloro-4-methoxyphenyl)methanone (110 mg, 63%) as a brown solid. ESI-MS: m/z 345.04 [M + H]+. 
Benzo [1,3]dioxol-5-yl-cyclopropanecarboxylic acid (20.6 mg, 0.1 mmol) was resuspended in 
anhydrous DMF (1 mL); HATU (38 mg, 0.1 mmol) and DIPEA (35 L, 0.2 mmol) were added. The 
reaction was vigorously stirred for 5 min and (2-amino-4-phenyl-thiazol-5-yl)(3-chloro-4-
methoxyphenyl)methanone  (40 mg, 0.1 mmol) in anhydrous DMF (500 L)was added. The 
reaction was kept at T= 50 °C until completeness (18-24 h) and then purified by preparative HPLC. 
The peak of interest was concentrated to obtain the title compound as a white solid with a purity 
of >95% as determined by HPLC-MS (14.5mg, 27%). 
1H NMR (200 MHz, DMSO‑d6)  12.14 (s, 1H, NH); 8.03e6.75 (m,11H, arom); 6.06 (s, 2H,OCH2O); 
3.77 (s, 3H, OCH3); 1.78e1.46 (m, 2H, CH2, cyclopr); 1.42e1.10 (m, 2H, CH2, cyclopr). 
13C NMR (50 MHz, DMSO‑d6)  184.5, 171.5, 162.2, 156.8, 153.1, 146.8, 146.3, 140.5, 
137.2,131.2,128.8, 128.2, 123.3, 118.1, 113.6,110.2, 107.7, 100.6, 55.3, 30.3, 15.6. 
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HRMS (ESI) calculated for C28H22ClN2O5S: [M + H]+ 533.09379; found 533.09336. 
6.1.6 (7w) N-(5-(3-allyl-4-hydroxybenzoyl)-4-phenylthiazol-2-yl)-1- (benzo[d][1,3]dioxol-
5-yl) cyclopropanecarboxamide 
 
A solution of 2-bromo-1-[4-hydroxy-3-(prop-2-en-1-yl)phenyl]ethan-1-one (128 mg, 0.5  mmol) and 
N-(bis(4-methoxybenzyl)carbamothioyl)-benzamide (210 mg, 0.5 mmol) in N, N-
dimethylformamide (DMF) (3 mL) was stirred at T = 85 °C for 3h. After cooling to room 
temperature, the mixture was partitioned between EtOAc and H2O. The organic layer was washed 
with brine and dried over anhydrous Na2SO4. After filtration, the solvent was removed in vacuum 
and the residue was stirred in trifluoroacetic acid (TFA) (4 mL) at T = 80 °C for 24-36 h until 
complete deprotection. Most of the TFA was removed under reduced pressure. The residue was 
then neutralized with NaHCO3 1N, and then extracted with EtOAc for 3 times. The combined 
organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the 
solution was concentrated and further crystallized in acetonitrile to afford (3-allyl-4-
hydroxyphenyl)(2-amino-4-phenylthiazol-5-yl)methanone (115 mg, 68%) as a brown solid. ESI-MS: 
m/z 345.04 [M + H]+. 
Benzo [1,3]dioxol-5-yl-cyclopropanecarboxylic acid (20.6 mg, 0.1 mmol) was resuspended in 
anhydrous DMF (1 mL); HATU (38 mg, 0.1 mmol) and DIPEA (35 L, 0.2 mmol) were added. The 
reaction was vigorously stirred for 5 min and (3-allyl-4-hydroxyphenyl)(2-amino-4-phenylthiazol-
5-yl)methanone   (34 mg, 0.1 mmol) in anhydrous DMF (500 L)was added. The reaction was kept 
at T ¼ 50 °C until completeness (18-24 h) and then purified by preparative HPLC. The peak of 
interest was concentrated to obtain the title compound as brown solid with a purity of >95% as 
determined by HPLC-MS (10 mg, 19%). 
1H NMR (200 MHz, DMSO‑d6)  12.02 (s, 1H, NH); 9.73 (s, 1H,OH); 7.88e6.72 (m, 11H, arom); 6.05 
(s, 2H, OCH2O); 5.95e5.61 (m,1H, CH2CH]CH2); 4.92e4.68 (m, 2H, CH2CH]CH2); 3.18 (d, J ¼ 15.2, 
2H, CH2CH]CH2); 1.77e1.43 (m, 2H, CH2, cyclopr);1.42e1.14 (m, 2H, CH2, cyclopr). 
13C NMR (50 MHz, DMSO‑d6)  178.4, 170.5, 161.1, 156.2, 152.9,146.9, 146.3, 145.2, 136.9, 136.5, 
131.2, 128.8, 128.3, 123.4, 114.2,110.2, 107.8, 100.6, 34.9, 30.3, 15.6. 
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HRMS (ESI) calculated for C30H25N2O5S: [M + H]+ 525.14841;found 525.14803. 
6.1.7 (7z) 1-(Benzo[d][1,3dioxol-5-yl)-N-(5-(benzo[d][1, 3]dioxole-5- carbonyl)-4-
phenylthiazol-2-yl) cyclopropanecarboxamide 
 
A solution of 5-(bromoacetyl)-2-hydroxybenzamide (129 mg, 0.5  mmol) and N-(bis(4-
methoxybenzyl)carbamothioyl)-benzamide (210 mg, 0.5 mmol) in N, N-dimethylformamide 
(DMF) (3 mL) was stirred at T = 85 °C for 3h. After cooling to room temperature, the mixture was 
partitioned between EtOAc and H2O. The organic layer was washed with brine and dried over 
anhydrous Na2SO4. After filtration, the solvent was removed in vacuum and the residue was 
stirred in trifluoroacetic acid (TFA) (4 mL) at T = 80 °C for 24-36 h until complete deprotection. 
Most of the TFA was removed under reduced pressure. The residue was then neutralized with 
NaHCO3 1N, and then extracted with EtOAc for 3 times. The combined organic layers were 
washed with brine and dried over anhydrous Na2SO4. After filtration, the solution was 
concentrated and further crystallized in acetonitrile to afford 4-(2-amino-4-phenyl-1,3-thiazole-5-
carbonyl)-2-hydroxybenzamide  (90 mg, 53%) as a brown oil. ESI-MS: m/z 345.04 [M + H]+. 
Benzo [1,3]dioxol-5-yl-cyclopropanecarboxylic acid (20.6 mg, 0.1 mmol) was resuspended in 
anhydrous DMF (1 mL); HATU (38 mg, 0.1 mmol) and DIPEA (35 L, 0.2 mmol) were added. The 
reaction was vigorously stirred for 5 min and 4-(2-amino-4-phenyl-1,3-thiazole-5-carbonyl)-2-
hydroxybenzamide    (32.4 mg, 0.1 mmol) in anhydrous DMF (500 L)was added. The reaction was 
kept at T = 50 °C until completeness (18-24 h) and then purified by preparative HPLC. The peak of 
interest was concentrated to obtain the title compound as brown oil with a purity of >95% as 
determined by HPLC-MS (15.5 mg, 30%). 
1H NMR (200 MHz, DMSO‑d6)  12.08 (s, 1H, NH); 7.77e6.68 (m, 11H, arom); 6.07 (s, 2H, OCH2O); 
6.03 (s, 2H, OCH2O); 1.64e1.41 (m, 2H, CH2, cyclopr); 1.41e1.00 (m, 2H, CH2, cyclopr). 
13C NMR (50 MHz, DMSO‑d6)  178.8, 171.4, 159.3, 154.8, 151.5, 146.9, 146.3, 137.0, 131.2, 128.8, 
128.1, 127.4, 123.2, 114.6, 110.3, 107.8, 100.6, 30.3, 15.4. 
HRMS (ESI) calculated for C28H21N2O6S: [M + H]+ 513.11203; found 513.11187. 
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6.1.8 (12a) 2-(1-(Benzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)- N,4-
diphenylthiazole-5-carboxamide  
 
A solution of ethyl 2-amino-4-phenylthiazole-5-carboxylate(248 mg, 1 mmol), di-tert-butyl 
carbonate (262 mg, 1.2 mmol) and catalytic 4-(N,N-dimethylamino) pyridine (8 mg, 0.07 mmol) in 
anhydrous THF (1 mL) was stirred for 4 h at room temperature. The mixture was concentrated 
under vacuum and after extraction with EtOAc (3 x 3 mL), washed with H2O (3 x 2 mL). The 
organic phases were dried over Na2SO4 and concentrated under vacuum. Crystallization in 
acetonitrile afford ethyl 2-((tert-butoxycarbonyl)amino)-4-phenylthiazole-5-carboxylate (170 mg, 
49%) which was used in the next step without further purification. ESI-MS: m/z349.1 [M+H]+. 
A solution of ethyl 2-((tert-butoxycarbonyl)amino)-4-phenylthiazole-5-carboxylate (170 mg, 0.49 
mmol) in THF-EtOH(2.5 mL, 1:1.5) and 6 N aq KOH solution (1 mL) was heated at 
T = 55 °C for 4 h. The solution was cooled to T = 0°C and acidified with conc. HCl to pH 1. The 
solution was then concentrated in vacuum, and after extraction with diethyl ether (3 x 3 mL), 
washed with H2O (3 x 2 mL) and dried over anhydrous Na2SO4. After filtration, the solution was 
evaporated to obtain 2-[[(tert-butyloxy)carbonyl]-amino]-4-phenyl-1,3-thiazole-5-carboxylic acid 
(100 mg, 64%) as a brown solid. ESI-MS: m/z 321.1 [M+H]+. 
The 2-[[(tert-butyloxy)carbonyl]-amino]-4-phenyl-1,3- thiazole-5-carboxylic acid (75 mg, 0.23 
mmol) was resuspended in anhydrous DMF (1 mL), HATU (87 mg, 0.23 mmol) and DIPEA (40 L, 
0.23 mmol) were added. The reaction was vigorously stirred for 5 min and aniline (23 mL, 0.24 
mmol) in anhydrous DMF (500 L) was added. The reaction was kept at T = 40°C for 2 h. The 
solvent was removed under reduced pressure and the residue was partitioned between diethyl 
ether and water. The combined organic layers were washed with water (3 x 2 mL) and dried over 
anhydrous Na2SO4. After filtration, the solvent was removed in vacuum, and the residue was 
stirred in a mixture of TFA: DCM 1:1 (2 mL) at T = 0 °C until complete deprotection (4-5 h). Most of 
TFA was removed under reduced pressure. The residue was neutralized with NaHCO31 N and 
then extracted with EtOAc for 3 times. Crystallization in acetonitrile furnishes 2-amino-N,4-
diphenylthiazole-5- carboxamide (30 mg, 44%). ESI-MS: m/z 296.1 [M+H]+. 
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Benzo [1,3]dioxol-5-yl-cyclopropanecarboxylic acid (20.5 mg,0.1 mmol) was resuspended in 
anhydrous DMF (1 mL); HATU (38 mg, 0.1 mmol) and DIPEA (18 L, 0.1 mmol) were added. After 
5 min, 2-amino-N, 4-diphenylthiazole-5-carboxamide (30 mg, 0.1 mmol) in anhydrous DMF (500 
L) was added. The reaction was kept at T = 50°C until completeness (about 24 h). 
The mixture was concentrated under vacuum and after extraction with EtOAc (3 x 3 mL),washed 
with H2O (3 x 2 mL). The organic phase was dried over Na2SO4, concentrated under reduced 
pressure and purified by preparative HPLC. The peak of interest was concentrated to obtain the 
title compound as white solid with purity of >95% as determined by HPLC-MS (10 mg, 21%). 
1H NMR (200 MHz, DMSO‑d6):  12.08 (s, broad, 1H, NH); 10.63 (s, broad, 1H, NH); 7.79e6.75 (m, 
13H, arom); 6.05 (s, 2H OCH2O);1.81e1.45 (m, 2H, CH2, cyclopr); 1.43e1.01 (m, 2H, CH2, cyclopr). 
13C NMR (50 MHz, DMSO‑d6)  183.5, 165.5, 161.9, 151.0, 146.8, 
146.3,137.9,137.0,129.2,128.9,128.7,128.0,127.5,121.6,116.0,110.8, 107.2, 101.2, 30.3, 15.6. 
HRMS (ESI) calculated for C27H22N3O4S: [M + H]+ 484.13309; found 484.13277. 
6.1.9 (12b) N-(2-(1-(Benzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-4-(4-
methoxyphenyl)thiazol-5-yl) benzamide 
To a stirred solution of 4-methoxyphenacyl bromide (229 mg, 1 mmol) in diethyl ether (2 mL) was 
added hexamethylenetetramine (140 mg, 1 mmol) all at once and the mixture was stirred for 2 h at 
room temperature. The resulting solid was centrifugated, washed with diethyl ether (2 mL), and 
dried under reduced pressure to afford the quaternary salt. To the compound, EtOH (2 mL) and 
conc. HCl (0.1 mL) were added and the mixture was refluxed for 3 h. After cooling to room 
temperature, the solid was centrifugated, washed with EtOH (3 x 2 mL), and dried under vacuum 
to afford pure 4-methoxy20amino-acetophenone hydrochloride in near quantitative yield. ESI-MS: 
m/z 202.6 [M+H]+. 
NaHCO3 (252 mg, 3 mmol) was added to a solution of 4-methoxy20amino-acetophenone 
hydrochloride (202 mg, 1 mmol) in anhydrous THF (2 mL) with stirring at room temperature. 
Benzoyl chloride (116 ml, 1 mmol) was added to the solution and stirred for about 3 h at room 
temperature. The solvent was removed under reduced pressure to leave a yellow oil. The product 
was extracted with dichloromethane (DCM) (3 x 3 mL) and washed with H2O (3 x 2 mL). The 
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organic phase was dried over Na2SO4 and then concentrated under reduced pressure. Removal of 
the solvent produced the N-(2-(4-methoxyphenyl)-2-oxoethyl)benzamide as a white solid of 
sufficient purity to be used in the next step (202 mg, 75%). ESI-MS: m/z 269.1 [M+H]+. 
N-(2-(4-methoxyphenyl)-2-oxoethyl)benzamide (107 mg, 0.4 mmol) and thiourea (30 mg, 0.4 
mmol) were solved in EtOH at room temperature. To this solution I2 (101 mg, 0.4 mmol) and 
triethylamine (TEA) (11 ml, 0.2 mmol) were added. The reactions were stirred at T = 80°C 
overnight. The mixture was concentrated under vacuum and after extraction with EtOAc (3 x 3 
mL), was washed with H2O (3 x 2 mL). The organic layer was dried over anhydrous Na2SO4. After 
filtration, the solvent was removed in vacuum to obtain N-(2-amino-4-(4-methoxyphenyl)thiazol-
5-yl) benzamide (40 mg, 31%). The thiazole was used without further purification. ESI-MS: m/z 
325.1 [M+H]+. 
Benzo [1,3]dioxol-5-yl-cyclopropanecarboxylic acid (25 mg, 0.12 mmol) was resuspended in 
anhydrous DMF (1 mL), HATU (45 mg, 0.12 mmol) and DIPEA (42 L, 0.24 mmol) were added. 
After 5 min, N-(2-amino-4-(4-methoxyphenyl)thiazol-5-yl)benzamide (40 mg, 0.12 mmol) in 
anhydrous DMF (500 L) was added. 
The reaction was kept at T = 50°C until completeness (about 24 h). The mixture was concentrated 
under vacuum and after extraction with EtOAc (3 x 3 mL), washed with H2O (3 x 2 mL). The 
organic phase was dried over Na2SO4, concentrated under reduced pressure and purified by 
preparative HPLC. The peak of interest was concentrated to obtain the title compound as brown 
solid with a purity of >95% as determined by HPLC-MS (11 mg, 18%). 
1H NMR (200 MHz, DMSO‑d6):  12.19 (s, broad, 1H, NH); 11.59 (s, broad, 1H, NH); 8.02e6.81 (m, 
12H, arom); 6.04 (s, 2H OCH2O); 3.86 (s, 3H, OCH3); 1.78e1.44 (m, 2H, CH2, cyclopr); 1.41e1.08 (m, 
2H, CH2, cyclopr). 
13C NMR (50 MHz, DMSO‑d6)  180.8, 167.3, 160.5, 151.4, 146.9, 146.4, 137.8, 136.8, 129.2, 128.9, 
128.1, 127.5, 121.7, 116.3, 110.8, 107.2, 101.2, 53.7, 30.3, 15.5. 
HRMS (ESI) calculated for C28H24N3O5S: [M þ H]þ 514.14366; found 514.14359. 
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6.1.10 (12c) 1-(Benzo[d][1,3]dioxol-5-yl)-N-(5-(4-methylbenzoyl) thiazol-2-
yl)cyclopropanecarboxamide  
 
N,N-Dimethyl formamide dimethyl acetal (1036 mL, 7.8 mmol) was added to a suspension of 
thiourea (198 mg, 2.6 mmol) in DCM (2 mL). The mixture was heated at reflux for 4 h. The solvent 
was removed, and the residue was crystallized from diethyl ether to 
obtain (1E, 10E)-N’,N’’-thiocarbonylbis (N,N-dimethylformimidamide) (400 mg, 83%). ESI-MS: 
m/z 187.1 (M + H) +. 
(1E, 1’E)-N’,N’’-Thiocarbonylbis-(N,N-dimethylformimidamide (100 mg, 0.53 mmol) was 
suspended in THF (1 mL) and 2-bromo40-methylacetophenone (113 mg, 0.53 mmol) was added. 
The mixture was stirred at room temperature for 15 min and then TEA (147 mL,1.16 mmol) was 
added, and the mixture was heated at reflux for 18 h. The mixture was concentrated under 
vacuum and after extraction with EtOAc (3 x 3 mL), washed with H2O (3 x 2 mL). The organic 
phase was dried over Na2SO4, concentrated under reduced pressure to obtain (Z)-N’-(5-(4-
methylbenzoyl) thiazol-2-yl)-N,Ndimethylformimidamide(108 mg, 70%). ESI-MS: m/z 273.1(M + 
H) +. 
A 33% (wt./wt.) aqueous methylamine (400 L) was added to a solution of (Z)-N’-(5-(4-
methylbenzoyl)thiazol-2-yl)-N,N-dimethylformimidamide (101 mg, 0,37 mmol) in THF (1 mL) and 
the mixture was stirred for 24 h at room temperature. The mixture was concentrated under 
vacuum and after extraction with EtOAc (3 x 3 mL), washed with H2O (3 x 2 mL). The organic 
phase was dried over Na2SO4, concentrated under reduced pressure to obtain a pale yellow oil. 
Crystallization in acetonitrile furnishes (2-aminothiazol-5-yl) (p-tolyl)methanone (36 mg, 45%). 
ESI-MS: m/z 219.1 [M+H]+. 
Benzo [1,3]dioxol-5-yl-cyclopropanecarboxylic acid (33 mg, 0.16 mmol) was resuspended in 
anhydrous DMF (1 mL), HATU (61 mg, 0.16 mmol) and DIPEA (56 L, 0.16 mmol) were added. 
After 5 min, (2-aminothiazol-5-yl) (p-tolyl) methanone (35 mg, 0.16 mmol) in anhydrous DMF (500 
L) was added. The reaction was kept at T = 50 °C until completeness (about 24 h). 
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The mixture was concentrated under vacuum and after extraction with EtOAc (3 x 3 mL),washed 
with H2O (3 x 2 mL). The organic phase was dried over Na2SO4, concentrated under reduced 
pressure and purified by preparative HPLC. The peak of interest was concentrated to obtain the 
title compound as pale yellow solid with purity of >95% as determined by HPLC-MS (32.4 mg, 
50%). 
1H NMR (200 MHz, DMSO‑d6): d 11.87 (s, broad, 1H, NH); 8.05 (s,1H, arom); 7.81e6.78 (m, 7H, 
arom); 6.04 (s, 2H OCH2O); 2.32 (s,3H, CH3); 1.81e1.42 (m, 2H, CH2, cyclopr); 1.41e1.00 (m, 2H, 
CH2,cyclopr). 
13C NMR (50 MHz, DMSO‑d6) d 186.2, 173.6, 146.8, 146.3, 137.0,133.1, 129.6, 129.1, 121.3, 110.8, 
107.2, 101.2, 30.3, 24.6, 15.5. 
HRMS (ESI) calculated for C22H19N2O4S: [M + H]+ 407.10654; found 407.10608. 
6.1.11 (12d) 1-(Benzo[d][1,3]dioxol-5-yl)-N-(5-(4-methoxybenzoyl) thiazol 
yl)cyclopropanecarboxamide 
 
(1E, 1’E)-N’,N’’-Thiocarbonylbis-N,N-dimethylformimidamide (100 mg, 0.53 mmol) was 
suspended in DCM (1 mL) and 2-bromo- 40-methoxyacetophenone (121 mg, 0.53 mmol) was 
added. The mixture was stirred at room temperature for 15 min and then TEA (147 L,1.16 
mmol)was added. The mixture was heated at reflux for about 20 h. At the end of the reaction the 
solution was concentrated under vacuum and after extraction with EtOAc (3 x 3 mL), washed with 
H2O (3 x 2 mL). The organic phase was dried over Na2SO4, concentrated under reduced pressure to 
obtain (Z)-N’-(5-(4-methoxybenzoyl) thiazol-2-yl)-N,N-dimethylformimidamide (108 mg, 70%). 
ESI-MS: m/z 290.1 [M+H]+. 
A 33% (wt./wt.) aqueous methylamine (600 L) was added to a solution of (Z)-N’-(5-(4-
methoxybenzoyl)thiazol-2-yl)-N,N-dimethylformimidamide (108 mg, 0.37 mmol) in THF (1 mL) 
and the mixture was stirred for 24 h at room temperature. The solution was then concentrated 
under vacuum and after extraction with EtOAc (3 x 3 mL), washed with H2O (3 x 2 mL). The 
organic phase was dried over Na2SO4, concentrated under reduced pressure to obtain a yellow oil. 
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Crystallization in acetonitrile furnishes (2-aminothiazol-5-yl) (4-methoxyphenyl)methanone (46 
mg, 53%). MS ESI-MS: m/z 235.1 [M+H]+. 
Benzo [1,3]dioxol-5-yl-cyclopropanecarboxylic acid (39 mg, 0.19 mmol) was resuspended in 
anhydrous DMF (1 mL), HATU (72 mg, 0.19 mmol) and DIPEA (66 L, 0.19 mmol) were added. 
After 5 min, (2-aminothiazol-5-yl) (4-methoxyphenyl)methanone (45 mg, 0.19 mmol) in anhydrous 
DMF (500 L) was added. The reaction was kept at T = 50°C until completeness (about 36 h). The 
mixture was concentrated under vacuum and after extraction with EtOAc (3 x 3 mL),washed with 
H2O (3 x 2 mL). The organic phase was dried over Na2SO4, concentrated under reduced pressure 
and purified by preparative HPLC. The peak of interest was concentrated to obtain the title 
compound as brown solid with purity of >95% as determined by HPLC-MS (26.6 mg, 33%). 
1H NMR (200 MHz, DMSO‑d6):  11.87 (s, broad, 1H, NH); 8.08 (s,1H, arom); 7.79e6.81 (m, 7H, 
arom); 6.04 (s, 2H OCH2O); 3.89 (s,3H, CH3); 1.78e1.41 (m, 2H, CH2, cyclopr); 1.40e1.03 (m, 2H, 
CH2,cyclopr). 
13C NMR (50 MHz, DMSO‑d6)  182.7, 171.9, 146.9, 146.3, 137.1,133.0, 129.7, 128.8, 121.4, 110.8, 
107.2, 101.2, 55.9, 30.3, 15.5. 











6.2.1. Cell culture 
The bronchial epithelial cell line CFBE41o-with stable coexpression of F508del-CFTR and the 
halide-sensitive yellow fluorescent protein (HS-YFP) was cultured with MEM medium 
supplemented with 10% fetal calf serum, 2 mM L-glutamine, 100 U/mL penicillin, and 100 mg/mL 
streptomycin. 
6.2.2. Fluorescence assay for CFTR activity 
CFBE41o-cells with the expression of mutant CFTR and HS-YFP were plated on clear-bottom 96-
well black microplates at a density of 50,000 cells/well and kept at 37°C in 5% CO2 for 24 h. For the 
corrector assay, CFBE41o-cells were treated for a further 24 h with compounds and/or VX-809 or 
VX-661. After treatment, the culture medium was removed and cells in each well were stimulated 
for 30 min at 37°C with 60 mL PBS (containing 137 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4, 1.5 
mM KH2PO4, 1 mM CaCl2, and 0.5 mM MgCl2) plus forskolin (20 M) and genistein (50 M). 
At the time of assay, microplates carrying CFBE41o-cells were transferred to a microplate reader. 
The plate reader was equipped with high-quality excitation and emission 
filters for YFP. The assay consisted of a continuous 14 s fluorescence reading with 2 s before and 12 
s after injection of an iodide containing solution (165 mL of a modified PBS containing I- instead of 
Cl-; final I- concentration in the well: 100 mM). To determine fluorescence quenching rate 
associated with I- influx, the final 10 s of data for each well were fitted with an exponential 
function to extrapolate the initial slope (dF/dt). Dose-response relationships from each experiment 
were fitted to calculate EC50, maximal effect, and Hill coefficient. 
 
6.2.3. Transepithelial electrical resistance (TEER) evaluation 
Primary bronchial epithelial cells obtained from one patient with CF (homozygous for F508del 
mutation) were seeded at high density on porous membranes for transepithelial 
electrical resistance (TEER). To test putative correctors, compounds were added to the basolateral 
medium for 24 h at 37°C and 5% CO2 before measuring the TEER. Control epithelia were treated 
with vehicle alone (DMSO). TEER was measured in each well under basal conditions, after ENaC 
120 
 
inhibition with apical amiloride (10 M), after CFTR stimulation with forskolin (10 M) and 
genistein (50 M) on both sides, and after CFTR inhibition with apical PPQ102 (30 M).  
6.2.4. Biochemical analysis of CFTR expression pattern 
CFBE41o-cells stably expressing mutant CFTR and HS-YFP were grown to confluence on 60-mm 
diameter dishes and treated for 24 h with test compounds or vehicle alone. After 24 h, cells were 
lysed in RIPA buffer containing a complete protease inhibitor. Cell lysates were subjected to 
centrifugation at 12000 rpm at 4°C for 10min. Equal amounts of protein (10 mg) were separated 
onto gradient (4-15%), transferred to a nitrocellulose membrane, and analyzed by Western 
blotting. Proteins were detected using monoclonal anti-CFTR or mouse monoclonal anti-GAPDH 
followed by horseradish peroxidase (HRP)-conjugated anti-mouse IgG (Abcam), and subsequently 
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A1. Chemical structure and biological activity of the hybrids 2-29 as F508del-CFTR correctors.  
 
 















































































































































































































































































































































































































































































































A6. Chemical structures and biological values of thienopyrazole derivatives 1-26 as F508del-CFTR 
potentiators.  
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Cp. R1 R2 R3 pEC50  
57 
 
H OMe 5.00 
58 
 
H OMe 5.69 
59 
 
H OMe 5.58 
60 
 
H OMe 5.29 
61 
 
H H 4.79 
62 
 
H H 4.88 
63 
 





H OMe < 4.52 
65 
 
H H < 4.52 
66 
 
H OMe < 4.52 
67 
 
H OMe < 4.52 
68 SO2Me H OMe < 4.52 





















Cp. R1 R2 R3 pEC50  
70 OMe H 
 
4.82 
  71 OMe H 
 
< 4.52 
72 OMe H 
 
5.44 
73 OMe H 
 
< 4.52 
74 OMe H 
 
5.61 





76 OMe H 
 
< 4.52 
77 OMe H 
 
< 4.52 
78 OMe H 
 
5.76 
79 OMe H 
 
< 4.52 
































































































































































































































































































































A15. Experimental (Exp.pEC50) and predicted (Pred.pEC50) values of the training set compounds 
according to the refined QSAR model. 
 
Cp. Exp. pEC50 E_nb ASA- vsa_pol CASA+ CASA- E_ang Pred. pEC50 Residual 
3 6.52 40.201546 311.06015 43.506508 1127.1584 786.98218 121.59032 6.24 0.2800 
4 6.26 40.071484 295.21408 43.506508 1153.6713 754.27197 122.66916 6.39 -0.1316 
5 6.05 39.974373 292.46686 43.506508 1154.363 746.96039 121.56782 6.43 -0.3811 
6 5.54 37.910526 281.6275 29.939585 792.55768 580.71594 121.07256 5.47 0.0664 
7 5.72 38.121964 305.53513 29.939585 768.17029 622.6806 121.0268 5.20 0.5169 
8 5.64 37.865238 282.59271 29.939585 791.71173 582.98877 121.37415 5.47 0.1736 
9 5.80 37.621845 236.54544 29.939585 842.57831 492.01453 121.02081 5.92 -0.1225 
10 6.05 36.758995 252.77013 29.939585 846.78784 542.69745 122.49203 6.01 0.0352 
11 5.54 37.211922 277.50491 29.939585 728.87549 562.22498 120.49342 5.35 0.1880 
12 5.31 37.436359 298.69312 29.939585 708.33789 597.98364 120.47495 5.10 0.2088 
13 5.09 37.212086 280.57724 29.939585 743.19354 569.01068 120.71957 5.37 -0.2798 
15 5.68 35.795937 244.57336 29.939585 795.67621 516.53894 122.20341 5.98 -0.2962 
16 5.74 37.433041 230.66957 43.506508 890.95435 525.00391 121.43837 5.75 -0.0125 
17 5.64 37.343327 234.04518 43.506508 893.51337 533.62299 121.48071 5.76 -0.1192 
18 5.92 38.131062 238.4789 43.506508 966.19189 552.31714 121.81725 5.90 0.0249 
23 5.42 35.323212 381.84894 29.939585 698.24213 844.64984 120.17078 5.32 0.0989 
24 5.27 35.113384 358.79428 29.939585 723.77502 802.6228 120.48874 5.57 -0.3021 
25 5.89 34.822216 308.6485 43.506508 804.03973 757.4234 120.57159 5.84 0.0467 
26 5.77 34.670029 308.59375 43.506508 799.9693 756.05463 120.56307 5.84 -0.0710 
27 5.40 34.575485 355.2095 29.939585 662.57629 782.17133 119.65387 5.42 -0.0218 
30 5.55 82.923752 171.84309 30.614649 1648.9868 370.83737 20.736029 5.68 -0.1298 
176 
 
31 5.85 82.42186 184.62444 48.35714 1847.3866 444.39102 22.800692 5.61 0.2405 
32 5.55 106.46642 171.46677 48.35714 2676.562 455.58719 27.980944 5.44 0.1107 
37 4.00 144.48102 122.29909 22.730305 3444.0505 287.52515 32.371471 4.37 -0.3663 
38 4.00 153.96991 127.36039 17.047728 3526.8616 297.38651 36.52422 3.73 0.2738 
39 4.00 147.62102 126.22911 22.730305 3584.5537 293.60892 32.575783 4.36 -0.3587 
40 4.00 154.23276 123.18449 17.047728 3532.3589 284.55618 35.389881 3.73 0.2680 
41 4.00 158.429 119.46897 19.551485 4025.5757 309.06622 38.373356 4.62 -0.6234 
42 4.00 153.73146 153.67113 17.047728 3514.4336 374.03552 36.782146 3.71 0.2902 
43 6.40 110.90891 133.17619 33.118404 3017.5261 351.71832 33.262741 6.52 -0.1196 
44 5.46 87.505989 170.54222 50.860893 2184.323 448.35553 26.178873 6.06 -0.5979 
45 6.70 84.29599 134.07512 30.916637 2102.2649 341.48932 57.236408 6.49 0.2082 
46 5.64 111.44763 156.84193 50.860893 3098.0825 451.54794 31.014784 6.08 -0.4432 
47 6.52 93.705719 173.39532 33.118404 2326.9932 451.52142 33.383991 6.42 0.0951 
49 6.15 86.606331 225.05911 36.297226 1873.995 530.46436 21.122585 5.62 0.5286 
50 6.70 74.338272 152.44916 41.979801 1729.2054 368.77454 21.081335 6.62 0.0827 
54 6.05 148.64999 98.055092 17.047728 3884.696 228.27225 34.709503 5.37 0.6825 
55 4.00 132.28711 164.27565 30.614649 2949.2405 432.04498 31.816795 4.15 -0.1528 
56 4.00 123.07984 190.38725 49.064251 2928.6514 488.53369 46.862576 3.77 0.2313 
57 5.66 55.075397 237.48724 50.860893 923.78021 500.8606 22.470055 5.35 0.3140 
58 4.96 58.179813 234.20871 50.860893 911.40234 502.84613 22.384676 5.06 -0.1031 
59 5.52 56.934811 234.43777 50.860893 922.17236 493.72595 22.341722 5.16 0.3606 
60 4.00 54.783257 230.61339 54.039715 789.38843 457.07571 20.474987 4.76 -0.7638 
61 5.57 51.930538 229.52635 54.039715 774.53314 448.72403 19.566298 5.01 0.5581 
62 5.14 50.999371 214.56854 54.039715 781.28369 413.47357 20.403036 5.17 -0.0281 
177 
 
63 4.00 51.904221 252.33662 48.35714 709.98688 475.40222 19.385567 4.85 -0.8527 
65 5.82 63.475273 226.01973 53.364651 1141.8444 538.83099 24.826355 5.33 0.4917 
66 5.17 57.026089 191.64943 59.72229 882.32562 403.23041 19.090767 4.93 0.2428 
67 5.57 60.584358 218.01747 56.543472 1009.9583 490.53931 24.855558 4.98 0.5911 
68 5.43 62.59671 226.41823 53.364651 1151.2058 546.57361 23.791538 5.51 -0.0800 
70 5.34 58.139511 219.83636 50.860893 882.26208 469.1308 15.243285 5.19 0.1472 
71 5.37 57.90588 214.09308 50.860893 880.84534 456.23233 15.861175 5.23 0.1426 
73 5.52 54.521137 204.4958 54.039715 790.16455 404.9017 12.876506 5.11 0.4106 
74 4.88 52.395954 204.63695 54.039715 747.9267 399.45132 13.675772 5.17 -0.2899 
75 4.00 71.220154 226.46532 39.495743 989.84216 478.97415 20.628365 4.45 -0.4482 
76 4.00 71.40937 230.99619 39.495743 977.70166 479.77908 22.155819 4.28 -0.2833 
77 4.00 71.750427 227.05901 39.495743 986.42834 470.92038 22.093498 4.29 -0.2889 
78 4.00 70.656143 224.05431 42.674564 843.64532 437.12994 19.305321 3.78 0.2229 
79 4.00 66.774406 216.00131 42.674564 835.51776 415.37051 20.192486 4.16 -0.1615 














A16. Experimental (Exp.pEC50 ) and predicted (Pred.pEC50 ) values of the test set compounds 






















1 5.59 48.448597 381.67267 57.073425 725.31787 1243.8712 108.23756 5.93 -0.3400 
2 7.06 53.35915 305.88519 43.506508 1120.5023 774.80719 121.30415 6.65 0.4051 
14 5.92 37.931583 304.58237 29.939585 707.73633 608.5556 120.34983 5.41 0.5145 
19 5.41 38.162426 238.59331 43.506508 953.86444 551.62775 121.88371 5.85 -0.4416 
20 5.30 39.625359 255.47565 57.073425 1019.7084 648.90814 19.199339 5.63 -0.3321 
21 5.53 40.260384 255.33957 57.073425 1096.9369 657.75476 19.016466 5.83 -0.3000 
22 5.30 40.724495 233.93356 49.189083 1171.973 592.08582 18.133121 5.65 -0.3458 
28 5.10 36.033928 246.28993 24.25701 585.13702 430.02222 106.14865 4.32 0.7800 
29 5.66 48.590977 206.37631 29.939585 706.36316 397.68716 107.79346 5.34 0.3218 
33 5.51 146.15053 133.94344 22.730305 3419.7056 318.91934 30.880795 5.14 0.3719 
34 5.82 153.23914 136.87323 17.047728 3544.1233 323.7052 35.1539 5.87 -0.0456 
35 4.00 82.230225 180.92363 48.35714 1837.0845 429.87457 25.189426 4.33 -0.3304 
36 4.00 106.19363 165.49545 48.35714 2657.3655 434.75656 29.022572 4.38 -0.3754 
48 4.00 89.662857 233.99181 30.614649 1898.8805 553.62463 30.238689 4.97 -0.9700 
51 6.70 98.400475 154.97318 22.730305 2273.0305 328.85309 26.189623 5.97 0.7289 
52 6.70 138.94405 110.62077 17.047728 3588.1072 261.39685 55.438435 6.18 0.5214 
53 6.52 158.92085 142.09158 17.047728 3969.3804 352.67133 36.833698 6.42 0.0959 
64 5.38 63.195755 223.05199 53.364651 1137.3612 529.30237 24.910639 5.64 -0.2592 
69 4.00 61.174698 178.73625 50.860893 932.14954 388.21515 14.915898 4.27 -0.2692 
72 4.00 54.135616 218.24225 54.039715 736.79474 438.01221 13.264742 3.96 0.0440 
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A17.Experimental (Exp.pEC50) and predicted (Pred.pEC50) values of the test set compounds according to the developed QSAR model. The selected 






























































0 5.2812943 9.1278973 89.636139 28.926434 34.79628 4.7171016 0.26172695 0.41990376 527.75 127.625 4.62 0.3786 







0 2.7775381 5.9423227 54.252274 38.569443 34.7962
8 





12.949531 2.503756 27.047791 35.383869 22.531462 9.121018
4 



























0 0 0 33.241909 137.18106 1.550733
9 
25.383394 0.48546532 1.3971066 448.
5 
96.375 5.60 -1.1057 
181 
 
A18. Experimental (Exp.pEC50) and predicted (Pred.pEC50) values of the test set compounds according to the developed QSAR model. The selected 
2D Adjacency and Distance Matrix Descriptors, Pharmacophore Feature Descriptors, Physical Properties, Atom Counts and Bond Counts 





















































-0.47616071 -0.36629966 0.80957109 2.9251747 0.125 -5.6871099 0.31962168 20 390.99222 5.67 -0.3738 
38  
5.00 
-0.53411287 -0.42294818 0.76985401 2.7408793 0.17857143 -4.0622401 0.090998821 17 314.42032 4.92 0.0811 
40  
4.25 
-0.50695312 -0.33814892 0.72322482 2.7434282 0.21875 -5.4211402 -0.35460791 20 369.87402 5.03 -0.7757 
55  
4.79 
-0.5048244 -0.41092402 0.74816161 2.7917297 0.20689656 -4.26401 0.043317597 18 341.32532 5.08 -0.2927 
57  
5.00 
-0.50591195 -0.34110171 0.69058079 3.0343418 0.12121212 -4.0710001 -0.099414699 24 451.85364 4.62 0.3786 
59  
5.58 
-0.50857282 -0.41164595 0.75098193 3.034306 0.090909094 -4.61058 -0.23075099 25 399.97519 5.23 0.3450 
66  
4.52 































A19. Experimental (Exp.pEC50) and predicted (Pred.pEC50) values of the training set compounds according to the developed QSAR model. The 
selected 2D Subdivided Surface Area, Adjacency and Partial Charge descriptors and the 3D Surface Area, Volume and Shape Descriptor values 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































64 4.52 0 2.777538 10.35312 54.2522
7 
5.243428 39.20708 4.717102 0.212023 0.72273
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A20. Experimental (Exp.pEC50) and predicted (Pred.pEC50) values of the training set compounds according to the developed QSAR model. The 
selected 2D Adjacency and Distance Matrix Descriptors, Pharmacophore Feature Descriptors, Physical Properties, Atom Counts and Bond Counts 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































71 4.52 -0.53808 -0.49986 0.854311 2.582083 0.11111
1 
-4.3668 -0.30719 14 300.680
6 
4.31 0.2087 
 
73 
 
4.52 
 
-0.54843 
 
-0.34375 
 
0.705257 
 
2.61022 
 
0.18181
8 
 
-5.77608 
 
-0.46157 
 
18 
 
380.179
1 
 
4.79 
-0.2698 
 
74 
 
5.61 
 
-0.49763 
 
-0.41475 
 
0.867923 
 
2.587962 
 
0.10344
8 
 
-6.65421 
 
-0.27854 
 
17 
 
335.579
8 
 
5.51 
0.0977 
 
75 
 
4.52 
 
-0.5085 
 
-0.3597 
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